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ABSTRACT   
Cognitive function is multidimensional and complex, and research 
indicates that it is impacted by age, lifetime experience, and ovarian 
hormone milieu. One particular domain of cognitive function that is 
susceptible to age-related decrements is spatial memory. Cognitive 
practice can affect spatial memory when aged in both males and females, 
and in females alone ovarian hormones have been found to alter spatial 
memory via modulating brain microstructure and function in many of the 
same brain areas affected by aging. The research in this dissertation has 
implications that promote an understanding of the effects of cognitive 
practice on aging memory, why males and females respond differently to 
cognitive practice, and the parameters and mechanisms underlying 
estrogen’s effects on memory. This body of work suggests that cognitive 
practice can enhance memory when aged and that estrogen is a probable 
candidate facilitating the observed differences in the effects of cognitive 
practice depending on sex. This enhancement in cognitive practice effects 
via estrogen is supported by data demonstrating that estrogen enhances 
spatial memory and hippocampal synaptic plasticity. The estrogen-
facilitated memory enhancements and alterations in hippocampal synaptic 
plasticity are at least partially facilitated via enhancements in cholinergic 
signaling from the basal forebrain. Finally, age, dose, and type of estrogen 
utilized are important factors to consider when evaluating estrogen’s 
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effects on memory and its underlying mechanisms, since age alters the 
responsiveness to estrogen treatment and the dose of estrogen needed, 
and small alterations in the molecular structure of estrogen can have a 
profound impact on estrogen’s efficacy on memory.  
Collectively, this dissertation elucidates many parameters that 
dictate the outcome, and even the direction, of the effects that cognitive 
practice and estrogens have on cognition during aging. Indeed, many 
parameters including the ones described here are important 
considerations when designing future putative behavioral interventions, 
behavioral therapies, and hormone therapies. Ideally, the parameters 
described here will be used to help design the next generation of 
interventions, therapies, and nootropic agents that will allow individuals to 
maintain their cognitive capacity when aged, above and beyond what is 
currently possible, thus enacting lasting improvement in women’s health 
and public health in general. 
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CHAPTER 1 
GENERAL INTRODUCTION  
Cognitive Aging and the Risk of Alzheimer’s Disease 
According to U.S. census projections there will be an estimated 1.5 
billion people over the age of 65 by the year 2050 (U.S. Census Bureau, 
2007). In many individuals, learning and memory function deteriorates with 
age. Normally aged individuals require more time to learn novel 
information when compared to young individuals, and they are more 
susceptible to interference (Tulving and Craik, 2000). Age is the number 
one risk factor for developing Alzheimer’s disease (AD), and there are 
more than 5 million people in the U.S. afflicted with AD (Alzheimer’s 
Association, 2007). Currently, no treatments exist to reverse the pathology 
associated with AD. However, there may be non-pharmacological and 
hormonal treatments to protect individuals from memory loss and brain 
changes due to normal aging as well as AD. 
Cognitive Activity  
A non-pharmacological treatment to protect individuals from 
memory loss may be cognitive activity throughout life. This tenet is 
supported by evidence that education decreases risk of developing 
dementia and/or the symptoms of AD. Many studies report lower 
education as a risk factor in developing AD and other dementias (Bowirrat 
et al., 2002; De Ronchi et al., 1998; Fritsch et al., 2002; Gatz et al., 2001; 
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Letenneur et al., 1999; Ott et al., 1999). Additionally, aged individuals 
maintaining higher cognitive activity through leisure activities had a lower 
risk of developing dementia, mild cognitive impairment (MCI), and 
vascular cognitive impairment than those who were less active (Verghese 
et al., 2009; Verghese et al., 2006; Verghese et al., 2003). Corroborating 
the above studies in humans, work in animals has provided evidence that 
environmental stimulation enhances markers of neuronal health in aged 
animals (for review see Frick and Benoit, 2010; Swaab et al., 2002). 
Collectively, these findings indicate that age-related memory changes can 
be influenced by numerous experiential factors including prior education 
and cognitively-stimulating activities, and cognitive practice may lead to 
neurobiological changes that attenuate age-related memory decline. 
Age-Related Changes in Rodent Memory 
 Similar to humans, rodents show age-related memory decline, 
specifically in reference memory (RM), a type of long-term memory where 
information remains constant, and working memory (WM), a type of short-
term memory where information needs to be updated. Numerous studies 
have demonstrated RM and WM decline with age in rodents (Ando and 
Ohashi, 1991; Barnes et al., 1980; Bimonte et al., 2003; Chrobak et al., 
1995; Frick et al., 1995; Matzel et al., 2011; Pitsikas and Algeri, 1992; 
Talboom et al., 2008; Wellman and Pelleymounter, 1999). Studies 
evaluating cognitive practice in animals have demonstrated that male rats 
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receiving practice on the spatial RM Morris maze for five days at 12 
months of age performed better at 24 months of age on this practice task, 
as compared to age-matched controls that had received no practice. 
However, this enhancement in performance was not found on passive 
avoidance, suggesting the protective effects of cognitive practice may not 
transfer to another type of task (Pitsikas et al., 1991). In another study, 
male rats received practice on the RM T-Maze, RM Morris maze, and the 
WM radial-arm maze at 2-3 and 12-14 months of age, and were then 
tested on these same mazes at 25-27 months of age. The final 
assessment showed an attenuation of age-related memory change in 
comparison to naïve age-matched controls on only the RM T-maze and 
Morris maze (Dellu et al., 1997). Thus, cognitive practice on multiple WM 
and RM maze tasks may not protect against age-related WM decline, as 
tested in the radial-arm maze, for male rats. More recent longitudinal 
research found that extensive WM practice on a modified radial-arm maze 
in mice from 3 to 18 months of age conferred an attenuation of age-related 
learning and attentional deficits evaluated by a battery of tasks when the 
mice were aged (Matzel et al., 2011). 
Unanswered Questions Regarding Cognitive Practice 
Although pivotal in understanding the effects of cognitive practice, 
previous reports evaluating the ability of cognitive practice to alter the 
trajectory of age-related cognitive changes in animals left several 
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questions unanswered. The study described in Chapter 2 was designed to 
directly and methodically address these unanswered questions in the 
literature. 
Ovarian Hormones and Cognition 
An important consideration when evaluating cognitive aging in 
females is ovarian hormone status, as several basic and clinical studies 
have linked cognitive decline with age-related alterations in the ovarian 
hormone milieu (for review see Bimonte-Nelson et al., 2010; Sherwin and 
Henry, 2008). For example, ovarian hormone loss due to surgical or 
natural menopause has been associated with cognitive decline in women 
(Nappi et al., 1999; Phillips and Sherwin, 1992; Sherwin, 1988), and 
hormone therapy (HT) can attenuate some of these declines (Sherwin, 
2006), although the parameters underlying the efficacy of this effect are 
controversial (see Craig et al., 2005; Sherwin, 2005). Estrogens are a 
class of hormones including 17β-estradiol (E2), estrone (E1), and estriol; 
for humans and rats E2 is the most potent naturally-circulating estrogen, 
followed by E1 and estriol, in order of receptor affinity (Kuhl, 2005; Sitruk-
Ware, 2002). E2 is the primary export product from the human ovary 
(Turgeon et al., 2004). The majority of studies evaluating activational 
effects of estrogens in ovariectomized (Ovx) animals for spatial learning 
and memory have been performed using young rodents, with many works 
showing enhancements due to treatment (Bimonte and Denenberg, 1999; 
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Daniel et al., 1997; Daniel et al., 1999; Dohanich et al., 1994; Galea et al., 
2001; Holmes et al., 2002; Luine et al., 2003; Luine et al., 1998b; Marriott 
and Korol, 2003; McLaughlin et al., 2008; Packard and Teather, 1997; 
Sandstrom and Williams, 2001; Singh et al., 1994). To summarize, these 
studies suggest that 1) ovarian hormone loss is detrimental, while HT is 
beneficial to cognition, 2) there are several estrogens naturally circulating 
in HTs with different potencies and receptor affinities, and 3) estrogen 
treatment enhances memory in young rodents. This work collectively 
supports the tenet that estrogen can help to attenuate age-related memory 
decline in females given the appropriate circumstances. However, what 
these appropriate circumstances are remain to be determined. 
Estrogen Effects in Older Rodents  
In some studies, E2 treatment has been shown to benefit memory 
in aged rodents (Aenlle et al., 2009; Foster et al., 2003; Frick et al., 2002; 
Gibbs, 2000b; Markham et al., 2002; Markowska and Savonenko, 2002a; 
Talboom et al., 2008); however, it is important to note that these effects 
depend on a multitude of factors, making the question of whether E2 can 
enhance memory in aged rodents more complex than it is for younger 
rodents. For example, two factors are the memory type evaluated and the 
demand placed on the memory system. WM enhancements due to tonic 
E2 treatment have been reported in aged Ovx rats, although this effect is 
more pronounced when memory demand is high (Gibbs, 2000b; Luine and 
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Rodriguez, 1994). My lab and others have shown E2-induced spatial WM 
improvements in young Ovx rats as well, an effect most pronounced when 
spatial WM demand is high (Bimonte and Denenberg, 1999), and is an 
effect that depends on administered E2 dose (Bimonte and Denenberg, 
1999; Daniel et al., 1997; Holmes et al., 2002; Sandstrom and Williams, 
2001). Furthermore, a higher supraphysiological E2 dose may be 
necessary to enhance spatial RM retention in rats approaching old age, as 
lower doses did not enhance RM retention (Foster et al., 2003).  
Responsivity to Estrogen Treatment  
A study has noted an age-related interaction with estrogen’s effects 
on spatial memory retention when testing multiple ages after treatment 
with two separate doses of estradiol benzoate, and although serum levels 
of E2 were assayed, the correlation with memory performance was not 
evaluated (Foster et al., 2003). This study suggested that there may be an 
age-related alteration in the responsivity to estrogen treatment in relation 
to spatial memory, and a novel analysis would be to assess the relation 
between serum estrogen levels and memory performance. Chapter 3 
evaluated the responsiveness of young, middle-aged, and aged Ovx rats 
to E2 treatment on the spatial RM Morris maze task. Chapter 3 also 
evaluated if circulating serum E2 levels correlated with spatial RM 
performance. 
Estrogens Commonly Used in HT and their Composition 
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To date, E2 has been the primary estrogen used to investigate the 
cognitive effects of HT in the animal model, despite the fact that Premarin® 
Hersh et al., 2004
(CEE) is the most commonly prescribed estrogen component of HT 
( ). CEE contains the sulfates of more than 10 equine 
estrogens (Kuhl, 2005). In humans, CEE-containing therapy improves 
memory in females (Campbell and Whitehead, 1977a; Kantor et al., 1973; 
Ohkura et al., 1995), although recently the Women’s Health Initiative 
(WHI) study found that CEE does not benefit cognition in women (for 
review see Coker et al., 2010). New evidence has demonstrated that both 
tonic and cyclic CEE, at doses relevant to what women take as HT, can 
enhance spatial memory and protect against cholinergic challenge on 
spatial tasks in middle-aged Ovx rats (Acosta et al., 2009b; Engler-
Chiurazzi et al., 2009). Although vital in understanding CEE’s effects on 
memory, these previous animal studies did not evaluate E2, so a direct 
comparison between the effects of CEE and E2 on memory was not 
possible. Chapter 4 assessed the effects of E2 and CEE on memory in 
middle-aged Ovx female rats. While Chapter 4 and other previous studies 
identified an efficacious dose of CEE and E2 in female rats, a full 
evaluation of the dose response effects of E2 and CEE on spatial memory 
has not been evaluated. In fact, few researchers have employed more 
than two doses in a single study. It is conceivable that the dose response 
curve for each hormone follows a quadratic or perhaps cubic function, 
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which would be difficult to evaluate with two or fewer doses. Chapter 5 
separately tested six tonic doses of E2 and CEE on the spatial WM Delay 
Match-to-Sample (DMS) Plus Maze task in middle-aged female Ovx rats.  
Components of CEE 
In the last decade, landmark basic science research from the 
Brinton laboratory has led to several discoveries regarding the 
neuroprotective properties of estrogens. This work demonstrated that 
some estrogen components of CEE enhanced markers of neuroprotection, 
while others showed little benefit (Brinton et al., 1997; Zhao and Brinton, 
2006). Specifically, Δ8,9-dehydroestrone (∆8
Zhao and Brinton, 2006
E1) and equilin, found naturally 
in horses but not in women or rats, were the two primary estrogenic CEE 
components that showed the most consistent and potent neuroprotective 
effects in vitro ( ). Despite these exciting in vitro 
findings regarding ∆8E1 and equilin, neither estrogen has been evaluated 
for their effects on memory or the cholinergic system. Chapter 6 assessed 
the effects of three separate doses of ∆8
Estrogen Prodrugs 
E1 and equilin on spatial memory 
via the DMS Plus Maze and Morris maze. 
Limited recent research has focused on developing prodrugs of E2 
and E1. Prodrugs are inactive precursors of the therapeutic agents that 
are converted to the biologically active agents by enzymatic and/or 
chemical transformation in vivo–preferably at the site of action (Albert, 
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1958; Wermuth et al., 1998). Brain-targeted estrogen prodrugs 
conceivably have the ability to target the action of the hormone to only the 
brain, and thereby reduce the systemic effects and provide an exciting 
new potential therapeutic option as a HT (Estes et al., 1994; Prokai et al., 
2003). My collaborators developed 10-hydroxyestra-1, 4-dien-3, 10-dione 
(E1-DHED) as a prodrug of E1, and indeed E1-DHED has been shown to 
protect against stroke-induced brain changes similar to the parent 
hormone E1 (see Prokai et al., 2003). More recently, 10,17β-
dihydroxyestra-1,4-dien-3-one (DHED) has been implicated as a prodrug 
for E2 by that group as well. Chapter 4, in addition to testing E2 and CEE, 
also evaluated the effects of DHED on memory in middle-aged Ovx 
female rats. 
The BF Cholinergic System, Estrogen, and Memory 
Basal forebrain (BF) cholinergic neurons project to the 
hippocampus and surrounding cortical areas, and play an important role in 
learning and memory (Hasselmo, 2006). E2 enhances BF cholinergic 
function, as evidenced by expression of different cholinergic markers and 
pharmacological cholinergic challenges (e.g., Gibbs, 2000a; Markowska 
and Savonenko, 2002a; Packard and Teather, 1997). In fact, choline 
acetyltransferase (ChAT), the acetylcholine (ACh) synthesizing enzyme, 
increases in the BF even months after transient exposure to E2 (Bohacek 
et al., 2008; Gibbs, 1997; Rodgers et al., 2010). Cholinergic signaling is 
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directed by muscarinic ACh receptors (mAChR) and nicotinic ACh 
receptors (nAChR), which are both present in brain regions facilitating 
memory (Clarke et al., 1985; Court and Clementi, 1995; Tice et al., 1996; 
Vaucher et al., 2002), and are implicated in memory processing 
(Hasselmo, 2006; Konopacki et al., 1992; Rouse et al., 1999). Estrogens 
bind to the α4β2-nAChR, the most abundant nAChR subtype in the brain, 
and directly alter its function (i.e., alters the receptor’s ion efflux) (Curtis et 
al., 2002; Paradiso et al., 2001). To address a potential mechanism of 
estrogen’s effects on memory, Chapter 4 also evaluated the effects of E2, 
CEE, and DHED on BF ChAT positive cell counts in middle-aged Ovx 
female rats. Following simular lines of reasoning regarding the cholinergic 
system, Chapter 6 assessed the effects of ∆8
The Effects of Age and Estrogen on Synaptic Plasticity in Cognitive 
Brain Regions 
E1 and equilin treatments on 
nAChRs. 
Age-related cognitive decline likely involves neoplastic changes 
within the brain (Burke and Barnes, 2006), such as alterations in dendritic 
structure, spine number, and spine shape. Using various techniques, there 
is evidence that hippocampal and neocortical synapses decrease with 
normal aging (Bertoni-Freddari et al., 2003). Moreover, there are 
alterations in factors influencing synaptic transmission that occur with 
normal aging, including the reductions mentioned above in synaptic 
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density as well as dendritic regression in apical and basal neuron regions 
in brain areas that are known to be involved in memory processing (Esiri, 
2001). Gonadal hormones, especially estrogen, have been shown to have 
marked effects on neuron morphology (for review see Woolley, 2007). 
Early work found that hormone fluctuations with the estrous cycle affect 
brain regions involved in cognition (Foy, 2001; Terasawa and Timiras, 
1968). Subsequent studies have extended these findings to show that 
estrogens alter neuron morphology by increasing hippocampal CA1 spine 
density in Ovx rats (Gould et al., 1990; Silva et al., 2000; Woolley and 
McEwen, 1992; Woolley and McEwen, 1993). Dendritic spines have long 
been theorized to be a structural component of memory (Geinisman, 
2000; Kasai et al., 2003; Moser, 1999; Nimchinsky et al., 2002; Sorra and 
Harris, 2000), leading to wide-reaching implications regarding estrogen’s 
influence on cognitive function. Indeed, several studies have 
demonstrated that spatial WM and RM performance is enhanced after E2 
injections (McLaughlin et al., 2008; Sandstrom and Williams, 2001; 
Sandstrom and Williams, 2004) within the timeframes corresponding to 
E2-induced increases in hippocampal dendritic spines (Gould et al., 1990; 
Silva et al., 2000; Woolley and McEwen, 1992; Woolley and McEwen, 
1993) and other markers of synaptic plasticity (Foy, 2001). These studies 
suggest that age and ovarian hormones have a profound effect on 
hippocampal synaptic plasticity. Chapter 7 assessed how age and ovarian 
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hormone loss altered the distribution of excitatory and inhibitory putative 
synapses in several hippocampal lamina of female rats.  
It is my hope that the work in this dissertation will maximize 
opportunities for the discovery of new hormonal and behavioral therapies 
and subsequent interventions so that individuals can maximize their 
potential for brain health as aging ensues. With improvements in 
cognition, the ever aging population would be able to maintain their 
autonomy and overall health longer, thus improving their quality of life and 
in turn the quality of life of their family and loved ones. Collectively, these 
enhancements in the life of aged individuals would translate to 
improvements in public health while decreasing the enormous cost that 
the detrimental effects of aging place on society.   
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CHAPTER 2 
HOW LEARNING CAN HELP YOU REMEMBER: THE LONGITUDINAL 
EFFECTS OF LIFELONG REFERENCE MEMORY PRACTICE AND 
MEMORY TRANSFER IN MALE AND FEMALE RATS 
Increasing age is the number one risk factor for developing AD, and 
there are more than 5 million people in the U.S. afflicted with AD 
(Alzheimer’s Association, 2007). Currently, there are few treatments to 
alleviate the symptoms of AD, and no treatments exist to reverse the 
pathology associated with AD. However, there may be non-
pharmacological that can help protect individuals from memory loss due to 
normal aging as well as AD. One non-pharmacological treatment to deter 
age-related or neurodegenerative memory changes may be remaining 
cognitively active, as evidence supports the idea that education decreases 
risk of developing dementia and/or the symptoms of AD (see Chapter 1). 
Indeed, college professors (with 21-23 years of education) maintained 
cognitive performance as they aged, with professors in their sixties 
performing as well as professors in their thirties on proactive interference 
and some WM tasks (Shimamura et al., 1995). While, greater mental 
ability as a child- measured on a global scale of cognitive functioning, 
decreases the risk of developing late-onset dementia (Whalley et al., 
2000). Taken together, these suggest that cognitive practice may 
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attenuate age-related memory decline and perhaps protect against some 
of the symptoms of AD. 
 Rodent studies evaluating cognitive practice in addition to the ones 
mentioned earlier (see Chapter 1), found that cognitive practice is 
generally beneficial to aged cognition. Markowska & Savonenko (2002b) 
trained male rats on a battery of tests every six months, including RM and 
WM versions of the Morris Maze. When 24 months old, rats were 
assessed on the same battery of tests in which they had received practice 
on (Markowska and Savonenko, 2002b). Protection against age-related 
decline was found in both RM and WM Morris Maze tasks. Accurate 
spatial memory has also been found to be preserved after extensive 
testing for 10 months on the WM land radial-arm maze (Bierley et al., 
1986). Rats were tested on the WM land radial-arm maze from 3-11 
months of age; when 21.5 months of age, the experienced rats performed 
as well as young control animals (Bierley et al., 1986). More recent 
longitudinal research found that extensive WM cognitive practice on a 
modified radial-arm maze in mice from 3 to 18 months of age conferred an 
attenuation of age-related learning and attentional deficits evaluated by a 
battery of tasks when the mice were aged (Matzel et al., 2011). 
Although vital, few to no previous inquiries into the effects of 
cognitive practice on age-related memory decline have used a different 
maze for training and final assessment. Hence, it is unclear whether 
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cognitive practice protects only within the practiced memory domain or 
whether it has a global protection that includes other memory types. Most 
previous reports used the same maze for training and final assessment. 
Thus, the question of whether cognitive practice protects against age-
related memory changes on another non-practiced maze task has not 
been fully evaluated. These previous studies also did not control for the 
procedural aspects of maze testing. The procedural aspects of maze 
testing may provide protection against cognitive decline, insomuch as the 
act of maze testing involves aspects of enrichment that may enhance 
memory when aged (for review see Frick and Benoit, 2010). Finally, it is 
noteworthy that to the authors’ knowledge only one study has evaluated 
the effects of cognitive practice on memory in females, and in this study 
only females were evaluated so relation to males could not be determined 
(Ando and Ohashi, 1991). Hence, it remains to be elucidated in a single 
study if sex differences exist in the response to cognitive practice. 
BF cholinergic neurons project to the hippocampus and 
surrounding cortical areas, and play an important role in learning and 
memory (Hasselmo, 2006). Cholinergic neuron survival and maintenance 
is dependent on neurotrophins, which includes nerve growth factor (NGF) 
(Granholm, 2000; Levi-Montalcini, 1987; Woolf, 1991). Neurotrophin 
systems have been found to become aberrant with age (Mufson et al., 
1995). My lab has reliably shown that neurotrophins correlate with 
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cognitive performance in aging rats, in that higher levels of NGF within the 
hippocampus and cortex related to worse memory performance in ovary-
intact aged female rats (Bimonte et al., 2003; Bimonte-Nelson et al., 
2003a). It remains to be evaluated if cognitive practice can alter 
neurotrophin levels in cognitive and motor brain regions and whether aged 
neurotrophin levels relate to memory performance when young in male 
and female rats. 
 Noting the several questions remaining to be addressed or fully 
evaluated in the literature, the current experiment was designed to directly 
and methodically address the following questions: a) Does RM cognitive 
practice prevent loss only the RM domain, or does it extend protection into 
the WM domain? b) Is memory protection from cognitive practice due to 
the procedural components of testing or the cognitive demand of the maze 
task? c) Is age-related cognitive protection due to cognitive practice only 
seen when the aged assessment task is the same as the cognitive 
practice task? d) Do males and females differ when comparing their 
memory and the effects of cognitive practice? e) Does cognitive practice 
alter cognitive and motor brain region specific levels of NGF? f) Is memory 
performance when young related to aged brain region specific levels of 
NGF? g) Is the rate at which animals learned the cognitive practice task 
when young related to how they perform when aged? The hypotheses of 
this study were: a) RM cognitive practice will extend a global protection 
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into the WM memory domain, b) cognitive demand will be necessary for 
protection of the memory system when aged (e.g. experience with only the 
procedural components will not be sufficient to enhance performance 
when aged), c) memory protection will extend to novel maze tasks, d) 
males and females will differ regarding how cognitive practice attenuates 
age-related memory decline, e) cognitive practice will alter specific brain 
region levels of NGF, f) memory performance when young will be related 
to aged NGF levels, and g) an animal’s ability to learn the RM cognitive 
practice task when young will be related to its ability to perform when 
aged. 
Methods 
Subjects 
 Ninety 6 month old Fisher-344 rats (45 male, 45 female) were 
obtained from the National Institute on Aging colony at Harlan 
Laboratories and pair housed in the Arizona State University animal 
facility. Animals had exposure to food and water ad-lib, and were 
maintained on a 12-h light/dark cycle at 74 ºF (minimum 68 ºF / maximum 
78 ºF). Procedures were approved by Arizona State University Institutional 
Animal Care and Use Committee (IACUC) and adhered to the Guide for 
the Care and Use of Laboratory Animals and NIH standards. 
 The age of initiation of the cognitive practice and swim only testing 
schedule for the present study was based on a previous study indicating 
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that cognitive practice beginning at 6 months of age exerts the strongest 
attenuation of age-related changes in male rats as compared to age-
matched controls (Markowska and Savonenko, 2002b). Thus, maze 
practice period began when rats were 6 months of age. Practice continued 
for one year, with rats receiving their last practice session at 18 months of 
age. To keep the lifetime practice treatment conditions as constant and 
similar as possible, all lifetime practice groups were tested on a water-
escape T-Maze. For final assessments, several additional groups were 
evaluated that did not have exposure to the water-escape T-Maze 
throughout life. Specifically, the following groups were evaluated: (a) aged 
naïve (Aged-Naïve), (b) aged swim only (Aged-Swim Only), and (c) aged 
cognitive practice (Aged-Cog Prac). The Aged-Swim Only and Aged-Cog 
Prac groups received maze testing from 6 to 18 months of age during the 
practice period, and testing was conducted in a water escape T-Maze 
once every three months. 
All rats were divided into three testing waves with the same number 
of animals/treatment group per wave. This was done to allow the 
consecutive testing of a manageable number of animals. Thus, for the 
practice period, one wave of animals was tested every month; hence, 
each animal was tested once every three months. Put in other terms, 
there were three separate 6 month old cohorts of rats that started the 
cognitive practice or swim only task at different times (i.e. a new group 
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each month, with each group being tested every three months) to achieve 
the staggered three testing waves. For the final battery of tests, each 
wave was tested approximately three months after their last practice 
session. The final battery of testing also included an additional group of 6 
month old young naïve animals (Young-Naïve). After behavioral testing all 
animals were sacrificed to collect brain tissue for NGF evaluations, as 
detailed below. For sacrifice, I included a final group of aged animals that 
were never tested (Aged-Never Test) and sat in their cages their entire life 
until sacrifice. The next section provides a detailed description of each 
treatment group, and Figure 1 displays the timeline of the experimental 
procedures.  
Experimental Groups 
Cognitive practice group (Aged-Cog Prac). 
 From 6 to 18 months of age, Aged-Cog Prac animals were tested 
every 3 months for 5 days with 6 trials per day on the RM T-Maze. This 
procedure is a modified protocol (Denenberg et al., 1991; Denenberg et 
al., 1990; Gibbs et al., 2004). The testing room had salient visual extra-
maze cues that remained constant throughout testing. The black 
Plexiglass maze (each arm was 38.1cm x 12.7cm) was filled with water 
made opaque with black non-toxic paint, and had a hidden escape 
platform at the end of one of the two non-start arms. Each rat had an 
assigned exit location (East or West) for the entire duration of testing, 
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including when the RM T-Maze was evaluated on the final battery. Drop 
off locations varied between north and south arms to control for 
motoric/olfactory strategies for finding the platform. After a rat located the 
platform, it remained there for 5 seconds; the rat was then removed and 
placed in its heated cage for 30 seconds until the next trial. Between each 
animal the maze was cleaned with a net to further minimize the possibility 
of the animal using an olfactory strategy to solve the task. The dependent 
variable was the number of correct arm entries, quantified as the number 
of times an animal found the hidden escape platform within a day; this 
measure was capped at 6 since there were 6 trials per day. The Aged-Cog 
Prac group evaluated the effects of a lifetime of cognitive practice on aged 
cognitive performance.  
Aged swim only group (Aged-Swim Only). 
The Aged-Swim Only group received identical treatment conditions, 
in a T-Maze identical to the one used for the Aged-Cog Prac group, except 
the task was modified to minimize cognitive demand. For this group, exit 
arms were assigned randomly for each trial pair. With one arm blocked, 
the escape arm was the only other arm left open aside from the start arm; 
hence, Aged-Swim Only animals simply swam and turned once (i.e., a 
forced choice) to escape the maze and “win” each trial. The procedures 
minimized the cognitive demand placed on Aged-Swim Only animals. 
Drop off locations varied between north and south arms to maximize 
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swimming similarities to the Aged-Cog Prac group. The Aged-Swim Only 
group addressed whether the procedural aspects of maze testing 
throughout the practice period influenced age-related cognitive change. 
This group was used as the control group to evaluate the effects of 
cognitive practice, since they received the most similar lifetime 
experiences as compared to the Aged-Cog Prac group.  
Aged naïve animals (Aged-Naïve). 
The Aged-Naïve animals remained pair housed in their colony room 
cages for the entire practice period (i.e., from 6-21 months of age). Once 
the practice period was concluded, the Aged-Naïve animals were tested 
on the final battery. The Aged-Naïve group allowed me to make a 
comparison to the normally aged laboratory rat that did not receive any 
cognitive practice or the potentially enriching procedural components of 
testing. 
Young naïve animals (Young-Naïve).  
 The Young-Naïve group consisted of eighteen (9 male & 9 female) 
young rats that were added to the study during the final battery of tests. 
This group was added to the study so that a comparison to the best of a 
rat’s learning and memory ability could be made. It is important to note 
that these animals were 6 months of age when tested on the final battery, 
representing the age when cognitive practice started for the Aged-Cog 
Prac and Aged-Swim Only groups.  
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Aged never tested (Aged-Never Test).  
 The 18 (9 male & 9 female) Aged-Never Test animals remained in 
their colony room cages for the entire training period, and during the final 
battery testing period. Once the training and final battery testing period 
was concluded, the Aged-Never Test animals were sacrificed along with 
the other groups of animals. This group was included to evaluate 
neurotrophin levels in animals that simply sat in their cage their entire 
adult lives and represented normally aged laboratory rats not exposed to 
any behavioral testing.  
Mazes Used During the Final Battery 
The final battery of maze assessments was conducted when testing 
groups were 21 months of age (i.e., with the exception of the Young-Naïve 
group). The final battery of maze assessments included mazes tapping 
into both WM and RM. This was done so that an evaluation could be 
made of whether cognitive practice throughout life within the RM domain 
transferred to the WM domain once aged. Also, the final battery 
investigated whether training on the RM T-Maze benefited performance on 
other maze types. This was accomplished by testing rats on the WM and 
RM water radial-arm maze (WRAM), as well as the RM Morris maze; both 
mazes utilized novel RM and WM paradigms assessed in novel 
environments for all testing groups including the lifelong practiced Aged-
Cog Prac and Aged-Swim Only groups. 
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RM Morris Maze. 
The RM Morris Maze (Morris et al., 1982) consisted of a round tub 
(188 cm in diameter) filled with water made opaque with black, non-toxic 
paint. The rat was placed in the maze from any of four locations (i.e., 
North, South, East, or West) and had 60 seconds to locate a submerged 
hidden escape platform which remained in a fixed location (i.e., the target 
Northeast quadrant; NE) throughout testing. After 15 seconds on the 
platform, the rat was placed into its heated cage until the next trial; the 
inter-trial-interval was 5-8 minutes. For each rat, the testing session 
consisted of 4 trials/day for 5 days. A video camera recorded each rat, and 
a tracking system (EthoVision 3.1, Noldus Information Technology, 
Wageningen, Netherlands) analyzed each rat’s path. The dependent 
measure was swim distance (cm), with less swim distance interpreted as 
better spatial RM performance. To assess platform localization, a probe 
trial was given on an additional trial (trial 5) on the last day of testing, 
whereby the escape platform was removed from the maze. The 
dependent measures for the probe trial were the number of crossings 
where the platform previously was located, as well as the percentage of 
total swim distance (cm) in the target NE quadrant (i.e., quadrant that 
contained the platform on the test trials) as compared to the opposite 
Southwest (SW) quadrant. 
RM T-Maze. 
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 The procedure for the RM T-Maze during the final battery was 
identical to that given to the Aged-Cog Prac group during their cognitive 
practice sessions from 6 to 18 months of age. All platform locations 
remained constant for an animal during cognitive practice training/testing 
but were semi-randomly selected for each animal. Hence, Aged-Cog Prac 
animals escaped from the maze in the same location in space throughout 
all practice sessions and during the final battery. Data were scored via 
assessing the number of correct arm entries made within a daily session, 
which served as the dependent variable.  
WM and RM WRAM. 
  This win-shift radial 8-arm maze was constructed of black 
Plexiglass and filled with water (room temperature) made opaque via 
black non-toxic paint (e.g., Bimonte and Denenberg, 1999; Bimonte and 
Denenberg, 2000; Bimonte et al., 2000). It had hidden escape platforms 
with wire mesh tops (hidden about 1 cm below the water surface) placed 
in the ends of four of the 8 arms. Each subject had different platform 
locations that were semi-randomly determined and that remained fixed 
throughout testing.  
 A subject was released from the start arm and had 3 minutes to 
locate a platform. Once a platform was found, the animal remained on it 
for 15 seconds, and was then returned to its heated cage for a 30 s inter-
trial interval (ITI) until its next trial. During the interval, the just-chosen 
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platform was removed from the maze. The animal was then placed again 
into the start alley and allowed to locate another platform. For each 
animal, a daily session consisted of four trials, with the number of 
platformed arms reduced by one on each subsequent trial. Thus, WM 
systems were increasingly taxed as trials progressed, allowing me to 
assess WM load. Each subject was given one session a day for 12 
consecutive days. 
 The following quantification and blocking procedures are based 
upon previous studies using the WRAM (Bimonte-Nelson et al., 2003a; 
Bimonte and Denenberg, 1999; Bimonte and Denenberg, 2000; Bimonte 
et al., 2002; Bimonte et al., 2000; Bimonte et al., 2003; Hyde et al., 1998; 
Hyde et al., 2000). Behavioral testing took place between the hours of 
0800 and 1700. An arm entry was counted when the tip of a rat’s snout 
reached a mark delineated on the outside of the arm and not visible from 
the inside of the maze (11 cm into the arm). Errors were quantified using 
the orthogonal measures of WM and RM errors (Jarrard et al., 1984), as 
done previously in studies using the water escape radial-arm maze 
(Bimonte-Nelson et al., 2003a; Bimonte et al., 2002; Bimonte et al., 2000; 
Hyde et al., 2000). The last four days of testing were used to evaluate WM 
and RM competence, as this was after rules were learned and thereby 
evaluates a more pure measure of WM. WM correct (WMC) errors were 
the number of first and repeat entries into any arm from which a platform 
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had been removed during that day. RM errors (WRM) were the number of 
first entries into any arm that never contained a platform within a day. WM 
incorrect errors (WMI) were the number of repeat entries into an arm that 
never contained a platform within a day (i.e., within day repeat entries into 
a RM arm). The separate number of WMC, WMI, and WRM errors served 
as the dependent variables for statistical analysis. 
Brain Dissection  
At sacrifice, animals were anesthetized with isoflurane (Vetone, 
Meridian, Indiana) and decapitated according to NIH euthanasia 
guidelines, after which the brains were rapidly dissected. Using Paxinos 
and Watson (2005) as a reference, the right hemisphere, frontal cortex, 
parietal cortex, temporal cortex, striatum, and ventral hippocampus 
(CA1/2) were dissected for neurotrophin analyses. Dissected tissues were 
immediately placed in weighed microcentrifuge tubes and stored at -70 °C 
until tissue lysates were made. 
 NGF Quantification 
NGF levels were assessed using commercially available assay kits 
from Promega (Madison, WI). Neurotrophin assay procedures were done 
as previously described (Bimonte-Nelson et al., 2008; Bimonte-Nelson et 
al., 2003a; Bimonte-Nelson et al., 2004a; Bimonte et al., 2003; Engler-
Chiurazzi et al., 2009; French et al., 2006). Briefly, tissue lysates were 
made, and flat-bottom 96 well plates were coated with NGF capture 
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antibody. The captured NGF was bound by a second specific antibody, 
which was detected using a species-specific antibody conjugated to 
horseradish peroxidase as a tertiary reactant. All unbound conjugates 
were removed by subsequent wash steps according to the Promega 
protocol. After incubation with chromagenic substrate, color change was 
measured in a plate reader by measuring absorbance at 450 nm. Using 
these kits, NGF can be quantified in the range of 4.7-300 pg/ml and 7.8-
500 pg/ml, respectively. For each assay kit, cross-reactivity with other 
trophic proteins is < 2-3%. The amount of NGF (pg/mg of tissue) present 
in the brain region of interest was the dependent variable used for 
statistical analysis. 
Statistical Methods 
Composite dependent variable construction. 
Several composite dependent variables were created (see Table 1 
for a summary of the dependent variable composites). Specifically, 
composite measures were created for each maze by summing the 
dependent variable(s) across: all days and trials (overall performance), as 
well as the last few days of testing with all trials, or only the last trial, 
depending on the specific maze type (asymptotic performance). Two 
additional composites evaluated overnight retention on the Morris maze as 
similarly performed in previous studies (Acosta et al., 2009b; Bimonte-
Nelson et al., 2006; Markham et al., 2002), and young RM performance on 
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their first cognitive practice session at 6 months of age. Lastly, a global 
(i.e., multiple domains of memory) composite memory measure was 
created by using scores from all novel mazes (non-practiced tasks). For 
this composite, I converted the previously created RM Morris Maze 
distance composite (all days and trials) and RM and WM WRAM 
composite (WMC, WMI, & WRM errors) to z-scores and averaged them. 
This allowed evaluation of RM and WM performance during the final 
battery on tasks that were novel to the Aged-Cog Prac and Aged-Swim 
Only groups. I termed this composite measure the Aged Novel Global 
Memory Composite. The creation of these composites was based on 
previous animal work whereby analyses of variance (ANOVA) found 
effects on these tasks during similar blocks of days and trials (Bimonte 
and Denenberg, 1999; Daniel et al., 1997; Frick et al., 1995; Markham et 
al., 2002; Sandstrom and Williams, 2004; Talboom et al., 2010; Talboom 
et al., 2008), as well as previous clinical work in humans assessing global 
measures of memory (e.g., Huynh et al., 2011; Matzel et al., 2011). 
Planned contrasts. 
 Since my a priori design was to evaluate several cognitive practice 
research questions not previously or fully addressed in animal literature, I 
employed planned contrasts to evaluate pairwise comparisons of groups, 
which assessed my primary research questions. Each question followed 
by the contrast name is as follows: 1) does cognitive practice enhance 
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memory when compared to similarly practice aged animals without 
cognitive demand? Cognitive practice contrast, Aged-Swim Only were 
compared to Aged-Cog Prac animals, 2) does cognitive practice obviate or 
attenuate age-related memory decline? Aging with cognitive practice 
contrast, Young-Naïve were compared to Age-Cog Prac animals, 3) is 
cognitive demand necessary to alter age-related cognitive decline? 
Procedural component contrast, Aged-Naïve were compared to the Aged-
Swim Only group, and 4) does age alter performance on the final battery 
of mazes? Age without practice contrast
With specific a priori comparisons in mind, planned contrasts can 
aid in the interpretation of results and increase the statistical power in 
comparison to a less focused omnibus test (
, Young-Naïve animals were 
compared to Aged-Naïve animals. A final contrast evaluated the effects of 
age on brain NGF levels, independent of cognitive practice and behavioral 
testing; in this contrast Young-Naïve animals were compared to Aged-
Never Test animals.  
see section 8.5 in Cohen et 
al., 2003). Similar to a t-test, planned contrasts compare the means of two 
groups or a combination of groups; however, the error term (i.e., 
unexplained variance, Mean Square within-groups/error) is calculated 
from all the groups in the study (i.e., pooled within-group variance), not 
just the two groups being compared (see Rosenthal and Rosnow, 1985). 
Hence, statistical power can be increased by having a better estimate of 
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the unaccounted for variance (i.e., increase the t-value/ratio). Proc GLM 
was utilized in SAS (version 9.2, The SAS Institute Inc., Cary, NC) to 
evaluate each planned contrast by employing orthogonal contrast coding.  
Linear growth modeling. 
I utilized Mplus (version 5.21; Muthén & Muthén; Los Angeles, CA) 
to estimate a linear growth model that expressed the number of correct 
arm entries on the cognitive practice RM T-Maze (i.e., my outcome 
variable) as a function of Days 1-5 (i.e., my variable that captured the 
passage of time) during the first cognitive practice session when Cog Prac 
practice animals were 6 months of age (Enders, 2011). The unconditional 
linear growth model was estimated as follows: 𝑵𝑼𝑴𝑩𝑬𝑹 𝑪𝑶𝑹𝑹𝑬𝑪𝑻 =
𝐁𝟎 + 𝐁𝟏 (𝑫𝑨𝒀) + 𝒃𝟎 + 𝒃𝟏(𝑫𝑨𝒀) +  𝜺, where 𝑵𝑼𝑴𝑩𝑬𝑹 𝑪𝑶𝑹𝑹𝑬𝑪𝑻 was the 
number of correct arm entries made, 𝑫𝑨𝒀 was the value of elapsed time in 
days since the onset of the cognitive practice session, 𝐁𝟎 was the mean 
Intercept (i.e., mean initial performance), 𝐁𝟏 was the mean Slope (i.e., 
mean change per day), 𝒃𝟎 and 𝒃𝟏 were residuals (i.e., random effects) 
that allowed the intercepts and the growth rates to vary from one rat to 
another, and ε was a time-specific residual that captured the difference 
between an animal’s fitted linear trajectory and its observed data (Enders, 
2011).  
Growth models allow for the addition of predictors that can 
influence the Intercept, Slope, or both. As such, Sex as a binary predictor 
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(i.e., coded 0 for female and 1 for male) was added to the model in order 
to predict if males and females differed in their initial performance (i.e., the 
Intercept or test day 1) or the rate at which they learned (i.e., the Slope or 
change per day) the cognitive practice RM T-Maze at 6 months of age. 
Additionally, one of the strengths of Mplus is that the Intercept and the 
Slope can also serve as predictors of other outcomes. I capitalized on this 
tenet by adding to my model the Novel Global Memory Composite. This 
analysis was employed as I wanted to evaluate the question of whether 
how well an animal initially performed or the rate at which they learned the 
RM T-Maze cognitive practice task at 6 months of age was related to their 
overall cognitive performance when aged. An association between initial 
status/ability and aged cognitive ability has been previously suggested in 
the human literature (Whalley et al., 2000). Collectively, the expanded 
model was: 𝑵𝑼𝑴𝑩𝑬𝑹 𝑪𝑶𝑹𝑹𝑬𝑪𝑻𝒕𝒊 = 𝐁𝟎 + 𝐁𝟏 (𝑫𝑨𝒀) + 𝑩𝟐(𝑴𝑨𝑳𝑬) + 𝑩𝟑(𝑫𝑨𝒀)(𝑴𝑨𝑳𝑬) + 𝒃𝟎 + 𝒃𝟏(𝑫𝑨𝒀) +  𝜺, where 𝐁𝟎 and 𝐁𝟏 were the initial 
performance and rates of change per day for female rats and 𝐁𝟐 and 𝐁𝟑 
represent the amount by which values differed from females to males for 
initial performance and change per day, respectively. Figure 2a displays a 
plot of the linear growth model with the mean growth rate of Cog Prac 
animals at 6 months of age (sample) and the model estimated linear 
growth rate; 2b depicts a simplified path diagram of the full model with 
unstandardized path coefficients. 
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Results 
Orthogonal Planned Contrasts 
Effects of cognitive practice (Aged-Swim Only vs. Aged-Cog 
Prac, cognitive practice contrast). 
 There was a significant cognitive practice contrast for the RM T-
Maze on the composite of the number correct arm entries for all days and 
trials (F[1,71] = 31.31, p < 0.0001) as well as for the last 3 days of testing 
for all test trials (F[1,71] = 21.54, p < 0.0001, Figure 3a), with the Aged-
Cog Prac group outperforming the Aged-Swim Only group, suggesting 
that a lifetime of RM cognitive practice enhances RM performance in 
males and females on a familiar RM task in a familiar environment
The cognitive practice contrast for the RM Morris Maze approached 
significance for the composite of the last 3 days of testing and all test trials 
(F[1,73] = 3.37, p = 0.0564, Figure 3b). I next evaluated the overnight 
retention contrast (test days 2-5 on trial 1 alone), which approached 
significance (F[1,73] = 3.51, p = 0.0651). Examination of the learning 
curves across days 2-5 from trial 4 of the previous day to trial 1 of the next 
day (Figure 3c) led me to contrast males and females separately. Aged-
Cog Prac females performed better than Aged-Swim Only females 
(F[1,34]=6.26, p = 0.0017), an effect not found in males (F[1,39] = 1.03, p 
= 0.7280, Figure 3c). These RM Morris Maze results suggest that females, 
but not males, transferred the benefits of a lifetime of RM cognitive 
.  
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practice to a novel RM task in a novel environment. The evaluation of the 
Morris maze probe trial revealed that each treatment group localized to 
the previously platformed quadrant, indicated by a higher percentage of 
total swim distance traveled in the target NE quadrant as compared to the 
opposite SW quadrant (F[1,158] = 374.49, p < 0.0001, Figure 3d). The 
Aged-Cog Prac group and the Aged-Swim Only group did not show 
different patterns of quadrant preference (NE quadrant F[1,73] = 0.50, p = 
0.4838; SW quadrant F[1,73] = 1.22, p = 0.2724, Figure 3d), nor did they 
differ for number of platform crossings (F[1,73] = 0.11, p = 0.7461, Figure 
3e). These results suggest that all animals were able to localize the 
platform quadrant and that cognitive practice did not alter this ability. For 
WM performance on the WM and RM WRAM, there was a significant 
cognitive practice contrast on the composite of WMI errors for the last 4 
days of testing when WM load was the highest on trial 4 alone (F[1,75] = 
4.93, p = 0.0294, Figure 3f). This indicates that both male and female RM 
cognitive practice animals were able to transfer the benefits of a lifetime of 
RM cognitive practice to a novel WM task in a novel environment
The effects of cognitive practice to obviate or attenuate age-
related memory decline (Young-Naïve vs. Aged-Cog Prac, age with 
cognitive practice contrast). 
. 
For the RM T-Maze, the age with cognitive practice contrast was 
significant for all days and trials, and for the last 3 days of testing for all 
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test trials. Aged-Cog Prac animals outperformed Young-Naïve animals (for 
all days F[1,71] = 16.46, p < 0.0001; for the last 3 days F[1,71] = 12.57, p 
= 0.0007, Figure 4a), suggesting that a lifetime of RM cognitive practice 
enhanced performance on the cognitive practice RM task.  
Further analyses revealed that cognitive practice protected against 
age-related memory decline on the RM Morris Maze for overnight 
retention in females, as the young animals did not differ from aged 
animals that received cognitive practice (a significant contrast was not 
found (F[1,34] = 1.19, p = 0.2823, Figure 4b). For WRAM WMI errors, I 
found that cognitive practice attenuated age-related memory decline since 
Aged-Cog Prac animals outperformed the Aged-Swim Only group, but the 
Aged-Cog Prac group did not outperform the Young-Naïve group 
(summed across the last 4 days of testing on trial 4 alone (F[1,75] = 6.86, 
p = 0.0107, Figure 4c). When examining the probe trial on the Morris 
maze, I found the age with cognitive practice contrast was not significant 
when assessing percent swim distance in the NE and SW quadrants (NE 
F[1,73] = 1.29, p = 0.2604; SW F[1,71] = 1.50, p = 0.2241, Figure 3d). 
This indicated that the Young-Naïve and Aged-Cog Prac groups did not 
differ in their ability to localize the previously platformed quadrant. 
However, the age with cognitive practice contrast evaluating the number 
of platform crossings revealed that the Young-Naïve group made more 
crossings as compared to the Aged-Cog Prac group (F[1,73] = 9.48, p = 
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0.0029, Figure 3e). Collectively, these data suggest that although all 
animals were able to localize the general vicinity of platform location to the 
previously platformed quadrant of the maze, young animals were better 
able to localize to the specific previous platformed location. 
The effects of the procedural components of cognitive practice 
on memory (Aged-Naïve vs. Aged-Swim Only; procedural component 
contrast). 
An analysis of the WM and RM WRAM revealed a significant 
procedural component contrast on the composite created for WMC errors 
for all days and trials (F[1,75] = 9.97, p = 0.0023, Figure 4d); Aged-Swim 
Only animals committed more WMC errors as compared to the Aged-
Naïve group. When evaluating the ability of Aged-Naïve and Aged-Swim 
Only animals to localize the platform on the probe trial for the RM-Morris 
maze, the Aged-Naïve group did not differ from the Aged-Swim Only 
group (NE quadrant percent distance F[1,73] = 0.35, p = 0.5564; SW 
quadrant percent distance F[1,73] = 0.58, p = 0.4469, Figure 3d; number 
of platform crossings F[1,71] = 0.58, p = 0.4469, Figure 3e). This indicates 
that that being exposed to the procedural components cognitive practice 
does not attenuate age-related changes in memory. In fact, exposure to 
the procedural components of cognitive practice may impair WM 
performance when aged.  
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The effects of age (Young-Naïve vs. Aged-Naïve; age without 
cognitive practice contrast).  
 The Young-Naïve group consistently outperformed the Aged-Naïve 
group on some measures of the RM Morris Maze (overnight retention in 
females F[1,34] = 13.35, p = 0.0009, Figure 5b; number of platform 
crossings F[1,73] = 12.44, p = 0.0007, Figure 3e) and the WRAM (WMI for 
all days and trials F[1,75] = 6.89, p = 0.0105; WRM for all days and trials 
F[1,75]=16.70, p = 0.0001; WMC across the last 4 days of testing for all 
test trials F[1,75] = 9.62, p = 0.0027, Figure 5c; WMI across the last 4 
days of testing for all test trials F[1,75] = 11.23, p = 0.0013; WRM across 
the last 4 days of testing for all test trials F[1,75] = 23.29, p < 0.0001; WMI 
across the last 4 days of testing for trial 4 alone F[1,75] = 9.77, p = 0.0025, 
Figure 5d). The age without cognitive practice contrast evaluating the 
composites of the RM T-Maze was not significant (for all days and trials 
F[1,71] = 0.54, p = 0.4669; for the last 3 days of testing and all trials 
F[1,71]=1.35, p = 0.2490, Figure 5a), indicating a lack of an age effect on 
this task. I also did not find a significant age without cognitive practice 
contrast for RM Morris Maze platform localization via my quadrant data, 
indicating that young and aged animals all learned the quadrant that 
contained the platform (NE quadrant percent distance F[1,73] = 1.75, p = 
0.1902; SW quadrant percent distance F[1,71] = 2.58, p = 0.1123, Figure 
3d).  
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Neurotrophin Contrast Analyses 
 For the cognitive practice contrast comparing Young-Naïve animals 
to Aged-Cog Prac animals, the Aged-Cog Prac group had significantly 
higher levels of NGF levels as compared to the Young-Naïve group in the: 
striatum (F[1,83] = 9.40, p = 0.0029), frontal cortex (F[1,84] = 6.71, p = 
0.0113), parietal cortex (F[1,84] = 4.49, p = 0.0370), and temporal cortex 
(F[1,84] = 4.59, p = 0.0351) (Figure 6a). Since these NGF level increases 
were found in the Aged-Cog Prac group without concomitant significant 
contrasts between the Young-Naïve and Aged-Naïve groups, or the 
Young-Naïve and Aged-Never Test groups, it appears that age and 
cognitive practice act together to increase NGF levels in the striatum, 
frontal cortex, and temporal cortex of rats. I found a significant age without 
cognitive practice contrast (Young-Naïve vs. Aged-Naïve) for parietal 
cortex NGF levels (F[1,84] = 4.67, p = 0.0335, Figure 6b), and another 
significant contrast for parietal cortex NGF levels between the Young-
Naïve and Aged-Never Test groups (F[1,84] = 7.11, p = 0.0092, Figure 
6c). This suggests that in the parietal cortex, age and not cognitive 
practice likely results in the observed NGF level increase in this brain 
region, since aged animals who received cognitive practice, aged animals 
that never received cognitive practice/testing, and aged animals that were 
only tested on the final battery all had increased parietal cortex NGF levels 
in comparison to young animals. Interestingly, the collected data indicate 
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that cognitive demand was necessary for the NGF level increase observed 
in aged animals within the striatum, frontal cortex, and temporal cortex. 
Regression Analyses: Relationships Between Memory Performance 
When Young and NGF Levels When Aged 
I conducted primary regression analyses relating ventral 
hippocampal and frontal cortex NGF levels to RM T-Maze performance 
during the Cog Prac group’s first cognitive practice session when they 
were 6 months of age. Specifically, RM T-Maze correct entries summed 
across all days and trials was the predictor variable, and NGF levels in the 
ventral hippocampus (CA1/2) and frontal cortex were the outcome 
variables. For male and female Aged-Cog Prac animals, there was a 
positive relationship between the number of correct arm entries made at 6 
months of age and ventral hippocampal NGF levels assessed when aged 
(b = 0.10, r = 0.59, z[19] = 2.72, p = 0.0065, Figure 7a); this association 
was not found in the frontal cortex. Since one of my primary research 
questions was to evaluate sex differences, I conducted these same 
regression analyses in males and females separately. For female Aged-
Cog Prac animals, there was a positive relationship between the number 
of correct arm entries made at 6 months of age and the measure of aged 
ventral hippocampal NGF levels (pg/mg) (b = 0.13, r = .79 z[8] = 2.39, p = 
0.0169, Figure 7b), as well as aged frontal cortex NGF levels (pg/mg) (b = 
0.26, r = .71 z[8] = 2.00, p = 0.0457, Figure 7c). These relationships were 
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not found when male Aged-Cog Prac animals were evaluated alone, 
suggesting that females were responsible for the association between 
young RM performance and aged hippocampal NGF levels. Taken 
together, these associations suggest that in females, better RM 
performance when young is related to higher levels of hippocampal and 
frontal cortex NGF when aged. 
Linear Growth Modeling 
An assessment of RM T-Maze performance across the first RM 
practice session via linear growth modeling revealed that 6 month old Cog 
Prac males and females made approximately four correct arm choices on 
the first day of RM T-Maze practice (Intercept/initial performance; B0 = 
4.03, p < .000). This analysis also revealed that 6 month old Cog Prac 
males and females learned the RM T-Maze at the rate of one-half of a 
correct arm entry per day (Slope/change per day; B1 = 0.45, p < 0.000, 
Figure 2a). Further analyses indicated that 6 month old female Cog Prac 
animals on their own across the first RM cognitive practice session made 
approximately three and a half correct arm entries on the first day of RM 
T-Maze practice (Intercept/initial performance; B0 = 3.56, p = 0.000, Figure 
2b) and learned at the rate of roughly one-half
When comparing 6 month old male and female Cog Prac animals 
on their performance during the first day of RM T-Maze practice as well as 
 of an additional correct arm 
entry per day (Slope/change per day; B1 = 0.58, p = 0.000, Figure 2b). 
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the rate at which they learned the RM T-Maze across the first RM practice 
session (i.e., intercept/initial performance and slope/change per day, 
respectively), the linear growth model revealed that 6 month old male Cog 
Prac animals made one additional correct arm entry on the first day of RM 
T-Maze practice as compared to 6 month old Cog Prac females (B2 = 
0.96, p = .003). In contrast, 6 month old male Cog Prac animals learned 
the RM T-Maze practice task at the rate of a third
Lastly, when relating the rate at which 6 month old Cog Prac males 
and females learned the RM T-Maze across the first RM practice session 
(i.e., slope/change per day) to the Novel Aged Global Memory Composite, 
I found a positive relationship between how fast Cog Prac males and 
females learned the RM T-Maze when young and their novel global 
memory performance when aged (i.e., a positive relationship between 
slope/change per day to the Novel Aged Global Memory Composite). 
Specifically, Cog Prac males and females that learned the RM T-Maze at 
a faster rate when young (i.e., 6 months of age) had enhanced WM and 
 of a correct arm entry 
per day less across the first RM practice session when compared to 6 
month old Cog Prac females (B3 = -0.27, p = 0.001). This suggests that 6 
month old Cog Prac males performed better than 6 month old Cog Prac 
females on the first day of RM T-Maze practice; however, 6 month old Cog 
Prac females learned the RM T-Maze practice task during the first practice 
session at a faster rate when compared to 6 month old Cog Prac males. 
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RM assessed on novel tasks during the final battery when aged (i.e., 21 
months of age) (B = 3.37, p ≤ .05, Figure 2b). The relationship between 
rate of learning when young (i.e., slope/change per day) and novel global 
memory performance when aged (i.e., the Novel Aged Global Memory 
Composite) was strong by conventional standards (see Cohen, 1988), as 
evidenced by a high Pearson r value (r = 0.83, p = 0.003). Collectively, 
these data suggest that young 6 month old male and female animals 
differed in their RM performance on the first day of RM T-Maze practice as 
well as the rate at which they learned the RM T-Maze task across the first 
RM practice session. These data also highlighted an exciting positive 
relationship between RM learning rate when young and global memory 
performance when aged. 
Discussion 
The primary findings in this study were that: a) cognitive practice 
enhanced RM performance for males and females on the cognitive 
practice task, b) cognitive practice attenuated age-related WM changes on 
a novel WM task for males and females, c) cognitive practice protected 
against age-related memory changes for overnight retention on a novel 
RM task for females only, e) cognitive demand was necessary for 
protection against age-related memory changes, f) age and cognitive 
practice acted together to alter NGF levels in the striatum, frontal cortex, 
and temporal cortex, g) better RM performance when young was related 
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to higher levels of hippocampal and frontal cortex NGF when aged in only 
females, and h) the faster an animal learned the cognitive practice task 
when young the better its global memory performance when aged. As 
outlined in the Introduction, several questions were specifically addressed 
in this study. The question and corresponding answer, as addressed by 
the current study, follow. 
 1. Does RM Cognitive Practice Prevent Loss Only the RM Domain, or 
Does it Extend Protection into the WM Domain?  
RM cognitive practice appears to protect in its own domain, as well 
as extending global protection into the WM domain. The results suggest 
that RM cognitive practice helped both aged male and female animals to 
handle an increasing WM load (i.e., effect found for trial 4 alone on the 
WRAM) on a novel WM task, and attenuated the age-related WM decline 
found on the WRAM in this and other studies (Bimonte-Nelson et al., 
2003c; Bimonte et al., 2002; Bimonte et al., 2003). Thus, the results 
indicate that RM cognitive practice exerts a global protection, including to 
WM systems. Since the Aged-Cog Prac males and females performed 
better on the RM T-Maze cognitive practice task during the final battery 
when compared to Aged-Swim Only and Young-Naïve animals, for both 
sexes RM cognitive practice protected in its own memory domain as well. 
However, this is not entirely clear as I did not find an age effect on the RM 
T-Maze during the final battery (i.e., Young-Naïve vs. Aged-Naïve 
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animals). This lack of an age effect corroborates previous research where 
no age effects were found on a land T-Maze except in the type of strategy 
that young and aged animals were more likely to use (i.e., aged = 
response and young = place) (Barnes et al., 1980). In females only, RM 
cognitive practice protected within its own domain on a novel RM task; on 
the RM Morris Maze for overnight retention, there was an age effect: 
Aged-Cog Prac females performed better than Aged-Swim Only females, 
and Aged-Cog Prac females did not differ from Young-Naïve females. 
Collectively, RM cognitive practice initiates a global protection into the WM 
domain, an effect that was observed on a novel WM task. Cognitive 
practice likely protected against age-related memory changes on the 
cognitive practice RM task and attenuated age-related WM deficits on a 
novel task. Interestingly, only females showed a cognitive practice-
facilitated enhancement in novel RM task performance that was protected 
against age-related memory changes. 
2. Is Age-Related Cognitive Protection Due to Cognitive Practice 
Only Seen When the Aged Assessment Task Is the Same as the 
Cognitive Practice Task? 
The present study found that cognitive practice can protect against 
age-related decline on novel tasks. Results revealed that a lifetime of 
cognitive practice protects memory on a novel WM task (i.e., WRAM) for 
males and females and a novel RM task (i.e., Morris Maze) for females 
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only. Since these effects were observed on mazes novel to the cognitive 
practice groups, the effects could not simply be due to familiarity or prior 
experience with the task. The enhanced ability of the Aged-Cog Prac 
group as compared to the Aged-Swim Only group on the RM T-Maze 
during the final battery is most likely due to retention and not relearning of 
the platform location since their last cognitive practice session, as scores 
were essentially asymptotic after the first cognitive practice session and 
persisted to the last session at 18 months. Hence, cognitive practice 
benefits are not just seen on the cognitive practice task, but transfer to 
novel tasks as well, an effect that differs by sex. 
3. Is Memory Protection From Cognitive Practice Due to the 
Procedural Components of Testing or the Cognitive Demand of the 
Maze Task? 
 This study found that rats receiving only the procedural aspects of 
the task exhibited no protection against age-related memory decline. 
Indeed, in the Aged-Swim Only group, animals had to swim to find the 
platform without having to decide the correct arm in the water escape T-
Maze; thus, cognitive demand was minimized. Across all measures, Aged-
Swim Only animals did not outperform Aged-Naïve animals. In fact, Aged-
Swim Only animals demonstrated worse WM performed in comparison to 
the Aged-Naïve group on the WM and RM WRAM task (i.e., WMC errors). 
I decided to use the Aged-Swim Only group as the reference group to 
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analyze the effects of a lifetime of cognitive practice, as these animals had 
a similar non-cognitive experience to the Aged-Cog Prac group (i.e.,. 
stress, handling, and possible enrichment); thus, I thought it was safe to 
assume that the only difference between the Aged-Swim Only and Aged-
Cog Prac groups was cognitive demand. Taken together, this suggests 
that cognitive demand is necessary for a lifetime of practice to enhance 
aged memory performance or attenuate/obviate age-related memory 
changes.  
4. Do Males and Females Differ When Comparing Their Memory and 
the Effects of Cognitive Practice?  
I noted several differences between male and female animals. 
Specifically, the linear growth model revealed that male and female 
animals differed in their initial performance and how fast they acquired the 
RM T-Maze when young. However, all Aged-Cog Prac animals reached 
and maintained near asymptotic performance by the end of their first 
cognitive practice session, thereby limiting the possibility that the sex 
differences in relation to cognitive practice were due to differential learning 
of the cognitive practice task. Furthermore, aged females were the only 
group to transfer the benefits of cognitive practice to a novel RM task (i.e., 
RM Morris Maze overnight retention), and females were the ones to show 
the relationship between young RM performance and aged NGF levels. 
Taken together, this suggests that the ovary intact female is more 
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behaviorally plastic than their male counterparts, an effect perhaps related 
to their hormonal milieu and/or trophic systems. 
5. Does Cognitive Practice Alter Cognitive and Motor Brain Region 
Specific Levels of NGF? 
I found that that age and cognitive practice likely act together to 
increase NGF levels in the striatum, frontal cortex, and temporal cortex of 
male and female rats, while only age likely results in the observed NGF 
increase in the parietal cortex. Neurotrophins may be one mechanism of 
how cognitive practice enhances aged performance or attenuates age-
related cognitive changes. Survival and maintenance of cholinergic 
neurons are dependent upon neurotrophins, including NGF, and NGF has 
been associated with cognitive function (Bimonte-Nelson et al., 2008; 
Bimonte et al., 2003; Granholm, 2000; Levi-Montalcini, 1987; Siegel and 
Chauhan, 2000; Woolf, 1991). Thus, cognitive practice likely alters NGF to 
enhance synaptic efficacy or cholinergic activity, both of which have 
positive effects on memory and may explain why cognitive practice 
enhanced performance in the aged males and females. 
6. Is Memory Performance When Young Related to Aged Brain 
Region Specific Levels of NGF? 
Via regression analyses I noted sex-specific associations between 
RM performance when young and NGF levels when aged in cognitive 
brain regions. Specifically, the relationship between better RM 
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performance when young and higher levels of hippocampal and frontal 
cortex NGF levels when aged was found only in the female Aged-Cog 
Prac group. My lab and others have found associations between brain 
region NGF levels and memory (Albeck et al., 2005; Bimonte et al., 2003), 
and my lab has previously noted associations between frontal cortex 
brain-derived neurotrophic factor (BDNF) and memory in Ts65Dn mice 
and female rats (Bimonte-Nelson et al., 2003a; unpublished observations). 
Collectively, this suggests that memory performance when young is 
related to NGF levels when aged, an effect seen in females only. 
7. Is the Rate at Which Animals Learned the Cognitive Practice Task 
When Young Related to How They Perform When Aged? 
Indeed, I found a positive relationship between aged memory 
performance and “rate of change/learning” (i.e., slope of the growth 
model) when young. This finding is corroborated in part by another study 
where a negative relationship was found between late-onset dementia and 
“level” of mental ability when young (Whalley et al., 2000). Collectively, 
these data suggest that cognitive faculty measured early in life can predict 
aspects of aged memory in both rats and humans.  
General Discussion 
To my knowledge, the current study is the first single study to 
specifically address and fully evaluate several gaps in our understanding 
of the effects of cognitive practice on male and female rats. Overall, the 
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results show that spatial WM and RM decline with age, and that some of 
these age-related effects can be attenuated or obviated by cognitive 
practice. The finding that cognitive practice attenuates or obviates age-
related changes in RM corresponds to other studies finding this same 
effect in males (Dellu et al., 1997; Markowska and Savonenko, 2002b; 
Pitsikas et al., 1991). The current study extends these works by showing 
that it is specifically the cognitive demand that is protective. Additionally, it 
is specifically RM cognitive practice that enhanced RM in both sexes. As 
previously shown in other studies on the WM and RM WRAM (Bimonte-
Nelson et al., 2003c; Bimonte et al., 2002; Bimonte et al., 2003), I found 
that Aged-Naïve male and female rats showed an age-related memory 
decline in comparison to their Young-Naïve counterparts. This finding is 
also apparent on the RM Morris Maze in females, where Aged-Naïve 
animals exhibited poorer performance when compared to the Young-
Naïve group. These findings are consistent with others showing age-
associated memory decline on the RM Morris Maze (Markowska and 
Savonenko, 2002b; Pitsikas et al., 1991). Studies report that both RM and 
WM cognitive practice given to the same animals did not attenuate age-
related WM decline (Dellu et al., 1997). Yet, others found that extensive 
WM cognitive practice (Bierley et al., 1986), or WM and RM cognitive 
practice (Markowska and Savonenko, 2002b), attenuated or reversed age-
related WM decline. Thus, this study extends the previous findings by 
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showing that in both males and females, RM cognitive practice attenuated 
age-related WM changes. In addition, given that the Aged-Swim Only 
group did not show protection against age-related memory changes on 
any measure, the cognitive demand placed on the animals by the 
cognitive practice task was likely the reason why this study found age-
related protection due to maze testing throughout life. The effects were not 
due to familiarity with the task or the handling by the experimenter that 
coincides with maze testing.  
I would be remiss if I did not note the possibility that exercise 
played a role in the ability of cognitive practice to attenuate age-related 
memory changes. Studies have reported in rodents that exercise on a 
treadmill or running wheel enhances spatial memory on the radial-arm 
maze (Anderson et al., 2000), Morris maze (Liu et al., 2011), and the T- 
and Y-Mazes (Pang et al., 2006). However, the possibility that exercise 
was responsible for the effects of cognitive practice in the current study is 
diminished by the fact that exposure to the procedural components of 
testing (i.e., the Aged-Swim Only group), which included all the motoric 
and swimming (i.e., exercise) components of cognitive practice with 
minimal cognitive demand, did not enhance performance. This suggests 
that RM cognitive practice can attenuate age-related memory changes, an 
effect that is not linked solely to exercise. The next step is to fully elucidate 
the associated neurobiological changes, and how these effects are 
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modulated by sex. Spatial memory is intimately linked to hippocampal 
functioning, and researchers have suggested that learning may influence, 
and be dependent on, cell proliferation in the dente gyrus of the 
hippocampus (Klempin and Kempermann, 2007). Recently, in male rats 
who had the best performance on the RM Morris Maze, Drapeau et al. 
(2007) found that cells in the dentate gyrus generated before learning had 
occurred had an increased rate of survival, while those that were 
generated after the initial learning phase had a decreased rate of survival. 
The tenet that the integration of new neurons into existing neural networks 
may confer plasticity and thus enhance ability for learning and memory 
when aged is an exciting explanation for the present results. Adult 
neuronal neogenesis facilitated via learning and memory processes 
supports the hypothesis that you “use it or lose it”, as well as supporting 
the hypothesis that there is a mechanism for developing a “cognitive 
reserve” (Katzman et al., 1988). It may be that the demand of storing 
information long-term (i.e., RM), which increases the survival rate and 
integration of neurons from the dentate gyrus, enhances spatial memory in 
aged animals who have had a lifetime of cognitive demand.  
Aside from newly generated neurons, another theory is that the 
biological underpinnings of memory may also be influenced by cognitive 
practice. Synaptic plasticity, thought to be the neurobiological correlate of 
memory, has been extensively studied under the paradigm of long-term 
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potentiation (LTP) and long-term depression (LTD) (see Bliss et al., 2003). 
LTP and LTD paradigms reveal that correctly timed presynaptic and 
postsynaptic high frequency bursts of current can alter many proteins in 
the area of the synapse (i.e., synaptic plasticity), leading to an alteration in 
the amplitude of excitatory postsynaptic currents, with the summed 
alteration in excitatory postsynaptic currents of numerous synapses being 
the hypothesized engram (see Bliss et al., 2003). LTP paradigms have  
also been shown to increase dendritic spine formation (Harris et al., 2003), 
and previous literature has found that memory decline in aged rats is 
related to decreased dendritic spine density (Wallace et al., 2007), but not 
the postsynaptic protein spinophilin (Calhoun et al., 2008). Taken 
together, it is conceivable to think that the neural activity generated by 
cognitive practice may be similar to the neural activity necessary to 
experimentally generate LTP and LTD, in turn enhancing synaptic 
plasticity and synaptic spine number. Collectively, this suggests that 
cognitive practice may lead to enhancements in neural activity, synaptic 
plasticity, and synaptic spine number, which may be responsible for the 
presently observed effects of cognitive practice.  
 One possibility for the sex differences found in this study is related 
to the work showing that ovarian hormones have a profound effect on 
neurotrophin systems. E2 is most potent activator of the classical genomic 
pathway and the primary export product of a woman’s ovary (Prokai et al., 
  
52 
2003). Neurotrophin and neurotrophin receptor mRNA levels have been 
found to fluctuate across the estrus cycle (Gibbs, 1998). E2 treatment 
significantly impacts neurotrophins in young and aged Ovx rats (i.e., rats 
with their endogenous source of E2 removed) by increasing neurotrophin 
protein mRNA as well as neurotrophin receptor (e.g., TrkA) mRNA levels 
in the BF, frontal cortex, and hippocampus (Gibbs, 1998; McMillan et al., 
1996; Pan et al., 1999), and elevating NGF protein levels in cognitive brain 
regions (Bimonte-Nelson et al., 2004a). Taken together, this suggests that 
E2 alters the neurotrophic system (i.e., neurotrophins and neurotrophin 
receptor levels) in cognitive brain regions; this may be one reason why 
females appeared more behaviorally plastic, which allowed them to 
transfer a lifetime of RM cognitive practice to the novel RM Morris Maze. 
Indeed, this tenet is supported by the fact that females appeared to be 
responsible for the association between young RM performance and aged 
hippocampal and frontal cortex NGF levels, two brain regions necessary 
for RM and WM performance (Balota et al., 2000; Eichenbaum, 2000; 
O'Keefe and Nadel, 1978). It is conceivable that E2 facilitates female 
alterations in trophic systems that may enhance cognitive brain regions in 
a manner that facilitates behavioral plasticity and a better cognitive aging 
profile in comparison to males.  
In conclusion, males and females differed in their initial 
performance on the cognitive practice task when young. When aged, 
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males and females benefited from cognitive practice on the cognitive 
practice RM task and a novel WM task, but only females transferred this 
benefit to a novel RM task. Furthermore, aged NGF levels were altered by 
cognitive practice and age, and were related to young memory 
performance only in females. Lastly, the faster an animal learned the 
cognitive practice task when young the better his or her aged memory 
performance, suggesting a link between genes and/or early life experience 
and the formation of a “cognitive reserve” that ultimately alters the 
trajectory of age-related cognitive changes. Future research using both 
males and females could be conducted in order to assess the effects that 
cognitive practice has on cholinergic tone, excitatory synapses, and the 
effects and interactions that neurotrophins have on these systems. 
Specifically, this could be done by evaluating if neurotrophins and 
cognitive practice alter ACh levels and the number of glutamate receptors 
in cognitive brain regions. Finally, since dendritic spines are thought to be 
the functional neuroanatomical units of plasticity whereby learning and 
memory occur, a direct evaluation of the changes in dendritic spines as a 
result of a lifetime of cognitive practice may yield exciting information. 
Collectively, this information could one day lead to new treatments and 
therapies to prevent, attenuate, or reverse, age and disease related 
memory decline, thereby reducing the strain that aging and dementia 
places on individuals, their families, and the public health system.  
  
54 
CHAPTER 3 
HIGHER LEVELS OF ESTRADIOL REPLACEMENT CORRELATE WITH 
BETTER SPATIAL MEMORY IN SURGICALLY MENOPAUSAL YOUNG 
AND MIDDLE-AGED RATS 
There is abundant clinical and basic science evidence that 
estrogens impact cognitive function (Dohanich, 2002). Since the first 
controlled clinical evaluation showing that estrogen injections given to 75 
year-old women enhanced memory (Caldwell and Watson, 1952), there 
have been numerous studies showing cognitive decline after ovarian 
hormone loss, and enhancement after estrogen treatment, in menopausal 
women (Sherwin, 2006). However, several newer clinical studies, 
including the large, placebo-controlled, multi-center Women’s Health 
Initiative Memory Study (WHIMS), have indicated that certain regimens of 
hormone treatment (e.g., use of CEE with or without 
medroxyprogesterone acetate [MPA]) can have no effect on, or even be 
detrimental to, cognition and dementia risk in women (for review see 
Coker et al., 2010). 
A majority of the animal studies evaluating the effects of estrogens 
on learning and memory have been performed in young rodents (See 
Chapter 1). While there has been a recent increase in the number of 
studies evaluating estrogen effects in middle-aged or older female 
rodents, most using the most potent estrogen, E2 (Bimonte-Nelson et al., 
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2006; Foster et al., 2003; Frick et al., 2002; Gibbs, 2000b; Luine and 
Rodriguez, 1994; Markham et al., 2002; Markowska and Savonenko, 
2002a; Savonenko and Markowska, 2003; Ziegler and Gallagher, 2005), 
there is only limited work comparing estrogen treatment effects in Ovx 
animals at different ages within the same study (Foster et al., 2003). 
Hence, it is still a question whether age changes responsiveness to 
ovarian hormone replacement. This is a clinically important question, as 
some menopausal women begin HT at a younger age, while some start 
later in life. Women in the WHIMS were 65 years of age and over, which 
may have played a critical role in the lack of efficacy of estrogen treatment 
since age may impact responsiveness (Craig et al., 2005). 
Animal work that has been done testing E2 treatment at multiple 
ages showed that administered E2 dose impacted spatial memory 
retention, and that these effects acted together with age in Ovx rodents 
(Foster et al., 2003). My Lab and others have also noted divergent 
cognitive effects depending on administered estradiol dose in mice and 
rats (Bimonte-Nelson et al., 2006; Bimonte and Denenberg, 1999; El-Bakri 
et al., 2004; Frick et al., 2002; Gresack and Frick, 2004; Holmes et al., 
2002; Packard and Teather, 1997; Rissanen et al., 1999). In these 
studies, however, serum hormone levels were estimated based on prior 
studies or manufacturer reports (Bimonte-Nelson et al., 2006; Bimonte 
and Denenberg, 1999; El-Bakri et al., 2004; Frick et al., 2002; Gresack 
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and Frick, 2004; Holmes et al., 2002; Packard and Teather, 1997; 
Rissanen et al., 1999), or circulating E2 levels were determined but 
statistical correlations with performance were not reported (Foster et al., 
2003). In fact, in no animal study testing estrogen treatment have serum 
levels within individual animals been correlated with memory scores. 
There may be a positive correlation between circulating estrogen level and 
memory, as seen with endogenous levels in healthy menopausal women 
(Phillips and Sherwin, 1992; Wolf and Kirschbaum, 2002) , and after 
exogenous estradiol administration to postmenopausal women with 
probable mild to moderate AD (Asthana et al., 1999). Alternatively, the 
relation between serum estrogen level and memory could hold to an 
inverted U-shaped function, whereby very low or very high values result in 
the poorest cognitive function. Many biological systems fit this quadratic 
function (Bimonte et al., 2002), and low, but not high, estradiol levels have 
been associated with better cognitive performance in older women 
(Barrett-Connor and Goodman-Gruen, 1999). Hence, while some studies 
suggest that estrogen treatment influences cognition in women and the 
rodent model, the relation between circulating level of estrogen and 
memory performance is unclear. 
My Lab previously showed that Ovx did not influence spatial RM 
performance in middle-aged female rats (Bimonte-Nelson et al., 2006). 
Yet, in this age group E2 treatment resulted in marked enhancements in 
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spatial RM performance (Bimonte-Nelson et al., 2006). These data 
suggest that (1) naturally circulating, endogenous estrogen in an ovary-
intact individual may relate to cognition in a different way than 
exogenously administered estrogen due to replacement after Ovx, and (2) 
sensitivity to ovarian hormone loss does not predict sensitivity to estrogen 
replacement for spatial RM. My Lab and others have shown, in young rats, 
WM deficiencies after Ovx and enhancements after estradiol treatment 
(Bimonte and Denenberg, 1999; Daniel et al., 1997; Daniel et al., 1999; 
Holmes et al., 2002; Sandstrom and Williams, 2001). Additionally, in 
middle-aged rats no RM deficiencies were seen after Ovx, but benefits of 
estradiol treatment were observed (Bimonte-Nelson et al., 2006). While 
suggestive of differences in response to ovarian hormone loss and 
treatment depending on age, these separate studies could have been due 
to memory type and not age. 
The current studies examined the spatial RM effects of Ovx and E2 
treatment in young, middle-aged and aged rats. my lab and others have 
found significant variability in circulating E2 levels after treatment with the 
same manufacture-labeled dose of E2 pellets from Innovative Research of 
America (unpublished observations; Diel et al., 2005). Here I capitalized 
on this range of serum E2 levels to investigate relation with memory 
scores. Circulating E2 levels were determined in all animals with the 
intention of correlating these values with maze performance. I performed 
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correlation analyses in animals that were ovary-intact to determine 
associations between endogenous E2 levels and performance, and within 
animals that had received Ovx plus E2 treatment to determine relations 
between exogenous
Bimonte-Nelson et al., 2006
 E2 levels and performance. The relation between 
circulating E2 and cognition may be affected by whether the E2 is 
endogenous (via an intact ovary) or exogenous (experimentally 
administered) due to presence of progesterone in ovary-intact animals 
( ; Bimonte-Nelson et al., 2004a; Bimonte-
Nelson et al., 2004b; Johansson et al., 2002; Nilsen and Brinton, 2002a; 
Nilsen and Brinton, 2002b; Woolley and McEwen, 1992), as well as the 
cyclicity of E2 exposure (e.g. cyclic from the ovary vs. a tonic regimen of 
treatment; Bimonte-Nelson et al., 2006; Bimonte-Nelson et al., 2004b; 
Gibbs, 2000b; Johansson et al., 2002; Markowska and Savonenko, 
2002a; Nilsen and Brinton, 2002a; Nilsen and Brinton, 2002b; Woolley and 
McEwen, 1992).  
Methods 
Subjects and Treatment Procedures 
For Study 1, subjects were 34 young (4 months old at test) and 33 
middle-aged (16 months old at test) Fischer-344 female rats born and 
raised at the National Institute on Aging at Harlan Laboratories 
(Indianapolis, IN). After arrival, animals were pair housed, had exposure to 
food and water ad lib, and were maintained on a 12-h light/dark cycle. All 
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procedures were approved by IACUC and adhered to NIH standards. 
Each young and middle-aged group contained the following treatment 
groups: ovary-intact sham (Sham), Ovx with no hormone treatment (Ovx), 
Ovx plus a 0.25 mg/60 day release E2 pellet and Ovx plus a 0.50 mg/60 
day release E2 pellet. Thus, there were a total of eight groups: Young-
Sham (n=8), Young-Ovx (n=9), Young-Ovx + 0.25 E2 pellet (n=8), Young 
Ovx + 0.50 E2 pellet (n=9), Middle-aged-Sham (n=8), Middle-aged-Ovx 
(n=9), Middle-aged Ovx + 0.25 E2 pellet (n=8), and Middle-aged Ovx + 
0.50 E2 pellet (n=8). Ovx surgery was performed two months before 
testing at 2 and 14 months of age for young and middle-aged groups, 
respectively. Rats were anesthetized with an intraperitoneal injection of 70 
mg/kg ketamine (Fort Dodge Animal Health, Fort Dodge, IA, USA)/and 6 
mg/kg xylazine (Lloyd Laboratories, Shenandoah, IA, USA). For Ovx, 
bilateral dorsolateral incisions were made in the skin and peritoneum, and 
the ovaries and tips of uterine horns were ligatured and removed. The 
muscle was then sutured and the skin stapled. Sham surgery consisted of 
skin incision and staple in the same fashion. 
E2 treatment via pellets (Innovative Research of America, 
Sarasota, Florida) was administered one month after Ovx, one month 
before testing ensued, at 3 months old for young rats, and 15 months old 
for middle-aged rats. Since pellets released hormone for 60 days, animals 
with the pellets received E2 for the entire study, including during 
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behavioral testing and through sacrifice. Under Ketamine/Xylazine 
anesthesia, a small incision was made in the scruff of the neck, and a 
subcutaneous pocket was created. For animals receiving E2, one pellet of 
the appropriate dose was inserted and the skin stapled. The groups not 
receiving E2 treatment (Sham and Ovx groups) received a sham pellet 
surgery, which included identical procedures except the pocket was left 
empty. 
For Study 2, subjects were 6 young (4 months old at test) and 21 
aged (24 months old at test) Fischer-344 female rats born and raised at 
the aging colony of the National Institute on Aging at Harlan Laboratories 
(Indianapolis, IN). There were a total of four groups in Study 2: Young-
Sham (n=6), Aged-Sham (n=6), Aged-Ovx (n=7), and Aged-Ovx-E (n=7). 
Just one type of E2 pellet was chosen for this study (0.25 mg pellet) since 
the variability and mean levels were comparable between the 0.25 and 
0.50 doses in Study 1. The timeframes and surgical procedures of Study 2 
were identical to those of Study 1. 
Assessment of Serum Hormone Levels 
For both studies, after behavioral testing rats were anesthetized 
with Halothane anesthesia and decapitated. Blood was collected from the 
trunk (Vacutainer 367986, Becton Dickinson and Company, Franklin 
Lakes, NJ), was allowed to clot at 4º C and serum was collected after 
centrifugation (3220xG, 20 min). Serum was stored at -20º C until E2 
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assays were performed by the Core Endocrinology Laboratory at 
Pennsylvania State University College of Medicine using a kit from 
Diagnostic Products Corporation, Los Angeles, CA (Coat-A-Count E2 kit, 
product number TKE21). E2 was determined in serum by a solid-phase 
radioimmunoassay based on E2-specific antibodies that are immobilized 
to the wall of polypropylene tubes and 125I -labeled E2 as the tracer 
following extraction with diethyl ether. Serum (2.4. ml) was extracted and 
the ether portion collected and evaporated to dryness. The sample was 
reconstituted in assay buffer and a competitive radioimmunoassay was 
performed using 125
Spatial RM Morris Maze Testing 
I E2 with high specific activity and a high affinity, highly 
specific antibody. Separation of bound from free was achieved with 
activated charcoal and the data reduction was performed with the use of a 
five point standard curve and purified E2 standards. The functional 
sensitivity of the assay was 5 pg/ml. The interassay precision at a 
concentration of 35 pg/ml was 8%.  
Rats in both studies received identical testing on the Morris maze, 
which consisted of a round water-filled tub with a hidden platform. The rat 
was placed in the maze from any of four locations (North, South, East, or 
West) and had 60s to locate the platform which remained in a fixed 
location throughout testing. After 15s on the platform, the rat was removed 
from the maze and placed into its heated cage until the next trial. Rats 
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were given 3 trials a day for 5 days. After the last trial on Day 5, each rat 
was given a 60s probe trial whereby the platform was removed. A video 
camera suspended on the ceiling above the maze tracked the rat’s path 
and a tracking system (SMART system, San Diego Instruments) was used 
to analyze each rat’s tracing. 
Dependent Variables and Statistical Methods 
Analyses for study 1. 
Using StatView (version 5.01, The SAS Institute Inc., Cary, NC), 
performance was assessed by swim path distance (centimeters) to the 
platform. I also analyzed swim speed (distance/time) since it can be 
affected by age, cognitive demand, and estradiol treatment; this measure 
may aid interpretation of my findings (Bimonte-Nelson et al., 2006; Foster 
et al., 2003; Markowska and Savonenko, 2002a; Markowska and 
Savonenko, 2002b). Studies 1 and 2 were analyzed separately, as were 
Distance and Speed measures. For Study 1, the E2 groups (Ovx + 0.25 
pellet and Ovx + 0.50 pellet) were combined into one group (Ovx-E; Table 
2). To analyze Study 1, I first performed an omnibus 3 x 5 x 3 mixed 
model ANOVA within each age with Treatment (Sham, Ovx, Ovx-E) as the 
between-subjects factor, and Days (1-5) and Trials (1-3) as repeated 
measures. Specific a priori, planned contrasts were run to further evaluate 
significant omnibus ANOVA main effects or interactions with Treatment. 
Unless otherwise specified, these analyses were run as described above 
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but with one between-subject factor (Treatment) comparing two groups 
(Sham vs. Ovx to determine Ovx effects, and Ovx vs. Ovx-E to ascertain 
E2 treatment effects). Post hoc comparisons across ages were used 
selectively to aid interpretation of E2-related effects. To evaluate effects of 
age, I used the same mixed model ANOVA, except Age (young vs. 
middle-aged) was the between-subject variable and the comparison was 
limited to the Sham groups.  
To assess whether rats localized the platform to the spatial location 
and to confirm that animals were not utilizing a motoric strategy to solve 
the task, the platform was removed after all testing trials were completed 
and animals’ swim distance was quantified (day 5, trial 4 was the probe 
trial). The maze was virtually divided into four equal quadrants (Bimonte-
Nelson et al., 2006). Percent of total distance in the platform quadrant 
(NE, or target) was compared to the quadrant diagonally opposite (SW). 
Rats that learned the platform location and were not using a motoric 
strategy were expected to spend the greatest percent of total distance in 
the quadrant that had contained the platform. Probe trial data were first 
analyzed using a 2 x 2 mixed model ANOVA within each age, with 
Treatment as the between-subjects variable and maze Quadrant as the 
within-subjects variable (Bimonte-Nelson et al., 2006). Unless otherwise 
specified, follow-up two group comparisons and age effects were analyzed 
as above, except Treatment or Age were the between variable. E2 levels 
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were run similar to the above procedures; post-hoc evaluations were run 
using t-tests.  
To evaluate potential relations between maze scores and E2 levels, 
multiple regression analyses and Pearson correlations were run to 
analyze E2’s association with five performance variables: distance score 
on the final test trial (day 5, trial 3), distance score averaged across all five 
days, percent of total distance in the target (NE) quadrant on the probe 
trial, speed on the final test trial, and speed averaged across all five 
testing days. I also evaluated the correlation between speed and distance, 
and speed and percent distance swum for the target (NE) quadrant on the 
probe trial. Each of these were run as follows: average of days 1-5 
distance was correlated with the average of days 1-5 speed, distance on 
the final test trial was correlated with speed on the final test trial, and the 
average of days 1-5 speed was correlated with percent distance in the 
target (NE) quadrant for the probe trial. Unless otherwise specified, 
multiple regression analysis and Pearson correlations were run within 
ovary-intact groups, within Ovx groups and within E2 treatment groups 
collapsed across young and middle-aged animals. Next, Pearson r 
correlations within each young and each middle-aged group were run 
(thus, ages run separately), for these groups. 
Analyses for study 2. 
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For Study 2, using StatView (version 5.01, The SAS Institute Inc., 
Cary, NC), distance scores, speed, and probe trial data were analyzed via 
an omnibus mixed model ANOVA within the three Aged groups (Aged-
Sham, Aged-Ovx and Aged-Ovx-E) and repeated measures as described 
above. For E2 levels, an omnibus ANOVA was run within the three Aged 
groups. Age effects and follow up two-group comparisons were run as for 
Study 1. Multiple regression analyses and correlations including E2 were 
not run for Study 2 since two serum samples from the E2 group were of 
low quality and could not be assayed for E2, limiting the sample size to 
five for the E2 treatment group. For Study 2, I evaluated the correlation 
between speed and distance, and speed and percent distance swum for 
the target (NE) quadrant on the probe trial as described for Study 1 above. 
Correlations were run first with all subjects included, then within ovary-
intact groups collapsed across young and aged groups, and then within all 
aged groups combined.  
Results 
Study 1: Effects of Ovx and E2 Treatment in Young and Middle-Aged 
Animals 
Study 1: serum E2 levels. 
The top half of Table 2 shows the mean ±SE, range and median 
serum levels of E2 for each group of young and middle-aged rats. An 
omnibus one-way ANOVA [with the two dosage levels combined for one 
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E2 treatment group] for young animals revealed a Treatment main effect 
(F[2,29] = 35.17, p < 0.0001), as seen for middle-aged animals also 
(F[2,27] = 16.13, p < 0.0001). As expected, Ovx animals exhibited lower 
E2 levels than Sham animals for young (t[15] = 2.23, p < 0.05) and 
middle-aged (t[15] = 4.97, p < 0.0002) groups, and Ovx-E animals had 
higher levels than Ovx animals for young (t[22] = 6.83, p < 0.0001) and 
middle-aged groups (t[20] = 3.81, p < 0.001). Of importance, there was 
great variability within the E2-treated rats, as anticipated and detailed in 
Table 2. There were no mean differences in E2 level between any of the 
E2-treated groups, within and across ages (ps > 0.36).  
Study 1: maze performance. 
Figure 8 depicts the learning curves across days for each treatment 
group of a) young 4 month olds and b) middle-aged 16 month olds, and 
the inset graphs show the mean ± SE distance scores for each group 
collapsed across all testing days. The omnibus mixed model ANOVA in 
young animals revealed a main effect of Treatment (F[2,29] = 3.91, p < 
0.05), and a Day x Treatment interaction (F[8,116] = 3.74, p < 0.001); 
there was no main effects of interaction with Trial. Distance scores of 
Young-Ovx rats were higher than Young-Sham rats, although this main 
effect only approached significance (F[1,15] = 4.276, p = 0.06). For this 
analysis, there was a significant Day x Ovx interaction (F[4,12] = 3.137, p 
< 0.05), with Young-Ovx rats swimming a shorter distance to the platform 
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on day 1, but a greater distance on days 2-5 as compared to Young-Sham 
rats (Figure 8a). A post-hoc test comparing these two groups on day 1 
showed that Ovx did not influence performance on this first testing day. 
However, a post-hoc repeated measures ANOVA revealed that Young-
Ovx animals swam a greater distance than Young-Sham animals for days 
2-5 (F[1,15] = 7.83, p < 0.05). Young-Ovx-E animals showed lower 
distance scores than Young-Ovx animals across all testing days (E2 
Treatment main effect: F[1,22] = 6.39, p < 0.05, Figure 8a). 
For the omnibus ANOVA with middle-aged animals, there was a 
Day x Treatment interaction (F[8,120] = 2.41, p < 0.05), and a marginal 
Trial x Treatment interaction (F[4,60] = 2.34, p = 0.06), in the absence of a 
Treatment main effect. Distance scores of Middle-Aged-Sham and Middle-
Aged-Ovx rats did not differ, nor did Trial or Days interact with Ovx. 
Middle-Aged-Ovx rats showed enhancements due to E2 treatment, 
exhibiting faster learning of the platform location (Day x E2 Treatment 
interaction: F[4,92] = 2.66, p < 0.05, Figure 8b); a post-hoc assessment 
confirmed that E2 treatment enhanced performance on the initial two 
testing days in middle-aged animals (E2 Treatment main effect for days 1 
and 2: F[1,23] = 16.45, p < 0.001). 
There was a Trial x E2 Treatment interaction for middle-aged 
animals only, with E2-treated rats exhibiting lower distance scores on trial 
1 as compared to Ovx rats (F[2,46] = 3.64, p < 0.05, Figure 8c). Given 
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previous findings that E2 aids overnight retention of the platform location 
in middle-aged rats (Bimonte-Nelson et al., 2006; Markham et al., 2002) I 
further evaluated this effect by removing day 1 since there was no prior 
information about this maze to the animal on trial 1, day 1. E2 aided in 
remembering the platform location overnight in middle-aged rats, as 
shown by the Trial x E2 Treatment interaction for days 2-5 (F[2,46] = 3.21, 
p < 0.05). E2 did not influence overnight forgetting in young animals, as 
determined by the same analysis in young animals (Trial x E2 Treatment 
interaction, p > .86), nor did Ovx influence overnight forgetting in young or 
middle-aged animals (separate repeated measures ANOVAs within each 
age, Trial x Ovx interaction ps > .89). 
There was a main effect of Age for Distance scores. Young-Sham 
rats exhibited better performance than Middle-Aged-Sham rats (F[1,14] = 
14.50, p < 0.005). Post-hoc comparisons determined that Ovx in young 
rats impaired performance to the extent that the Young-Ovx group did not 
differ from the Middle-Aged-Ovx group or the Middle-Aged-Sham group for 
overall performance across the five testing days. However, Middle-Aged-
Ovx-E animals exhibited poorer overall performance than the Young-
Sham rats (F[1,22] = 6.48, p < 0.05), indicating that estrogen treatment did 
not reverse age-related performance deficiencies. 
Figure 9 shows the mean swim speed ±SE for each treatment 
group for a) young animals and b) middle-aged animals. While the 
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omnibus ANOVA for speed for young animals was not significant, for 
middle-aged animals there was a main effect of Treatment (F[2,30] = 
18.88, p < 0.0001). In middle-aged animals Ovx did not affect swim speed 
and E2 treatment decreased swim speed (F[1,23] = 16.56, p = 0.0005). 
Age did not influence swim speed (F[1,14] = 0.68, p = .42). 
Figure 8d depicts the mean percent distance ±SE spent in the 
target and opposite quadrants for the probe trial for each treatment group 
within each age. All groups localized to the platform location. As revealed 
by the omnibus ANOVA, all young animals spent a greater percent 
distance in the target versus the opposite quadrant (Quadrant main effect: 
F[1,28] = 156.16, p < 0.0001), regardless of treatment (Nonsignificant 
Treatment x Quadrant interaction). Identical findings were shown for 
middle-aged animals (Quadrant main effect: F[1,29] = 62.38, p < 0.0001; 
Treatment x Quadrant interaction not significant). For the analysis of Age, 
there was a Quadrant main effect (F[1,14] = 132.78, p < 0.0001) with a 
higher percent distance in the target quadrant, and a Treatment x 
Quadrant interaction (F[1,14] = 4.89, p < 0.05). A post-hoc t-test 
determined that Young-Shams spent a greater percent distance in the 
target quadrant than Middle-Aged-Shams (t[29] = 7.90, p < 0.05). 
Study 1: multiple regression and correlations.  
I conducted two primary regression analyses relating serum E2 
levels to performance measures in the young and middle-aged Ovx rats 
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with E2 treatment. Serum E2 level was related to maze performance on 
the last trial of testing (b = -2.11, r = -.38, t[26] = -20.09, p = 0.046, Figure 
10a) indicating that for each pg/ml increase in serum E2 level, there was a 
2.11 cm decrease in swimming distance. My collaborator used several 
procedures described in Cook and Weisberg (1999) to probe for possible 
curvilinear effects; none approached statistical significance. The Cook and 
Weisberg (1983) test could not reject the null hypothesis of constant 
variance and the results of an alternative regression analysis that used the 
log of swimming distance as the dependent variable to stabilize the 
variance did not differ from the first (t[26] = -20.09, p = 0.046). Finally, my 
collaborator found no difference in the slopes of the young and middle-
aged Ovx rats. These results show that the relationship approximates 
linearity over the range of serum E2 studied, which ranged from low 
physiological to supraphysiological (Butcher et al., 1974). 
Serum E2 level was also related to better spatial localization of the 
platform location during the probe trial in the young and middle-aged Ovx 
rats. Higher serum E2 levels were related to greater percent distance in 
the target quadrant (b = 0.257, r = 0.59, t[26] = 3.71, p = 0.001, Figure 
10b). Once again, my collaborator detected no evidence of curvilinearity, 
nonconstant variance, or differences in the slopes of Young-Ovx-E and 
Middle-Aged-Ovx-E groups. There were no significant E2-percent distance 
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relationships in the ovary-intact Young-Sham or Middle-Aged-Sham 
analyses when groups were analyzed together or separately. 
Speed did not significantly correlate with E2 levels for any 
assessment when young and middle-aged animals were analyzed 
together, or when they were analyzed separately. Moreover, speed did not 
significantly correlate with distance scores during testing, or with percent 
distance in the target quadrant on the probe trial, for Sham, Ovx or Ovx-E 
animals. This was true when young and middle-aged animals were 
analyzed together, as well as separately. 
Study 2: Effects of Ovx and E2 Treatment in Aged Animals 
Study 2 was performed to assess whether Ovx had an impact on 
performance in aged 24 month old animals, and whether this E2 treatment 
regimen was still effective in aged animals. Young 4 month old ovary-
intact sham animals were also evaluated to confirm age-related 
performance deterioration, and as a relative performance assessment for 
the E2-treated group.  
Study 2: serum E2 levels. 
The bottom half of Table 2 shows the mean ±SE, range and 
median serum levels of E2 for young and each group of aged rats in Study 
2. The omnibus ANOVA with all aged groups revealed a main effect of 
Treatment (F[2,15] = 21.91, p < 0.0001). Aged-Ovx animals exhibited 
lower E2 levels than Aged-Sham rats (t[10] = 2.65, p < 0.05), and Aged-
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Ovx-E rats had higher levels than Aged-Ovx rats (t[11] = 5.28, p < 
0.0005). Age did not influence E2 levels (p = 0.67). 
Study 2: maze performance. 
Figure 11a depicts the learning curves across days for each 
treatment group of aged of 21 month olds. Once again, an omnibus mixed 
model ANOVA including all three aged groups revealed no main effect or 
Day or Trial interactions with Treatment for distance scores. It was noted, 
however, that overall performance collapsed across all five testing days of 
the Aged-Ovx-E group appeared better than the Aged-Sham and Aged-
Ovx groups (Figure 11a). As a post-hoc assessment, repeated measures 
ANOVAs were used to test two-group comparisons. These analyses 
confirmed that the Aged-Ovx-E group did not significantly differ from the 
Aged-Ovx or the Aged-Sham group across the five testing days; this was 
true for both main effects and interactions with Treatment (ps > 0.12). 
Age influenced performance; Young-Sham rats exhibited lower 
distance scores collapsed across all days as compared to Aged-Sham 
rats (Age main effect: F[1,10] = 4.96, p = 0.05). There was also a Day x 
Age interaction (F[4,40] = 3.75, p < 0.05), with distance scores 
comparable on day 1 but markedly lower for days 2 through 5 for the 
Young-Sham group (Figure 11a). 
Figure 11b shows the mean swim speed ±SE for each aged group 
for each test day. The omnibus ANOVA for all aged groups revealed that 
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treatment affected swim speed as days progressed (Day x Treatment 
interaction: F[4,12] = 2.38, p < 0.05). There was no Ovx effect on swim 
speed. E2 treatment decreased swim speed (Treatment main effect: 
F[1,13] = 6.56, p < 0.05). Age influenced swim speed as days progressed, 
with Young-Sham animals swimming slower than Aged-Sham animals 
toward the end of testing (Day x Age interaction: F[4,40] = 4.16, p < 0.05, 
Figure 11b). A post-hoc repeated measures ANOVA (Day and Trial as 
repeated measures) for each sham group alone revealed that Young-
Sham animals did not change swim speed across days (p = 0.31), while 
Aged-Sham animals increased speed in the initial portion of testing 
(F[4,20] = -6.50, p < 0.05, Figure 11b). 
All aged rats localized to the target location. For the ANOVA with all 
aged groups included, there was a main effect of Quadrant, with rats 
spending a greater percent distance in the target versus the opposite 
quadrant suggesting platform localization (F[1,17] = 39.62, p < 0.0001, 
Figure 11d). The nonsignificant Group x Quadrant interaction indicated 
that all groups showed this pattern of spending a greater percent distance 
in the target versus opposite quadrant. To further detail potential E2 
treatment effects in aged animals, I performed a post-hoc analysis 
comparing the Aged-Ovx-E and Aged-Ovx groups on the probe trial. The 
repeated measures ANOVA (with E2 Treatment as the between variable 
and Quadrant as the repeated measures) revealed a Treatment x 
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Quadrant interaction (F[1,12] = 59.61, p < 0.05, Figure 11c). A post-hoc t-
test showed that aged Ovx animals receiving E2 spent a higher percent 
distance in the target quadrant as compared to aged Ovx animals that did 
not (t[12] = 3.11, p < 0.01). Young rats localized to the platform location, 
as shown on the probe trial with a greater percent distance spent in the 
target quadrant (main effect of Quadrant: F[1,5] = 7.50, p <0.05, Figure 
11d).  
Study 2: multiple regression and correlation. 
Speed did not significantly correlate with distance scores during 
testing, nor percent distance in the target quadrant on the probe trial, for 
any evaluation. 
Discussion 
The current findings show for the first time that higher serum levels 
of E2 treatment correlate with better maze performance in young and 
middle-aged Ovx animals. I found that higher exogenous E2 treatment 
levels were related to better spatial RM performance after surgical ovarian 
hormone loss, while endogenous E2 levels in ovary-intact animals did not 
relate to spatial RM performance in either age (Study 1). This report 
replicates my lab’s previous findings for spatial RM in middle-aged female 
rats, whereby Ovx does not affect performance, yet estradiol treatment 
enhances performance after Ovx (Bimonte-Nelson et al., 2006). I now 
extend these findings, demonstrating that in contrast to no effect of Ovx in 
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middle-aged females, Ovx impacts young females’ spatial RM 
performance. Young animals were responsive to both ovarian hormone 
removal and treatment, and middle-aged animals were not responsive to 
ovarian hormone removal but were responsive to estrogen treatment. 
Furthermore, at the current timing of ovarian hormone loss and regimen of 
E2 treatment, aged animals were not responsive to ovarian hormone 
removal or treatment for the test trials on the spatial RM Morris maze 
(Study 2). 
While Ovx did not influence spatial RM performance in middle-aged 
animals, in young animals Ovx compromised performance relative to 
young ovary-intact sham animals on days 2-5, the latter portion of testing. 
Ovx in young animals impaired performance to the point that this group 
did not differ from middle-aged Ovx or Sham animals. This negative effect 
of Ovx corresponds with findings of others that Ovx in young rats impairs 
Morris maze performance, specifically, at the end of a five-day testing 
period (Feng et al., 2004). Whether Ovx animals would have eventually 
attained performance comparable to that of young ovary-intact sham 
animals had testing continued remains to be determined. It is noteworthy 
that by the last trial on the last day of testing, however, Young-Ovx 
animals did learn the platform location. This is revealed by the probe trial 
data showing that all groups spent a greater percent distance in the 
platform versus the opposite quadrant. These findings, combined with the 
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lack of a Quadrant x Treatment interaction, suggest that regardless of 
ovarian hormone status all young and middle-aged groups learned the 
platform location by the end of testing. 
My observation that E2 enhances spatial RM on the Morris maze in 
young and middle-aged female rats is consistent with other studies using 
young to middle-aged rodents tested on the Morris maze (El-Bakri et al., 
2004; Feng et al., 2004; Markham et al., 2002; McLaughlin et al., 2008). It 
is noteworthy that I found E2-induced enhancements on the first two days 
of testing in middle-aged animals, indicating faster platform acquisition, yet 
the middle-aged Ovx group given E2 still performed worse than the young 
sham group. These findings indicate that while E2 does enhance learning 
of spatial RM on the Morris maze, it does not completely reverse age-
related performance deficiencies. 
In contrast to the current findings that E2 did not improve spatial 
learning in aged Ovx rats; some studies have shown that aged female 
rodents exhibit cognitive enhancements in response to E2 treatment. For 
example, estradiol injections enhanced spatial RM in 27-28 month old 
ovary-intact mice (Frick et al., 2002). The difference in results may relate 
to the type of estradiol administration as cyclic versus tonic; cyclic 
administration via daily injection was used in the Frick study (Frick et al., 
2002) described above, while tonic administration was used in the current 
studies. Providing further support for an influence of administration 
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method on cognitive effectiveness in aged rodents, priming with cyclic 
estradiol enhanced responsiveness to tonic estradiol in older Ovx rats 
(Markowska and Savonenko, 2002a). Whether estrogen treatment 
improves performance of aged animals may also relate to memory type. 
WM enhancements due to tonic estradiol treatment have been reported in 
aged Ovx rats (Gibbs, 2000b; Luine and Rodriguez, 1994). My lab and 
others have shown estradiol-induced WM improvements in young Ovx rats 
as well, an effect reported to depend on administered estradiol dose, 
although dose-dependent differences in circulating estradiol levels were 
not confirmed (Bimonte and Denenberg, 1999; Daniel et al., 1997; Holmes 
et al., 2002; Sandstrom and Williams, 2001). Accordingly, in young rats 
high physiological estradiol levels have been shown to enhance learning a 
place strategy and impair learning a response strategy on a land Plus 
Maze (Korol and Kolo, 2002). Further, while Foster et al. (2003) found that 
tonic estradiol treatment had no influence on acquisition of the Morris 
maze in 6, 12 or 17 month old Ovx rats, physiological-dose estradiol 
treatment influenced 24hr retention in the 12 month old rats only, and the 
supraphysiological dose influenced retention in the 17 month old rats only. 
Thus, a higher supraphysiological estradiol dose may be necessary to 
enhance spatial RM retention in rats approaching old age. 
Age impacted whether swim speed changed across days, an effect 
seen in Study 2 comparing Young-Sham and Aged-Sham animals (Figure 
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11b). Young-Sham animals showed no change in swim speed across 
days, and Aged-Sham animals increased swim speed across the initial 
testing sessions and stabilized by the end of testing. This increase in swim 
speed after day 2 in aged animals may be influenced by maze acclimation 
after an initial stress response due to the swimming component of the 
task, an effect which may not be seen in younger animals (Kramer and 
Bodnar, 1986). Swim speed in both middle-aged and aged animals 
decreased with E2 treatment (Studies 1 and 2), an effect observed 
previously in my and other laboratories (Bimonte-Nelson et al., 2006; 
Foster et al., 2003; Markowska and Savonenko, 2002a). Middle-aged and 
aged animals may be particularly sensitive to the motor effects of E2 
treatment. Indeed, E2 treatment did not influence swim speed in young 
animals in this study. Interestingly, swim speed did not correlate with 
distance to the escape platform nor probe trial performance, indicating that 
swim speed does not relate to a more- or less- direct search path to the 
platform. This was true when correlations were run within and across 
ages, and within and across treatment groups for Studies 1 and 2. 
Distances to the platform and probe trial measures have been asserted to 
be most reflective of task acquisition (e.g., Foster et al., 2003). The 
currently reported lack of correlation between distance and probe trial 
measures with speed, as well as other research showing that decreased 
motor function with age does not correlate with Morris maze performance 
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(Shukitt-Hale et al., 1998), support the tenet that there is a disconnect 
between cognitive status and sensory/motor performance variables such 
as latency and speed on this test. Yet, it is also tempting to speculate that 
a slower swim speed may be reflective of solving strategy wherein the 
animal is encoding or attending to spatial stimuli, with this process not 
necessarily related to final performance scores as operationally defined by 
distance swum. Further evaluations are necessary to decipher the 
complex age and E2 interactive effects on swim speed, as well as whether 
swim speed relates to encoding or utilization of spatial stimuli. 
It is noteworthy that the range of E2 levels using the pellets from 
Innovative Research of America was quite large. This has been discussed 
in prior work from other laboratories, and my lab has noted this in prior 
studies within as well (unpublished observations; Diel et al., 2005). While 
for the current experiments capitalized on this variability to address 
possible relationships between E2 treatment levels and memory scores 
within individuals, the lack of difference in the mean serum E2 level for the 
0.25 mg and 0.50 mg pellets is disconcerting, as is the similarity in range 
and median values. Importantly, sacrifice and blood collection for E2 
assays occurred within the 60 day timeframe of pellet release. 
Collectively, these findings suggest that serum E2 levels should be 
determined after using these pellets, and potentially other forms of 
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estrogen treatment as well, to ascertain an accurate estimate of estrogen 
levels and allow appropriate interpretation of findings. 
Performance on the hidden platform version of the Morris maze, as 
used in the current report, is known to be influenced by integrity of the 
hippocampus (e.g., Morris et al., 1982; Schenk and Morris, 1985). The E2-
induced spatial memory enhancement seen in the current and other 
reports coincides with evidence that estrogen influences the physiology, 
connectivity, and function of the hippocampus, including increases in 
dendritic spine density and reductions in GABA neurotransmission 
(Bimonte-Nelson et al., 2006; Gould et al., 1990; Murphy et al., 1998; 
Woolley and McEwen, 1992). While it is not currently known why variables 
such as specific estrogen regimen and age may influence efficacy of 
estrogen treatment for cognition, data from neurobiological experiments 
yield insight and suggest that such interactions are biologically plausible. It 
has been well-documented that age-related changes occur in neural 
systems known to influence learning and memory, and many of these 
neural systems are also influenced by estrogen. For example, short-term 
estrogen treatment via injection enhanced place-learning-induced 
hippocampal ACh release (Marriott and Korol, 2003). There are 
interactions between the cholinergic system, estrogen treatment and age; 
susceptibility to cholinergic challenge differed in middle-aged versus aged 
rodents given estradiol, with middle-aged, but not aged, animals showing 
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protection due to estradiol treatment (Markowska and Savonenko, 2002a; 
Savonenko and Markowska, 2003). In addition, there are age-related 
alterations in the number and activity of estrogen receptors (ER) which 
could also influence responsivity as aging ensues (Chakraborty and Gore, 
2004). Newer data suggest an estrogen-receptor dependent mechanism 
of estrogen-induced benefits on spatial memory, as the benefits of 
systemic estrogen treatment on place learning were reversed with 
hippocampal estrogen-receptor antagonism using ICI 182,780 (Zurkovsky 
et al., 2006). Thus, changes in ERs may relate to age-related 
responsiveness to estrogen for spatial memory. 
In summary, the current report indicates that for spatial RM, the 
effects of surgical ovarian hormone loss and E2 treatment change with 
age, at least for the temporal and dose parameters utilized in these 
studies. The data indicate that young and middle-aged animals that have 
undergone Ovx benefit from E2 treatment, and that higher exogenous E2 
levels relate to better spatial RM in both ages. Indeed, higher levels of E2 
treatment correlated with better maze performance during testing and 
enhanced platform localization as demonstrated during the probe trial. No 
relationships between endogenous E2 level and maze scores were seen 
in young and middle-aged sham animals that were ovary-intact. By old 
age, the E2 treatment regimen beneficial at earlier ages was no longer 
effective during testing, and had only minor benefits for platform 
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localization as assessed on the probe trial. My findings demonstrate a 
distinction between sensitivity to surgical ovarian hormone loss and 
responsiveness to E2 treatment after surgical ovarian hormone loss. 
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CHAPTER 4 
A PRODRUG OF 17β-ESTRADIOL ENHANCES SPATIAL COGNITION 
AND ALTERS THE CHOLINERGIC SYSTEM: COMPARISON TO 17β-
ESTRADIOL AND PREMARIN
Ovarian hormone output ends typically in the fifth decade of a 
women’s life in what is commonly termed as menopause; menopause and 
the postmenopausal state results in very low circulating levels of estrogen 
and progesterone (
®  
Timaras et al., 1995). It is estimated that by the year 
2050 there will be 45 million postmenopausal women in the U.S. alone 
(U.S. Census Bureau, Bureau, 2007). This, taken with the fact that 
menopause has been linked to a multitude of negative effects, including 
cognitive deficits (Nappi et al., 1999; Phillips and Sherwin, 1992; Sherwin, 
1988), which can diminish a women’s quality of life (Klein and Berlin, 
1996), makes the treatment and/or proper management of menopause an 
important public health concern. Estrogen-containing hormone therapies 
(HT) have been shown to obviate the vasomotor symptoms of menopause 
(Campbell and Whitehead, 1977b); and improve some menopause-related 
cognitive deficits (Campbell and Whitehead, 1977b; Duka et al., 2000; 
Kantor et al., 1973; Ohkura et al., 1995; Phillips and Sherwin, 1992; 
Sherwin, 1988; Wolf et al., 1999). However, conflicting reports in the 
literature suggest that the risk to benefit ratio for replacing ovarian 
hormones is currently unresolved.  
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CEE, a combination of estrogens derived from the urine of pregnant 
mares, is the most widely used HT in the U.S. (Stefanick, 2005). CEE has 
been found to enhance memory in menopausal women via self-report 
(Campbell and Whitehead, 1977a), case studies (Ohkura et al., 1995) and 
randomized psychometric evaluations (Kantor et al., 1973). In rats, CEE 
enhanced working and RM and hippocampal independent object 
recognition memory (Acosta et al., 2009b; Engler-Chiurazzi et al., 2009; 
Walf and Frye, 2008).Yet, findings from the WHIMS, the largest placebo-
controlled clinical trial performed to date, found no or detrimental effects 
on cognition and probable dementia risk when CEE was taken alone or in 
combination with MPA (Espeland et al., 2004; Shumaker et al., 2004; 
Shumaker et al., 2003), and recently, the WHIMS-MRI study found that 
CEE use with or without MPA was associated with small but measurable 
atrophy in the frontal cortex and hippocampus (Resnick et al., 2009). 
While noting many factors likely affected the WHIMS’ findings including 
the global nature of the cognitive measure, older age of participants, and 
duration of hormone deprivation before treatment initiation (see Sherwin, 
2005), these studies suggest that while the absence of ovarian hormones 
may be detrimental to a women’s health, so to may the currently 
prescribed HTs. Collectively, highlighting the necessity to develop novel 
HTs that maximize benefits while minimizing or obviating the risks 
normally associate with HT.  
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One of the risks linked to HT, and specifically to estrogen therapy 
(ET) alone, is the increased risk for developing endometrial hyperplasia. 
Classically ET is opposed with a progestin to combat the increased risk of 
endometrial hyperplasia (Smith et al., 1975; Ziel and Finkle, 1975). 
However, opposed ET comes with its own risks. In the WHIMS, CEE+ 
MPA treatment increased the risk of probable dementia (Shumaker et al., 
2004). Similarly, my lab has found in Ovx rats that progesterone treatment 
abolishes the beneficial cognitive and neurotrophin effects of E2 treatment 
(Bimonte-Nelson et al., 2006; Bimonte-Nelson et al., 2004a). Furthermore, 
my lab have found that MPA treatment is detrimental to cognitive 
performance in aged female Ovx rats, an effect comparable to 
progesterone (Braden et al., 2010). Together, this suggests that the 
necessity of opposing ET with a progestin may obviate the beneficial 
cognitive effects of ET. One method to sidestep the necessity of opposing 
ET with a progestin is to keep systemic estrogen stimulation at a minimum 
by restricting estrogen’s actions to a certain target site of action, for 
example, the brain. Prodrugs are inactive precursors of the therapeutic 
agents that are converted to the biologically active agents by enzymatic 
and/or chemical transformation in vivo–preferably at the site of action 
(Albert, 1958; Wermuth et al., 1998). Hence, brain targeted estrogen 
prodrugs conceivably have the ability to target the action of the hormone 
to only the brain, and thereby reduce the systemic effects (Estes et al., 
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1994; Prokai et al., 2003). Considering that 10-hydroxyestra-1,4-dien-
3,10-dione (E1-DHED) has been shown to be a prodrug for E1 (Prokai et 
al., 2003), My collaborators have implicated 10,17β-dihydroxyestra-1,4-
dien-3-one (DHED) as a prodrug for E2. As E2 is one of the most potent 
activators of the classical genomic pathway and the primary export 
product of a woman’s ovary (Prokai et al., 2003), the current study set out 
evaluate DHED’s in vitro conversion to E2 in as well as its effects on 
cognition in vivo. DHED has the possibility to revolutionize the field of HT, 
whereby, one day, there may be minimal risks that a woman needs to 
consider before initiating ET. 
The cognitive effects of estrogens are thought to be directed in part 
by enhancements in the cholinergic system (for review see: Gibbs and 
Aggarwal, 1998). The hippocampus and entorhinal cortex receive 
cholinergic innervation from the BF, which supports memory function (for 
review see Hasselmo, 2006). In animals, E2 and CEE enhance BF 
integrity (Acosta et al., 2009b; Gibbs, 1997). E2 potentiates increases in 
hippocampal ACh levels during maze learning relative to vehicle treatment 
in Ovx rats (Marriott and Korol, 2003), and E2-induced memory 
enhancements are present in animals with intact BF cholinergic neurons, 
but not in animals with BF cholinergic lesions (Gibbs, 2002). Treatment 
with E2 and CEE increases the number of ChAT immunoreactive (ChAT-
IR) positive cells in BF (Acosta et al., 2009b; Gibbs, 1997), and CEE and 
  
87 
E2 also protect against muscarinic cholinergic receptor challenges (i.e., 
scopolamine-induced amnesia) in rats (Acosta et al., 2009b; Packard and 
Teather, 1997; Rodgers et al., 2010; Savonenko and Markowska, 2003). 
Taken together, this suggests that E2 and CEE may enhance memory via 
the BF. However, no single study has compared CEE’s and E2’s ability to 
enhance BF health, nor a prodrug of E2. Research along this path is 
critical for the elucidation of estrogen-facilitated cognitive enhancement 
and for the development of novel optimal HTs benefiting cognition. 
The female rodent model can provide insight into the cognitive 
effects of hormones, allowing evaluative changes in cognition due to 
hormone withdrawal and treatment, while enabling experimental control 
not possible in clinical research. Utilizing this tenet, the current study was 
designed to confirm that DHED is converted to E2 in brain. Furthermore, I 
wished to evaluate the cognitive and cholinergic health effects of the 
prodrug DHED, with reference and comparison to, the most potent and 
frequently used estrogen in basic science research (E2), and the most 
commonly prescribe HT in women (CEE). Specifically, in study 1, I 
evaluated the conversion of DHED to bioactive E2 in brain tissue. In study 
2, utilizing a tonic dosing regimen, I evaluated the cognitive effects of 
DHED, E2 and CEE and on a battery of water-escape mazes designed to 
test spatial working and RM. Furthermore, I evaluated several peripheral 
markers that are routinely noted to change E2 and CEE, including vaginal 
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cytology, uterine weights, and serum blood levels of E2 and E1. At the 
conclusion of the study, brains were harvested, processed and the 
number of BF ChAT-IR positive neurons were counted. Lastly, as per prior 
studies in my lab (Engler-Chiurazzi et al., 2009; Talboom et al., 2008), I 
evaluated relations between serum E2 and E1 levels, memory measures 
and ChAT-IR neuron counts. 
Methods  
Study 1: In Vitro Prodrug Activation 
Compounds. 
 E2 was obtained from Steraloids Inc. (Newport, RI). All other 
chemicals and reagents were purchased from Sigma (St. Louis, MO), 
unless otherwise specified. DHED (10,17β-dihydroxyestra-1,4-dien-3-one) 
was prepared by a facile microwave-assisted organic synthesis reported 
earlier (Prokai-Tatrai et al., 2007). Briefly, E2 was oxidized with Pb(OAc)4 
in AcOH under microwave irradiation in a CEM (Matthews, NC) Discover 
monomode microwave apparatus at 40 °C for 15 min. The obtained DHED 
acetate was subsequently converted in 5 min to DHED by microwave-
assisted hydrolysis with NaOMe. Product isolation was done through 
column chromatographic purification. 
Animal subjects and surgeries.  
Tissue for in vitro biotransformation experiments were obtained 
from Ovx female rats housed at the animal facility of the University of 
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North Texas Health Science Center. All rats in the in vitro experiment were 
Ovx. For Ovx, bilateral dorsolateral incisions were made in the skin and 
peritoneum, and the ovaries and tips of uterine horns were ligated and 
removed. The muscle was then sutured and the skin stapled. 
In vitro prodrug activation.  
Rats were euthanized with CO2 asphyxiation approximately 2 
weeks after Ovx surgery. They were decapitated; the brain was carefully 
removed and transferred to a 15-mL glass, Potter-Elvehjem tissue grinder 
vessel (Wheaton, Millville, NJ) placed into an ice bath. After adding ice-
cold phosphate-buffered saline (PBS; the volume in ml was equivalent to 
4-times the weight of the tissue in grams), the homogenate (20%, w/v) 
was prepared by rotating the ball-shaped Teflon® pestle of the grinder, 
with the steel shaft connected to a motor-driven overhead stirrer 
(Wheaton), for 80 s at 1,500 rpm. Protein content of the brain 
homogenates was determined by a dye-binding assay using bovine serum 
albumin (BSA) as a reference (Lowry et al., 1951). Ten µl of DHED 
solution (100 μM, in ethanol) was added to 0.99 mL of tissue homogenate 
and aliquots (3 x 200 µL) were withdrawn from the mixture after 2.5 min of 
incubation at 37 °C in a shaking water bath. The aliquots were added 
respectively to glacial acetic acid (50 µL) containing 1 µM of d5-E2 (C/D/N 
Isotopes, Pointe-Claire, Quebec, Canada) as an internal standard in 1.5-
mL polypropylene centrifuge tubes. Ethyl acetate (3 x 500 µL) was added, 
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and the mixtures were vortexed for 1 min and centrifuged (10,000 rpm, 5 
min). From each centrifuge tube, the organic layers were removed, 
combined, and dried under a nitrogen stream to afford three samples for 
subsequent analysis by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS). 
E2 assay. 
The dried residue was re-dissolved in 50 µL of sodium bicarbonate 
buffer (100 mM, pH 10.5) and an equal volume of 1 mg/mL dansyl chloride 
in acetonitrile was added, vortexed for 1m, followed by incubation in a 
heating block at 60° C for 10 min. Analyses were performed on an LCQ 
ion-trap mass spectrometer (Thermo Fisher, San Jose, CA, USA) 
equipped with the manufacturer’s ESI source and operated in positive ion 
mode. The mobile phase (80% acetonitrile, 19% water and 1% acetic acid, 
v/v) was delivered by a PM-80 pump (BAS, West Lafayette, IN, USA) for 
LC separations on a 50 x 2.1 mm i.d. Discovery HS C18 column packed 
with 5 µm particles (Supelco, Bellefonte, PA, USA) at 250 µL/min flow 
rate. Samples were injected manually using a Rheodyne (Cotati, CA, 
USA) 7125 injection valve equipped with a 20 μL loop. The effluent was 
diverted to waste for 1 min after injection to reduce the amount of salt 
entering the ESI source in which nitrogen was used as both the sheath 
and auxiliary gas at a pressure of 40 and 10 units, respectively. The spray 
voltage was set at 4.0 kV and the capillary temperature was 200 °C. 
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Product-ion MS/MS spectra were obtained by collision-induced 
dissociation (with helium as target gas) and collected using 1.0 Th parent 
ion isolation width and 35% relative collision energy. The parent ions of 
dansylated E2 (m/z 506) and dansylated d5-E2 (m/z 511) were mass-
selected for MS/MS. Data acquisition and processing were performed by 
the manufacturer’s XCalibur (version 1.4) software. 
Study 2: In Vivo Behavior Testing and ChAT-IR Effects After Tonic 
Treatment in Middle-Aged Ovx Animals 
Subjects.  
Subjects were 42 middle-age (15-16 months old at test) Fischer-
344 female rats born and raised at the National Institute on Aging at 
Harlan Laboratories (Indianapolis, IN). After arrival, animals were pair 
housed, had exposure to food and water ad lib, and were maintained on a 
12-h light/dark cycle. Procedures were approved by the Arizona State 
University IACUC, and adhered to the Guide for the Care and Use of 
Laboratory Animals and NIH standards. 
Hormone treatment procedures. 
Middle-aged rats were separated into the following six groups: Ovx 
with only vehicle treatment (Ovx-Veh; n=8), Ovx plus a 4 µg/day of E2 
(Ovx-E2; n=7), Ovx plus a 12 µg/day of CEE (Ovx-CEE-Low; n=8), Ovx 
plus a 24 µg/day of CEE (Ovx-CEE-High; n=6), Ovx plus a 4 µg/day of 
DHED (Ovx-DHED-Low; n=7) and Ovx plus a 8 µg/day of DHED (Ovx-
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DHED-High; n=6). Ovx surgery was then performed approximately 40 
days before behavioral testing began at 13 months of age. For Ovx, rats 
were anesthetized with vaporized isoflurane inhalant, bilateral dorsolateral 
incisions were made in the skin and peritoneum, and the ovaries and tips 
of uterine horns were ligated and removed. The peritoneum and skin was 
then sutured. CEE, E2 and DHED treatment was initiated via Alzet®
Bimonte-
Nelson et al., 2006
 
pumps (Model 2ML4; Durect Corporation, Cupertino, California). 
Appropriate doses of prodrug or hormone were suspended in propylene 
glycol (PG); calculated to deliver the single and/or low and high dose 
described above for each hormone per day; this solution was then placed 
into the pump. For Ovx-Veh rats, pumps were only filled with the PG. 
Pumps were prepared the day before surgery and allowed to equilibrate in 
physiological saline at 37 °C overnight. Hormone treatment began 
approximately 20 days after Ovx, 20 days before testing ensued (
). For pump insertion, under vaporized isoflurane 
inhalant anesthesia, a small incision was made on the left side of the neck 
scruff, and a subcutaneous pocket was created. For each animal, one 
pump of the appropriate prodrug, hormone or vehicle was inserted into the 
pocket and the skin was stapled. Recovery from anesthesia occurred 
under a heat lamp with monitoring of body temperature. Since the pumps 
released hormone or vehicle for 28 days, animals received a pump 
replacement surgery 3 days before testing ensued; this ensured that all 
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animals had hormone or the prodrug on board for the duration of 
behavioral testing and through sacrifice.  
Morris maze: spatial RM.  
The Morris maze (Morris et al., 1982) consisted of a round tub (188 
cm in diameter) filled with water made opaque with black non-toxic paint. 
Each subject had 60 seconds to locate the hidden escape platform with a 
wire mesh top (hidden about 1 cm below the water surface) that remained 
in a fixed location (in the NE quadrant) throughout testing. If the rat did not 
find the platform in 60 seconds, it was gently guided to it. The trial was 
terminated when the rat found the platform. After fifteen seconds on the 
platform, the rat was gently removed from the maze and placed into its 
heated cage until the next trial. The rats were tested for five days, with 
four trials per day. The drop off location for each trial varied semi-
randomly. A video camera suspended on the ceiling above the maze 
tracked the rat’s path during each trial and a tracking system (Ethovision 
3.1, Noldus Information Technology, Wageningen, Netherlands) was used 
to analyze each rat’s swim path. The dependent measure was swim 
distance (cm) collapsed across all days and trials and a separate analysis 
for day three trial one. To assess platform localization, a probe trial was 
given on trial 5 of the last day of testing (i.e., day 5), whereby the platform 
was removed from the maze. For the probe, percent of total distance 
swum (cm) in the target NE quadrant (i.e., quadrant that contained the 
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platform) as compared to the opposite SW quadrant was the dependent 
measure. 
DMS Plus Maze: spatial WM. 
I tested spatial WM and short-term memory retention using a win-
stay DMS Plus Maze task, with the protocol based on studies showing E2-
induced improvements (Gibbs, 2000b; Korol and Kolo, 2002; Sandstrom 
and Williams, 2004), and CEE-induced improvements (Acosta et al., 
2009b) in Ovx rats. The black Plexiglass maze (each arm was 38.1cm x 
12.7cm) was filled with water made opaque with black non-toxic paint, and 
had a hidden platform at the end of one of the four arms. Start location 
varied across trials, and the platform location changed every day. Rats 
received either 2 or 6 trials within a daily session, for 13 days. Rats were 
given 90 seconds to locate the platform. Once on the platform, the rat 
remained on it for 15 seconds, followed by placement into a heated cage 
for a 30s inter-trial interval. An arm entry was counted when the tip of a 
rat’s snout reached a mark delineated on the outside of the arm and not 
visible from the inside of the maze (11 cm into the arm). Entry into any 
non-platformed arm was counted as an error. The dependent variables 
were the number of errors committed during a trial. Trial 1 was the 
information trial informing the animal where the platform was for that day's 
session, trial 2 was the WM test trial and trials 3-6 six were recent memory 
test trials (Frick et al., 1995).  
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After 8 days of acquisition testing (6 consecutive trials), rats were 
tested with delays to increase memory demand. First, on Day 9, a 4hr 
delay was initiated between test trials 1 and 2 to assess retention of recent 
memory. Since this delay did not influence performance, on Day 10, a 6h 
delay between test trials 1 and 2 was given. For delay testing, after the 
initial pre-delay trial/s, rats were taken to the colony room and were left in 
their testing cages until the end of the delay, at which time they were 
brought back into the testing room and tested on the post-delay trial/s. On 
day 12, following an additional acquisition/baseline day (day 11), where 
each animal received 6 consecutive trials, animals were then immediately 
taken in to an adjacent room containing a small rectangular tub (99.1 cm x 
58.4 cm) filled with black opaque water. Each subject had 2m to locate a 
hidden escape platform that remained in a fixed location. If the rat did not 
find the platform it was gently guided to it. The trial was terminated when 
the rat found the platform. After fifteen seconds on the platform, the rat 
was gently removed from the maze and placed into its heated cage for 
30s. The drop off location for each trial varied semi-randomly. After 5 
interference trials, rats were taken back into the DMS Plus Maze room to 
assess performance on the WM trial (trial 2). On day 13, rats received a 
0.2 mg/kg intraperitoneal injection of scopolamine (Sigma-Aldrich Inc., St 
Louis, MO) dissolved in physiological saline, 20m prior to testing on the 
DMS Plus Maze (6 consecutive trials).  
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The dependent measure for acquisition was the number of errors 
committed on the trials 2-6 on days 1-5 (i.e., initial acquisition of the task) 
(Acosta et al., 2009b). To assess performances after delay challenges, the 
dependent measure was the number of errors committed on trial 2 across 
the 4 and 6hr delays. To evaluate which groups were impaired by the 
delay and interference challenges, the dependent measure was the 
number of errors committed on trial 2 across the last baseline day and the 
number of errors committed on trial 2 during the specific challenge day. 
Lastly, I evaluated if groups were impaired by the scopolamine challenge, 
by analyzing the number of errors committed on trials 2-6 across the last 
baseline day to the number of errors committed on trials 2-6 during the 
scopolamine challenge. 
ChAT immunohistochemistry. 
Techniques were performed using previously published methods 
(Acosta et al., 2009b). At dissection brains were blocked. The anterior 
portion of the brain was post fixed in 4% paraformaldehyde in phosphate-
buffer solution (PB; pH 7.4). After 48 hours the brains were moved to PB 
until sectioning. Brains were sectioned (plates 1-25: Paxinos and Watson, 
2005) on a Vibratome (Vibratome 3000) in PBS (pH 7.4) at 40 µm 
throughout the BF and collected for immunohistochemistry (Granholm et 
al., 2002). Every 2nd section through the BF was selected for ChAT 
antibody stain and incubated for 15 minutes in a 0.03% Triton (Triton 
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100X) in phosphate-buffered saline tween (PBST) to permeabilize the 
tissue. The tissue was then blocked, by incubating tissues at room 
temperature (RT) for 30m in a blocking solution (BKS) containing 0.03% 
PBST and 0.03% heat inactivated horse serum (Fischer). Three PBS 
washes (3m each) were then done. The primary antibody, goat Anti-ChAT 
(1:1000, Chemicon), was added to each well, and sections were incubated 
overnight at 4° C on a Rocker II (Boekel Scientific, Feasterville, PA). Next, 
sections were washed in PBS three times (3m each) followed by 
immersion in the secondary antibody solution (1: 200 biotinylated Donkey 
anti-Goat IgG, Vector) and BKS for 45 min on a Titer Plate Shaker 
(Barnstead International, Dubuque, IO) at RT. Sections were washed 
three times in PBS (3m each), and then placed into an 11% methanol and 
1% H202 (Fischer) in PBS solution for 30m on a Titer Plate Shaker to 
quench endogenous peroxidase activity. After three washes in PBS (3m 
each), ABC reagent (Vector) was added to each well and incubated for 
45m at RT on a Titer Plate Shaker. Sections were washed three times in 
PBS (3m each), and were then incubated with DAB solution (Vector). After 
the desired color was achieved (dark purple), brain sections were washed 
three times in PBS (3m each), mounted on subbed slides, air dried, 
dehydrated and cover slipped with Permount. Each group was equally 
represented in each round of staining, to avoid group inter-variability in 
staining. Further, control procedures were run excluding primary and 
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secondary antibodies. Exclusion of the primary antibody resulted in no cell 
staining, and exclusion of secondary antibody resulted in lack of DAB 
color development. 
ChAT stereological cell counts. 
Quantitative estimates of the total number of ChAT-IR neurons in 
the BF were determined using an unbiased, stereological cell counting 
method as described in previous published work (Granholm et al., 2002). 
Briefly, the optical fractionator system consisted of a computer assisted 
image analysis system including a Olympus BX-51 microscope hard-
coupled to a MAC 5000 computer controlled x–y–z motorized stage, an 
mbf CX9000 video camera, a Dell Precision 390 computer and 
StereoInvestigator 8.31 stereological software (MicroBrightField, 
Colchester, VT). The region of interest was outlined under a low 
magnification (4x), and the outlined region was measured with a 
systematic random design of disector counting frames (the size of the 
counting frames was 100x100 mm). A 40x objective lens with a 0.75 
numerical aperture was used to count and measure individual cells within 
the counting frames. The first section in the rostral portion of the BF was 
selected randomly, thereafter every second section was evaluated with 
ChAT immunohistochemistry and total cell counts were generated. The 
following landmarks were used: the rostral border consisted of the medial 
orbital cortex (at the level of the midline fusion of the corpus callosum), the 
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caudal border consisted of the midline fusion of the anterior commissure, 
and the lateral borders consisted of the nucleus accumbens shell. At least 
150 sites were counted in each brain. The counting brick was 
approximately 20-mm thick (18-21 mm). The analysis rendered a mean 
coefficient of error of .16, as calculated according to Gundersen (i.e., m = 
1 on SteroInvestigator), with most coefficient errors in the range of 0.11-
0.21. An upper and lower guard zone of 2 mm was excluded from 
counting. Data were available from 7 Ovx-Veh, 5 Ovx-E2, 7 Ovx-CEE-
Low, 6 Ovx-CEE-High, 5 Ovx-DHED-Low and 4 Ovx-DHED-High animals. 
Counts and region area measurements were then exported to Excel 
2007(Microsoft, Redmond, WA). Three or more sections per animal were 
quantified, corresponding to plates 13-17 from Paxinos and Watson 
(2005), similar to prior publications (Acosta et al., 2009b). The number of 
ChAT-IR positive cells counted in the medial septum (MS) was the 
dependent measure.  
Serum E2 and E1 assays. 
E2 and E1 levels were determined in animals. Rats were 
anesthetized with vaporized isoflurane inhalant and decapitated. Blood 
was collected from the trunk at the time of decapitation into a serum 
separator tube (Vacutainer 367986, Becton Dickinson and Company, 
Franklin Lakes, NJ). Blood was allowed to clot at 4º C and serum was 
collected after centrifugation (3220xG, 20m). Serum was stored at -20 ºC 
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until assays were performed. E2 and E1 hormone assays were performed 
by the Core Endocrinology Laboratory at Pennsylvania State University 
College of Medicine using a kit from Diagnostic Products Corporation, Los 
Angeles, CA (Coat-A-Count E2 kit, product number TKE21). E2 and E1 
was determined in serum by a solid-phase radioimmunoassay based on 
E2- and E1-specific antibodies that are immobilized to the wall of 
polypropylene tubes and 125I -labeled E2 or E1 as the tracer following 
extraction with diethyl ether. Serum (2.4. ml) was extracted and the ether 
portion collected and evaporated to dryness. The sample was 
reconstituted in assay buffer and a competitive radioimmunoassay was 
performed using 125
Vaginal smears and uterine weights. 
I E2 or E1 with high specific activity and a high affinity, 
highly specific antibody. Separation of bound from free was achieved with 
activated charcoal and the data reduction was performed with the use of a 
five point standard curve and purified E2 or E1 standards. The functional 
sensitivity of the assay was 5 pg/ml. The interassay precision at a 
concentration of 35 pg/ml was 8%. The dependent measure was the 
amount of E1 or E2 in pg/ml of serum. 
To evaluate uterine stimulation, vaginal smears were taken before 
the first pump insertion, the day of the second pump insertion as well as 
the morning on the day of sacrifice. Smears were classified as proestrus, 
estrous, metestrus or diestrus (Goldman et al., 2007). For collection of 
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uterine tissues, after sacrifice, a ventral incision was made in the 
abdominal region, and the uterus was cut above the junction with the 
cervix and on the uterine horn below the ligature remaining from Ovx 
(Acosta et al., 2009b; Ashby et al., 1997a; Engler-Chiurazzi et al., 2009). 
The wet weight (g) of uteri, trimmed of fat and connective tissue, was the 
dependent measure. 
Statistical methods. 
In study 2, since my interest was to determine whether each 
hormone or prodrug dose enhanced performance relative to the Ovx-Veh 
group, all of my follow-up two-group comparisons for each hormone type 
employed Fisher’s Protected Least Significant Difference (PLDS) post hoc 
tests when a significant omnibus ANOVA was found, noting that Type 1 
error correction is not necessary with orthogonal planned comparisons 
(Keppel and Wickens, 2004). Alpha was set at 0.05 for all tests. For 
behavior assessments and biological measurements, data were analyzed 
separately for each maze or measurement, first with an omnibus one–way 
or mixed model ANOVA with Treatment as the between variable and Days 
and/or Trials as the within variable, as appropriate for the specific maze 
test or biological measure. Due to my lab’s previous findings whereby 
CEE enhanced the learning on the DMS Plus Maze task and overnight 
retention on the Morris maze (Acosta et al., 2009b), acquisition on the 
DMS Plus Maze and day 3 trial 1 on the Morris maze was assessed via a 
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priori planned comparisons using t-tests; alpha was set at 0.05, two-tailed. 
StatView (version 5.01, The SAS Institute Inc., Cary, NC) was used for all 
analyses. 
Results 
Study 1: In Vitro Prodrug Activation  
As shown in Figure 12a, there was a facile DHED to E2 (prodrug to 
drug/hormone) biotransformation in the brain. Even within 2.5 min 
incubation of 100 μM DHED, the formation of approximately 10 μM E2 
was detected in this tissue homogenate (20% w/v), thus, the initial rate of 
E2 formation was approximately 200 nmol⋅ min-1 ⋅ (mg protein)-1. At the 
same time, as shown in Figure 12b, in a control experiment where no 
brain tissue was present (PBS only), My collaborators did not detect the 
formation of E2 from its DHED precursor. 
Study 2: In Vivo Behavior Testing and ChAT-IR Effects After Tonic 
Treatment in Middle-Aged Ovx Animals 
Morris maze: spatial RM. 
Figure 13 depicts a) the learning curves (i.e., mean swim distance 
±SE) for all days and all trials for each group, the inset graph depicts swim 
distance from day 2 trial 4 to day 3 trial 1, and b) the percent distance 
swam in the target as compared to the opposite quadrant on the probe 
trial. No main effects or interactions were found for swim distance across 
days. The graphical representation of the data (Figure 13a) revealed that 
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the Ovx-CEE-High group showed markedly better performance on day 3, I 
evaluated performance for the first trial on day three; the Ovx-CEE-High 
group had decreased distance as compared to the Ovx-Veh group 
(F[1,14] = 7.48, p = 0.0161). The probe trial revealed a main effect of 
Quadrant (F[1,43] = 302.71, p < 0.0001), in the absence of a main effect 
of Treatment (F[5,43] = 2.16, p = 0.0758), and a Treatment x Quadrant 
interaction (F[5,43] 
DMS Plus Maze: spatial WM.  
= 1.38, p = 0.2506). This indicated that rats swam 
significantly more in the quadrant that once contained the platform as 
compared to the opposite quadrant during the probe trial, a pattern that 
was consistent for all groups. This indicated that each group of animals 
was able to localize to the hidden escape platform regardless of treatment. 
In figure 14, bars represent mean number ±SE of errors for a) 
acquisition b) after delay challenges. Line graphs depict the mean number 
±SE errors from baseline day 11 to c) interference challenge (day 12) and 
d) scopolamine challenge (day 13). The Ovx-CEE-High group displayed 
superior acquisition during the initial learning phase (t[13] = 2.34, p = 
0.0357). No other estrogen impacted performance during acquisition or 
initial learning. After the acquisition, I increased the memory demand of 
the task to test retention by instituting delay challenges. There was a 
Treatment main effect (F[5,38] = 2.74, p = 0.0331]. Each hormone group 
made fewer errors than the Ovx-Veh group (ps < 0.0442). A further 
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analysis of the delay challenges revealed that only the Ovx-Veh group 
increased the number of errors they committed from baseline day 8 to the 
delay challenges (F[1,7] = 5.9, p = 0.0452). The delay had no impact on 
the estrogen- or prodrug-treated group performance for this measure. All 
groups increased errors after the interference challenge [main effect of 
Day, (F[1,37] = 12.32, p = 0.0012, post-hoc ps < 0.05; nonsignificant 
Hormone Treatment x Day interaction). Pharmacological challenge via 
administration of the M1 muscarinic antagonist scopolamine also impaired 
the performance of all groups [main effect of Day, (F[1,36] = 11.19, p = 
0.0019, post-hoc ps < 0.05; nonsignificant Hormone Treatment x Day 
interaction). 
BF ChAT neuron counts. 
Figure 15 represent the mean ±SE stereological ChAT-IR neuron 
counts in the MS of the BF. There was a main effect of Hormone 
Treatment (F[5,28] 
Serum E2 and E1 levels.  
= 3.23, p < 0.0200). The Ovx-E2, Ovx-CEE-Low and 
Ovx-DHED-Low group had the highest number of ChAT-IR neurons, 
which differed from the Ovx-Veh group (post-hoc ps < 0.0438).  
In figure 16, bars depict the mean serum hormone levels ±SE 
[pg/ml] for a) E2 b) E1. There was a main effect of Hormone Treatment 
(E2 F[5,23] = 85.89, p < 0.0001; E1 F[5,23] = 8.25, p = 0.0001). The Ovx-
E2 group had the highest serum E2 and E1 levels, which differed from the 
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Ovx-Veh group (post-hoc ps < 0.0001). Due to the high variability within 
the Ovx-E2 group (E2: Mean Square with the Ovx-E2 group = 2332.840 
vs. Mean Square without the Ovx-E2 group = 42.107; E1: Mean Square 
with the Ovx-E2 group = 139.469 vs. Mean Square without the Ovx-E2 
group = 105.576), a second set of analyses were performed in order to 
elucidate further group differences between the Ovx-Veh compared to the 
non-E2 hormone-treated groups. The analysis excluding the Ovx-E2 
group, revealed a main effect of Hormone Treatment (E2 F[4,20] = 6.73, p 
= 0.0013; E1 F[4,20] = 9.74, p = 0.0002). Both doses of CEE increased 
serum E2 and E1 levels as compared to Ovx-Veh animals (post-hoc ps ≤ 
.05). Importantly, both DHED doses did not increase serums levels of E2 
or E1, as both DHED groups did not differ from the Ovx-Veh group (post-
hoc ps > 0.32). 
Uterine weights.  
The bars in figure 17 represent the mean uterine weight ±SE for 
each group. A main effect of Hormone Treatment was found (F[5,34] = 
5.12, p = 0.0013). E2 treatment had the most profound effect for 
increasing uterine weight when compared to the Ovx-Veh group (post-hoc 
p = 0.0001). However, due to the high variability within the Ovx-E2 group 
(Mean Square with the Ovx-E2 group = 1.442 vs. Mean Square without 
the Ovx-E2 group = 0.075), a second analysis was performed in order to 
elucidate further group differences between the Ovx-Veh compared the 
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other hormone-treated groups. For this second analysis, excluding the 
Ovx-E2 group, revealed a main effect of Hormone Treatment (F[4,28] 
Vaginal smears. 
= 
7.87, p = 0.0002). Both CEE doses increased uterine weight (post-hoc ps 
< 0.0007) as compared to the Ovx-Veh group. Neither DHED dose 
increased uterine weight (post-hoc ps >.1577), suggesting the DHED did 
not stimulate the uterus like E2 and CEE. 
Initial vaginal smears after Ovx confirmed that each animal was in 
an anestrous state. After pump insertion and at sacrifice, vaginal smears 
confirmed that all Ovx-Veh rats consistently maintained an anestrous state 
(i.e., no uterine stimulation), while Ovx-CEE-High, Ovx-CEE-Low and Ovx-
E2-treated rats demonstrated consistent estrus smears indicative of 
uterine stimulation. However, every rat in the Ovx-DHED-Low and Ovx-
DHED-High groups presented a diestrus smears which looked identical to 
those of Ovx-Veh rats, thereby indicating no uterine stimulation (data not 
shown).  
Regression: relations between serum E2, E1 ChAT-IR neuron 
counts and memory. 
Since I and others in my lab have previously found that the serum 
levels of E2 and E1 are related to memory performance (Engler-Chiurazzi 
et al., 2009; Talboom et al., 2008); I conducted a primary regression 
analysis relating serum E2 and E1 levels to performance on each maze 
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and to the number of ChAT-IR neurons in the MS. There were a total of 
six separate analyses: (α was set to 0.05 for each separate effect). 
Specifically, serum E2, serum E1 or MS ChAT-IR were separate predictor 
variables in the model, and Morris maze distance scores collapsed across 
all days, the mean win-stay DMS Plus Maze WM errors collapsed across 
all days, or MS ChAT-IR counts were the outcome variables. To ensure 
that significant regression models were not attributable to group 
differences in my outcome or predictor variables, due to the experimental 
manipulations, I centered the data by subtracting the mean score of the 
treatment group [from which the animal belonged] from each animal’s 
score (for detailed methods and rationale see Enders and Tofighi, 2007; 
Hallahan and Rosenthal, 2000). Figure 18a and 18b depicts scatterplots of 
serum E2 and E1 levels respectively and the number of MS ChAT-IR 
neurons for the Ovx-E2, Ovx-CEE-Low and Ovx-CEE-High groups (i.e., 
groups with detectable hormone levels). Serum E2 and E1 were 
negatively related to the number of MS ChAT-IR neurons (E2 b = -8.31, r 
= -.64, z[17] = -2.83, p = .0046; E1 b = -3.13, r = -.56, z[17] = -2.38, p = 
.0174). Figure 18c and 18d depicts scatterplots of serum E2 and E1 levels 
respectively and Morris maze distance scores collapsed across all days 
for the Ovx-E2, Ovx-CEE-Low and Ovx-CEE-High groups. Serum E2 and 
E1 were negatively related to the mean distance swam on the Morris 
maze (E2 b = -8.31, r = -.54, z[17] = -2.28, p = .0228; E1 b = -3.13, r = -
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.57, z[17] = -2.40, p = .0163). Serum E2 and E1 levels were not related to 
DMS Plus Maze errors. As my lab has found previously, ChAT-IR counts 
were not related to memory outcome variables (data not shown Acosta et 
al., 2009b). 
Discussion 
In the current two studies, I evaluated if DHED, a prodrug of E2, 
was converted to E2 in brain and compared the cognitive and peripheral 
effects of DHED to its parent compound E2 (i.e., the most commonly 
studied hormone in preclinical research), and CEE (i.e., the number one 
prescribed HT in the U.S.;  Hersh et al., 2004). In study 1, I found that 
DHED was converted to E2 in brain tissue. In study 2, this conversion 
presumably led to bioactive E2 being present in brain, which in turn 
enhanced WM on the DMS Plus Maze, as well as increased in the number 
of ChAT-IR neurons in the MS, similar to the effects of E2 alone. My data 
also suggest that CEE may be the most beneficial hormone preparation 
for cognition under the current experimental paradigm. CEE enhanced 
overnight retention on the Morris maze, enhanced the acquisition (i.e. 
learning) of the DMS Plus Maze and protected against the delay 
challenges (i.e. retention) and increased the number of ChAT-IR positive 
neurons in the MS. As expected, treatment with CEE and E2 stimulated 
the uterus, as demonstrated by consistent estrus vaginal cytology and an 
increase in uterine weight. CEE’s and E2’s uterine stimulation was 
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accompanied by raised serum E2 and E1 levels. Importantly, DHED did 
not affect any peripheral marker of estrogenic action nor raise serum 
levels of E2 or E1. Taken together, my data suggest that tonic CEE is 
beneficial to memory over and above E2 under the current paradigm. 
Furthermore, DHED is converted into bioactive E2 in the brain, but not the 
periphery, where it exerts its effects on memory in the same manner as 
E2. Earlier experiments have indicated that NAD(P)H is a coenzyme 
involved in the conversion from DHED to E2, although the full mechanism 
of this conversion remains to be elucidated (Prokai-Tatrai et al., 2008; 
Prokai et al., 2003; Rivera-Portalatin et al., 2007). 
The present CEE data corroborate previous findings from my lab 
and others whereby CEE enhances memory (Acosta et al., 2009b; Engler-
Chiurazzi et al., 2009; Walf and Frye, 2008). My lab has previously noted 
modest enhancements on the Morris maze with cyclic CEE treatment (i.e., 
overnight retention) (Acosta et al., 2009b); indeed, here again, I found that 
the high dose of CEE enhanced overnight retention between days two and 
three on the Morris maze. Furthermore, my lab has have previously found 
that CEE treatment enhances acquisition (Acosta et al., 2009b), and 
protects against memory challenges on the DMS Plus Maze (Engler-
Chiurazzi et al., 2009), here again I noted these same CEE-facilitated WM 
enhancements. In study 2, DHED was similar to E2, whereby both did not 
affect Morris maze performance, but did protect against the delay 
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challenges on the DMS Plus Maze. Specifically, both DHED and E2 did 
not enhance spatial RM, but did enhance spatial WM retention after a 
delay was imposed to increase memory demand. This finding is not 
surprising, as many studies report no effect or modest effects regarding 
E2’s effects on RM performance (for review see Dohanich, 2002), but do 
find reliable WM enhancements after E2 treatment (Bimonte and 
Denenberg, 1999; Daniel et al., 1997; Daniel et al., 2005; Fader et al., 
1999; Gibbs, 1999; Hruska and Dohanich, 2007; Luine and Rodriguez, 
1994). Despite the fact that no treatment effects were found on the Morris 
maze, serum E2 levels were related to Morris maze performance. Higher 
circulating serum E2 and E1 levels were related to less distance swam 
and better performance, an effect I have found previous for E2 (Talboom 
et al., 2008).  
E2 has been found to have a profound impact on numerous 
measures of cholinergic system integrity (Gibbs, 1997; Gibbs et al., 1994; 
Luine, 1985), thought to support memory processing (see Hasselmo, 
2006). Thus, cholinergic system modulation is one hypothesized 
mechanism for estrogen’s effects on memory (for review see: Gibbs and 
Aggarwal, 1998). In addition to my current finding where E2 treatment 
increased the number of ChAT-IR positive neurons in the MS, E2 has also 
been found to alter ChAT in the MS of young Ovx animals (Gibbs, 1996; 
Gibbs, 1997; Gibbs and Pfaff, 1992; Gibbs et al., 1994), and my lab has 
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found that CEE treatment increases the number of ChAT-IR positive 
neurons vertical diagonal band in middle-aged rats (Acosta et al., 2009b). 
Moreover, E2 treatment has been found to alter multiple markers of ChAT 
in middle-aged and aged animals, which appears to differ depending on 
duration of ovarian hormone deprivation before treatment as well as 
specific brain region and BF nuclei evaluated (Bohacek et al., 2008; 
Kompoliti et al., 2004; Singer et al., 1998). In young adult Ovx rats, delay 
match-to-position acquisition correlated with increased ChAT activity in the 
hippocampus and frontal cortex (Gibbs, 2000a), two targets of BF 
cholinergic innervation where high affinity choline uptake was also 
increased (O'Malley et al., 1987; Singh et al., 1994). It is likely that the 
current DHED-spatial memory enhancements are also directed by the 
cholinergic system, as DHED increased the number of ChAT-IR positive 
neurons in the MS. Collectively, CEE and DHED, similar to the effects of 
E2, likely enhance the BF cholinergic system leading to cognitive 
enhancement. 
Some of the results of study 2 may appear counter-intuitive at first. 
Specifically, the Ovx-CEE-High and Ovx-DHED-High groups exhibited 
superior memory performance as compared to Ovx animals, but did not 
demonstrate elevated numbers of ChAT-IR neurons in the MS, similar to 
their low dose counterparts, when compared to Ovx animals. An 
explanation for this discrepancy may lie in the fact that Gibbs (1997), 
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found that estrogens effect on the BF varied as a function of dose. Higher 
doses of E2 induced a more rapid increase in the number of ChAT-IR 
neurons in the BF, which quickly diminished, as compared to a lower dose 
of E2 (Gibbs, 1997). Hence, in the current study, higher estrogenic 
stimulation over a long time frame (i.e., 30 days) may have initially led to 
an increase in ChAT which diminished by the time the brains were 
harvested. In addition to the dose of the hormones used, properties of 
CEE and DHED may have caused these compounds to produce higher 
levels of estrogenic stimulation as compared to E2. CEE is made up of 
several estrogenic components, and many of these component estrogens, 
on different measures, have been found to exert greater biological activity 
than E2 (Bhavnani, 2003; Bhavnani et al., 2008). If fact, recently I have 
shown that one such CEE component ∆8
Talboom et al., 2010
E1, had a marked impact on 
spatial RM, over and above the modest effects generally found with E2 
( ). Regarding DHED, due to the structural 
modification of E2 to create the prodrug, DHED is likely not bound by sex 
hormone binding globulin, and since my data support the fact that DHED 
is not converted into E2 within peripheral tissues (study 1), nor found 
naturally in the body; DHED likely rapidly pulled into the brain via diffusion. 
Both of these factors would lead to high levels of DHED in the brain which 
in turn produce high levels of E2 in brain. Taken together, my current 
findings are not surprising, as the higher doses of CEE and DHED, 
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producing higher levels of estrogenic stimulation, may have initially and 
rapidly increased the number of ChAT-IR cells in the MS, this effect likely 
diminished upon completion of the study when the brains were harvested 
for ChAT analysis. These data also suggest that estrogen-induced 
alterations in the number of ChAT-IR neurons may not necessarily 
correspond to actually cholinergic function, as it has been found that E2- 
facilitated increases in potassium-evoked ACh release are still present 
(i.e., 12-13 weeks) (Gabor et al., 2003), long after the number ChAT-IR 
neurons have been found to decrease (i.e., 4 weeks) (Gibbs, 1997). This 
suggests a dissociation between ChAT-IR positive cells, cholinergic 
function, and memory, a tenet further supported by my data in study 2, 
whereby serum E2 and E1 levels were inversely related to the number of 
ChAT-IR neurons in the MS and spatial memory in the Morris maze (i.e., 
less distance equals better performance). In future experiments I wish to 
evaluate brain region specific levels of E2 and the amount of ACh 
released from the BF utilizing the same dosing and treatment regimens 
used in the present study.  
In the current report, CEE treatment produced a beneficial memory 
profile that exceeded E2’s and DHED’s; this effect was not expected. An 
explanation may lie in the composition of CEE; since CEE is made up of 
several estrogenic components, the actions of some unique components 
such as ∆8E1, may under the current experimental paradigm, create a 
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more favorable environment for brain health and memory enhancement 
than E2 alone (for discussion see Bhavnani, 2003; Utian et al., 2006). 
Furthermore, like many biological systems, it has been noted that 
estrogen’s effects on multiple systems follows a nonmonotonic inverted-U 
or quadratic function, whereby low or high levels of estrogens produce 
minimal effects and a more moderate doses produce a larger effect (Alyea 
and Watson, 2009; Welshons et al., 2003). Taking into account the high 
E2 levels in my E2-treated animals (i.e., around high proestrus levels; 
Butcher et al., 1974), which has been noted to impair spatial memory 
(Warren and Juraska, 1997); perhaps E2 was at the high end of the 
inverted-U, and CEE, producing lower levels of E2, fell closer to the 
middle. Lastly, estrogenic effects may be also directed by membrane 
bound G-protein coupled receptors (i.e., ER-X and/or GPR30) (see: 
Prossnitz et al., 2008b; Toran-Allerand, 2005), whereby different 
estrogens, including component estrogens of CEE, may bind with various 
affinities and ultimately differentially modulate memory and endocrine 
responses through these receptors. Further studies are necessary; 
evaluating dose, regimen and the region specific genomic and/or 
proteomic profile of CEE, DHED and E2. Studies of this nature will begin 
to elucidate the mechanistic differences between these hormones that 
lead to differing cognitive and brain health profiles. 
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I and others in my lab have previously found RM enhancement 
after tonic treatment with E2 (Bimonte-Nelson et al., 2006; Talboom et al., 
2008). An explanation for the differences in effects between my lab’s 
previous reports and the ones discussed currently may lie in the fact that 
in previous studies conducted in my lab had purchased premade hormone 
pellets from Innovative Research of America instead of employing Alzet®
Talboom et al., 2008
 
pumps. I noted that E2 treatment with the Innovative Research of America 
pellets produced substantial variability in the circulating E2 levels 
( ), whereas the Alzet® pumps used in the present 
study did not. Specifically, although the current mean E2 levels produced 
by the Alzet® 2008 pumps were close to those found in Talboom et al., ( ) (≈ 
56 pg/ml compared to ≈ 54 pg/ml respectively), the range of serum E2 
levels were vastly different (56.7-87.4 pg/ml as compared to 15-121 pg/ml 
respectively). Conceivably, my disparate RM effects could be due to this 
variation in the range of serum levels. Indeed, RM performance has been 
found to fluctuate with physiological levels of E2 (Warren and Juraska, 
1997), although an exception has been noted (Berry et al., 1997). In this 
view, study 2’s consistent proestrus levels of E2 (Butcher et al., 1974), 
may have been too high for RM enhancement, an effect that has been 
found in another lab (Warren and Juraska, 1997).  
I would be remiss if I did not note the fact that the current report is 
somewhat in opposition to the findings in a recently published paper from 
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my lab (Engler-Chiurazzi et al., 2009). The previous publication from my 
lab found that the 12 μg tonic dose of CEE was detrimental to 
performance on the Morris maze and DMS Plus Maze. Specifically, this 
low 12 μg tonic dose decreased the number of platform crossings during 
the probe trial on the Morris maze, indicating that this group was not able 
to localize to the previously platformed location as well as the Ovx group. 
Furthermore, the 12 μg tonic dose increased the number of total errors 
committed on the DMS Plus Maze during all acquisition days and on day 4 
alone before a delay was instituted. In fact, since animals receiving 12 μg 
were already impaired on the final acquisition day, no further impairment 
was observed on the following day when a 6hr delay was instituted 
between trial 1 and 2. In the current report, I observed no such 
impairment, and in fact I observed enhancement on the DMS Plus Maze 
and an increase in the number if ChAT-IR neurons with the group 
receiving 12 μg CEE via the same tonic dosing regimen (i.e., Alzet® 
pumps). I think that there are two primary reasons for this discrepancy; the 
first is that both doses of CEE in the current report raised both serum 
levels of E2 (M = 4.82) as well as E1 (M = 7.02) which differed significantly 
from the Ovx-Veh group. It was noted in my lab’s previous report that the 
12 µg dose impaired performance, but only under the conditions where 
serum E1 (M = 7.32) levels were raised not in the presence of raised 
serum E2 levels (M = 3.43) (i.e., levels of E2 which did not differ from the 
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Ovx-Veh group) (Engler-Chiurazzi et al., 2009). This hypothesis is further 
supported by the fact that in the current report higher levels of E1 were 
related to better performance on the Morris maze, whereas higher levels 
of E1 in my lab’s previous report were related to worse performance on 
the Morris maze (Engler-Chiurazzi et al., 2009). Hence, the 12 µg dose 
may have been beneficial in the current report due to the levels of 
circulating E1 in the presence of higher levels of E2. Further research 
should be directed towards an evaluation of CEE’s and DHED’s ability to 
stimulate brain derived ERs (both classic and newly discovered) as well as 
the effect that an animal’s E1 to E2 ratio has on cognition. 
In summary, with the staggering number of menopausal women in 
the next 41 years who will have to make the choice of weather to use HT 
or not (U.S. Census Bureau, Bureau, 2007), current evidence from the 
WHI and ancillary WHIMS studies, suggests that CEE-containing HT 
should not be used (Shumaker et al., 2004). While noting that the WHIMS’ 
results were likely affected by factors other than just CEE treatment (see 
Sherwin, 2005); a new option for these women may be estrogen prodrugs. 
Prodrugs are inactive precursors of the therapeutic agents that are 
converted to the biologically active agents by enzymatic and/or chemical 
transformation in vivo–preferably at the site of action (Albert, 1958; 
Wermuth et al., 1998). The application of prodrugs to overcome barriers to 
a drug's usefulness and improve its therapeutic index is an established 
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method (Ettmayer et al., 2004; Prokai and Prokai-Tatrai, 1999). Although 
previous efforts to utilize this approach to improve targeting of E2 into the 
brain have shown increased brain-uptake of E2 and reduced systemic 
burden (for review see: Prokai et al., 2000), further developments are 
needed to realize the potential of the DHED as a new class of HT. I 
believe the current report is an important step in realizing this approach 
leading to the synthesis a more optimal HT.  
In the current study I found, in middle-aged Ovx rats receiving a 
tonic regimen, CEE enhanced spatial working and RM, and protected 
against WM challenges. Tonic DHED and E2 enhanced WM and 
protected against delay challenges. Unlike CEE and E2, treatment with 
DHED did not affect peripheral markers of estrogenic actions. Within the 
parameters of the current study, the data suggests that tonic CEE is more 
cognitively beneficial than DHED and E2. Furthermore, CEE, DHED and 
E2 treatment resulted in an increase in the number of ChAT-IR positive 
neurons in the BF, an indicator of cholinergic modulation by these 
hormones. Serum E2 and E1 levels were related to spatial memory and 
the number of ChAT-IR neurons in the MS. Hence, these hormone 
treatments likely provide cognitive benefits via alterations of the 
cholinergic system. Further inquiry is necessary evaluating CEE’s and 
DHED’s mechanistic effects on cognition in comparison to E2; however, 
the results in the current study support the tenet that DHED is a promising 
  
119 
drug candidate for a different class of future HTs, which maximize the 
beneficial cognitive effects while minimizing unwanted peripheral effects.  
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CHAPTER 5 
THE RIGHT DOSE: 17β-ESTRADIOL AND PREMARIN’S®
By the year 2050, an estimated 45 million postmenopausal women 
in the United States will have to make the choice of whether to utilize HT 
(
 DOSE 
RESPONSE EFFECTS ON SPATIAL WORKING MEMORY 
U.S. Census Bureau, Bureau, 2007). Ovarian hormone loss due to 
surgical or natural menopause has been associated with cognitive decline 
in women (Nappi et al., 1999; Phillips and Sherwin, 1992; Sherwin, 1988); 
however, the question of how HT impacts cognition is unclear. CEE, a 
complex preparation synthesized from the urine of pregnant mares, has 
been given since 1942 and is the most widely used estrogen component 
of HT in the United States (Hersh et al., 2004; Stefanick, 2005). Some 
studies in women demonstrate that CEE-containing HT improved memory 
(Campbell and Whitehead, 1977a; Kantor et al., 1973; Ohkura et al., 
1995). However, WHI study found that CEE does not benefit cognition in 
women (for review see Coker et al., 2010). While noting many factors 
likely affected the WHI findings, including the global nature of the cognitive 
measure, older age of participants, and duration of hormone deprivation 
before treatment initiation (for discussion see Sherwin, 2005), the 
collected findings suggest that although the absence of ovarian hormones 
is not optimal for cognition, neither is the most commonly utilized HT. 
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To date, E2 has been the primary estrogen used to investigate the 
cognitive effects of HT in the animal model, despite the fact that CEE is 
the most commonly prescribed estrogen component of HT (Hersh et al., 
2004). CEE contains the sulfates of more than 10 equine estrogens 
(Bhavnani, 2003; Bhavnani et al., 1998; Mayer et al., 2008; Sitruk-Ware, 
2002). New evidence has demonstrated that both tonic and cyclic CEE, at 
doses relevant to what women take as HT, can enhance spatial memory 
and protect against cholinergic challenge on spatial tasks in middle-aged 
Ovx rats (Chapter 4; Acosta et al., 2009b; Engler-Chiurazzi et al., 2009). 
Although vital in understanding CEE’s effects on memory, these previous 
animal studies did not evaluate E2, so a direct comparison between the 
effects of E2 on memory (the most common estrogen employed in animal 
models of cognition) to CEE (the most commonly perscribed estrogen 
component of HT) was not possible.  
Unpublished regression analyses from studies previously 
conducted in my lab revealed that serum levels of E1 and E2 were 
positively rank-ordered according to the dose of CEE given (Engler-
Chiurazzi et al., 2009). That is, the low dose of CEE produced lower 
circulating levels of E1 and E2, whereas the higher dose of CEE produced 
higher levels of E1 and E2. Using these data, I performed further 
analyses, which revealed that serum E1 and E2 levels have a linear or 
nonlinear relationship depending on the day and trial block composite 
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measure of WM and recent memory performance. Furthermore, several 
studies have noted that cognition is related to circulating ovarian hormone 
levels in humans and animals (Asthana et al., 1999; Engler-Chiurazzi et 
al., 2009; Lebrun et al., 2005; Phillips and Sherwin, 1992; Ryan et al., 
2010; Talboom et al., 2008; Wolf and Kirschbaum, 2002). Despite these 
findings, no single study to my knowledge has assessed memory 
performance across a range of E2 and CEE doses, whereby there were 
more than three doses given. It is conceivable that the dose response 
curve for each hormone may follow a linear, quadratic or even a cubic 
relationship with spatial memory; relationship is difficult to evaluate with 
three or fewer doses. Indeed, nonlinear effects of E2 and CEE on memory 
would be of particular importance to elucidate in that future studies could 
establish an a priori range of doses with a reduced chance of getting 
unexpected effects due to an unknown curvilinear relationship at lower or 
higher doses. To that aim, in middle-aged female Ovx rats, I separately 
tested a 0 dose (i.e., Ovx animals receiving only vehicle) and five tonic 
doses of E2 and CEE for their effects on spatial working/recent memory 
assayed via the DMS Plus Maze task. The hypothesis was that E2 and 
CEE would follow a quadratic relationship (i.e., across the tested dose 
range) with working/recent memory performance. 
Methods 
Subjects 
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Subjects were 36 middle-aged (12-13 month old) Fischer-344 
female rats born and raised at the National Institute on Aging colony at 
Harlan Laboratories (Indianapolis, IN). Animals were acclimated for 
several weeks and pair housed with an identical treatment assigned cage-
mate in the Arizona State University animal facility. All animals had 
exposure to food and water ad-lib, and were maintained on a 12-h 
light/dark cycle at 23 °C. Procedures were approved by Arizona State 
University IACUC and adhered to the Guide for the Care and Use of 
Laboratory Animals and NIH standards. 
Ovx Surgery and Hormone Treatments 
At 12 months of age, approximately 28 days before behavioral 
testing ensued, all rats underwent Ovx surgery. Under isoflurane 
anesthesia, dorsolateral incisions were made in the skin and peritoneum, 
and ovaries and tips of uterine horns were ligated and removed. Ovx rats 
were then separated into the following groups to estimate a dose 
response curve of tonic subcutaneous CEE and E2: Ovx plus vehicle 
polyethylene glycol (PEG; Ovx-Veh, n = 4), Ovx plus 6 µg/day of CEE 
(Ovx-n = 4), Ovx plus 12 µg/day of CEE (n = 4), Ovx plus 36 µg/day of 
CEE (n = 3), Ovx plus 60 µg/day of CEE (n = 4), Ovx plus 72 µg/day of 
CEE (n = 4), Ovx plus 0.75 µg/day of E2 (n = 4), Ovx plus 1.5 µg/day of 
E2 (n = 4), Ovx plus 2.25 µg/day of E2 (n = 4), Ovx plus 3 µg/day of E2 (n 
= 4), and Ovx plus 3.75 µg/day of E2 (n = 4). CEE was manufactured by 
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Wyeth (Philadelphia, PA) but purchased from a commercial pharmacy via 
veterinary prescription. I chose the 36μg/day as the medium dose of CEE 
as it approximated a rat equivalent of the daily 0.625mg CEE dose that 
was evaluated in the WHIMS and is the dose commonly prescribed to 
women (see Shumaker et al., 1998; Stefanick, 2005). Moreover, the 
36μg/day dose of CEE is also the approximate dose of CEE or its 
component estrogen ∆8
Acosta et al., 2009b
E1 that my and my lab’s previous studies have 
found to enhance working and/or recent memory on the DMS Plus Maze 
(Chapter 4; ; Engler-Chiurazzi et al., 2009; Talboom et 
al., 2010). The highest dose of E2 (Sigma) was based on a previous study 
from my laboratory where a 4μg/day tonic dose of E2 delivered via Alzet®
For CEE, two doses below the middle 36μg dose (6 & 12µg/day) 
and two doses above (60 & 72µg/day) were tested; for E2, four doses of 
E2 below the high 3.75μg (0.75, 1.5, 2.25, and 3.0µg/day) were also 
tested to expand the dose range for the sake of an evaluation of the dose 
response curve. Hormone treatment began approximately 14 days after 
Ovx, and treatments (vehicle PEG or PEG + CEE) were administered via 
Alzet
 
pumps enhanced WM with minimal negative physiological effects (i.e., 
higher doses of E2 were detrimental to the animals’ health and 
performance; unpublished observations; Chapter 4). 
® osmotic pumps (Model 2004; Durect Corporation, Cupertino, 
California). CEE was suspended in PEG (Sigma), and the solution was 
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placed into pumps before insertion. For pump insertion, under isoflurane 
anesthesia, a small incision was made in the dorsal scruff of the neck, and 
a subcutaneous pocket was created. For each animal, one pump of the 
appropriate hormone dose was inserted into the pocket and the skin was 
stapled. Animals were treated with their appropriate hormone dose or 
vehicle 12 days before behavioral testing began. All animals had hormone 
exposure for the duration of behavioral testing through sacrifice.  
Vaginal smears and uterine weights  
To confirm Ovx, E2, and CEE treatment, vaginal smears were 
taken at three times: 13 days following Ovx surgeries, 11 days following 
pump insertion and just prior to sacrifice (26 days after pump insertion). 
Smears were classified as either: proestrus, estrous, metestrus, or 
diestrus (Goldman et al., 2007). To examine the effects of Ovx and 
subcutaneous E2 and CEE on stimulation of uterine tissues, after maze 
testing animals were anesthetized with isoflurane and sacrificed. A ventral 
incision was made in the abdominal region, and the uterus was cut above 
the junction with the cervix and on the uterine horn below the ligature 
remaining from Ovx (Ashby et al., 1997b). Uteri were trimmed of all visible 
fat and were immediately weighed (wet weight). This weight in grams (g) 
served as the dependent variable for statistical analysis. 
Working/Recent Memory DMS Plus Maze 
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The testing procedure has been previously published (Acosta et al., 
2009b; Engler-Chiurazzi et al., 2009; Talboom et al., 2010). This task 
assesses spatial working/recent memory. The apparatus had four arms 
(each 38.1 cm long and 12.7 cm wide) and was filled with room 
temperature water made opaque with black non-toxic paint. The maze had 
a hidden escape platform at the end of one of the four arms. The platform 
location changed every day, but was fixed within a day. Entry into an arm 
with no platform counted as an error. WM performance was evaluated by 
assessing the ability to navigate to the new platform location on trial 2. 
Hence, trial 1 was the information trial, trial 2 was the WM test trial, and 
trials 3-6 six were recent memory test trials (Acosta et al., 2009b; Engler-
Chiurazzi et al., 2009). Rats were dropped off in a semi-randomly chosen 
start arm location, and were given a maximum of 90 s to swim to the 
platform. Once on the platform, the rat remained on it for 15 s, followed by 
placement into a heated cage for a 30 s inter-trial interval (ITI). An arm 
entry was counted when the tip of a rat’s snout reached a mark delineated 
on the outside of the arm (11 cm into the arm). Animals completed six 
trials/day for seven days. The number of total errors (i.e., initial and repeat 
errors) and repeat errors (i.e., repeat entries into arms that did not contain 
the platform) committed on trials 2-6 across the first 5 days of testing (i.e., 
days 1-5 baseline learning), as well as errors committed on trials 2-6 
across all days of testing (i.e., days 1-7, overall performance) were the 
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four dependent measure composites created for statistical analysis, with 
one for each error type (see Table 3). These composites were created 
based on previous research where CEE and a component estrogen of 
CEE benefitted performance on this task across similar day and trial 
blocks (Chapter 4; Acosta et al., 2009b; Talboom et al., 2010).  
Statistical Methods 
To evaluate uterine weights, using StatView (version 5.01, The 
SAS Institute Inc., Cary, NC), I performed a one-way analysis of variance 
(ANOVA) separately in 1) the Ovx-Veh group compared to all E2 treated 
groups, and 2) the Ovx-Veh groups compared to all CEE treated groups. 
Since my a priori interest was to determine whether each hormone dose 
increased uterine weight relative to the Ovx-Veh group, all follow-up 
comparisons employed Fisher’s PLSD post-hoc tests when a significant 
omnibus ANOVA was found, noting that Type 1 error correction is not 
necessary with orthogonal planned comparisons (Keppel and Wickens, 
2004). 
 Using StatView (version 5.01, The SAS Institute Inc., Cary, NC), I 
performed an one-way analysis of variance (ANOVA) separately in 1) the 
Ovx-Veh group compared to all E2 treated groups, and 2) the Ovx-Veh 
groups compared to all CEE treated groups; this was conducted to 
determine differences between Ovx-Veh and E2 as well as Ovx-Veh and 
CEE treatments on uterine weights. Since my a priori interest was to 
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determine whether each hormone dose increased uterine weight relative 
to the Ovx-Veh group, all follow-up comparisons employed Fisher’s PLSD 
post-hoc tests when a significant omnibus ANOVA was found, noting that 
Type 1 error correction is not necessary with orthogonal planned 
comparisons (Keppel and Wickens, 2004).  
The primary goal of this study was to estimate the dose response 
curve for E2 and CEE’s effect on spatial working/recent memory, and to 
this aim I used multiple regression analyses to describe the form of the 
relationship between dose and working/recent memory errors (i.e., 
summed composite measure). The baseline linear regression model was 
as follows: 𝒀 =  𝑩𝟎 +  𝑩𝟏(𝑫𝑶𝑺𝑬), where B0 was the intercept and B1 was 
the linear coefficient. The quadratic and cubic regression models were 
𝒀 =  𝑩𝟎 +  𝑩𝟏(𝑫𝑶𝑺𝑬) +  𝑩𝟐 (𝑫𝑶𝑺𝑬𝟐) and 𝒀 =  𝑩𝟎 +  𝑩𝟏(𝑫𝑶𝑺𝑬) + 𝑩𝟐(𝑫𝑶𝑺𝑬𝟐) + 𝑩𝟑(𝑫𝑶𝑺𝑬𝟑), respectively, where B0 was the intercept, B1 
was the linear coefficient, B2 was the quadratic coefficient, and B3
Curve estimation was performed and partial R
 was the 
cubic coefficient. Collectively, the regression coefficients defined a 
function/relationship that allowed the outcome variable means to vary in a 
linear or nonlinear fashion depending on dose.  
2 values were 
calculated using SPSS (version 18.0; IBM Corporation; Somers, NY) after 
the data were graphed, a 48 segment cubic spline (i.e., a smooth 
line/curve through the set of data points) was fit to the data to visualize 
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trends, and outliers were identified and removed via the polynomial 
regression equation that best fit the cubic spline using GraphPad Prism 
(version 5.03, GraphPad Software, La Jolla, CA). Lastly, gain in prediction 
F-tests were used to evaluate whether or not there was a significant 
increase in the increment of prediction from a linear, a quadratic, or a 
cubic model to a full model with 5 terms (i.e., G [the number of groups] -1 
= 5). The software DataFit was used to estimate the model with 5 terms 
(i.e., 𝒀 =  𝑩𝟎 +  𝑩𝟏(𝑫𝑶𝑺𝑬) +  𝑩𝟐(𝑫𝑶𝑺𝑬𝟐) + 𝑩𝟑(𝑫𝑶𝑺𝑬𝟑) +  𝑩𝟒(𝑫𝑶𝑺𝑬𝟒) + 𝑩𝟓�𝑫𝑶𝑺𝑬𝟓�; version 9, Oakdale Engineering, Oakdale, PA) (see Cohen 
et al., 2003). 
Results 
Peripheral Markers of Estrogenic Action 
After Ovx, but before CEE administration, vaginal smears showed 
that all animals were in diestrus, indicating a lack of estrogenic stimulation 
(Goldman et al., 2007). After pump insertion, all Ovx-Veh rats exhibited 
continuous diestrus smears with few cells, and all Ovx-E2 and Ovx-CEE 
treated rats, regardless of dose, exhibited vaginal smears with many 
cornified cells. The presence of many cornified cells indicated estrogenic 
stimulation of uterine/vaginal tissues (Goldman et al., 2007). An evaluation 
of uterine weights in the Ovx-Veh and all Ovx-E2 groups as well as the 
Ovx-Veh and all Ovx-CEE groups revealed a significant treatment main 
effect for both analyses (E2 F[5,13] = 4.07, p = 0.0192; CEE (F[5,15] = 
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24.88, p < 0.0001). Post-hoc analyses revealed that each E2 and CEE 
treated group had higher uterine weights when compared to the Ovx-Veh 
group (ps < 0.0305, Figure 19). Collectively, these peripheral markers of 
estrogenic action indicate that Ovx-Veh animals likely had little to no 
circulating estrogen present, while all Ovx-E2 and Ovx-CEE treated 
animals had hormone on board at the initiation of treatment through 
sacrifice.  
Linear and Nonlinear Regression: Dose Response Effects of E2 and 
CEE on Working and Recent Memory 
Ovx-Veh and E2 treated animals.  
I used a regression model to describe the form of the relationship 
between E2 dose and repeat errors committed during the baseline 
learning phase 
Talboom et al., 2008
on the DMS Plus Maze (i.e., trials 2-6 across days 1-5). I 
found a significant omnibus F statistic for the linear regression model (F[1, 
22] = 5.19, p = 0.0328). This indicated that a straight line described the 
relationship between E2 dose and repeat errors committed during the 
baseline learning phase, an effect that was in line with my previous 
research ( ). The partial R2 statistic from the linear 
model was 0.19, suggesting that the linear relationship explained 19% of 
the variation in repeat errors. The magnitude of the partial R2
see Cohen, 1988
 statistic was 
considered a medium effect by convention ( ). The 
intercept and linear coefficients from the regression model were B0 = 2.71 
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and B1 = -0.58 respectively. Collectively, these coefficients describe the 
regression line in Figure 20a where repeat working/recent errors 
decreased in a linear fashion as the tonic dose of E2 increased. It is 
important to note that the quadratic regression model was significant (F[2, 
21] = 4.54, p = 0.0229, partial R2 
The regression model evaluating the relationship between 
= 0.14); however, a nonsignificant gain in 
prediction F-test (F[4,18] = 0.81, p = 0.5833) suggested that the full model 
with 5 terms did not enhance the increment in prediction over and above 
the linear model. This indicated that the linear model fit the data 
appropriately. 
E2 dose 
and repeat errors committed across all test days (i.e., overall 
performance) on the DMS Plus Maze (i.e., trials 2-6 across days 1-7), 
revealed a significant omnibus F statistic for the linear regression model 
(F[1, 22] = 6.32, p = 0.0197, Figure 20b), indicating a straight line 
described the relationship between tonic E2 dose and repeat errors 
committed across all test days and trials. The partial R2 statistic was 0.22 
and considered a medium effect by convention. The intercept and linear 
coefficients from the regression model were B0 = 3.14 and B1 = -0.68, 
respectively. Here again the quadratic regression model was significant 
(F[2, 21] = 3.76, p = 0.0403, partial R2 = 0.05), but the gain in prediction F-
test was not significant (F[4,18] = 0.65, p = 0.6561), indicating that the 
linear model was an appropriate fit to the data.  
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Collectively, these two models suggest that the tonic dose of E2 
(within the current dose range tested) had a negative linear relationship 
with repeat working/recent memory errors committed during the learning 
phase and across all days on the DMS Plus Maze. Specifically, increasing 
from 0μg/day of E2 (i.e., Ovx-Veh rats) to 3.75μg/day of E2, the higher the 
dose, the better an animal’s working/recent memory performance was. 
Nonsignificant regression models were found when attempting to describe 
the form of the relationship between E2 dose and total errors committed 
during the baseline learning phase or total errors for overall performance. 
Ovx-Veh and CEE treated animals. 
When describing the relationship between CEE dose and total 
errors committed across all test days on the DMS Plus Maze (i.e., overall 
performance, trials 2-6 across days 1-7), the linear regression model was 
not significant (F[1,19] = 1.72, p = 0.2048, partial R2 
Chapter 4; Talboom et al., 2010
= 0.08), which 
indicated that a linear model did not accurately fit the data. Although my 
previous research on CEE and one of its component estrogens did not 
lead me to expect a linear relationship ( ), 
the linear model provided a baseline for comparing a non-linear dose-error 
curve. Next, I fit two polynomial regression models: one that included a 
linear and a quadratic term (i.e., dose & dose squared), and another that 
included a linear, a quadratic, and a cubic term (i.e., dose, dose squared, 
& dose cubed); these terms served as explanatory variables. The 
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quadratic regression model was significant (F[2,18] = 5.51, p = 0.0136, 
partial R2 = 0.32); however, the cubic regression model was also 
significant (F[3,17] = 5.44, p = 0.0083), along with the gain in prediction F-
test for the full model with 5 predictors against the quadratic model 
(F[3,15] = 3.39, p = 0.0379), indicating that the cubic and not the quadratic 
model was a more appropriate fit to the data. An evaluation of the 
regression coefficient from the cubic model revealed that the cubic 
coefficient was not significant (B3 = 0.000, t = 1.92, p = 0.0720, Figure 
20c). Interestingly, the quadratic coefficient was significant (B2 = 0.008, t = 
2.93, p = 0.0089), collectively suggesting that the relationship between 
CEE dose and total working/recent errors committed during testing did not 
have extensive cubic but did have substantial quadratic curvature. The 
partial R2
Cohen, 1988
 statistic from the cubic model was 0.18, suggesting that the 
cubic relationship explained 18% of the variation in total errors; this was 
considered a medium effect by convention ( ). The intercept, 
linear, and quadratic coefficients from the cubic model were B0 = 16.36, 
B1 = 0.20, and B2 = -0.19, respectively. I would be remiss if I did not note 
the possibility of a 4th or higher order model being able to describe this 
relationship; however, the gain in prediction F-test from the cubic model to 
the full model with 5 predictors was not significant (F[2,15] = 2.85, p = 
0.0649), indicating that the cubic model was appropriate, not a model 
containing additional terms (i.e., 4th order). 
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An evaluation of the relationship between CEE dose and repeat 
errors committed during the baseline learning phase on the DMS Plus 
Maze (i.e., trials 2-6 across days 1-5), revealed a nonsignificant omnibus 
F statistic for the linear model (F[1,19] = 0.67, p = 0.4214, partial R2 = 
0.03). However, the quadratic regression model was significant (F[2,18] = 
8.30, p = 0.0028, Figure 20d), as was the test for the quadratic coefficient 
(B2 = 0.003, t = 3.93, p = 0.0009), indicating that the relationship between 
dose and repeat working/recent errors committed during the baseline 
learning phase had substantial curvature. The partial R2 for the quadratic 
model was 0.46 and considered a large effect by convention. The 
intercept and linear coefficients from the regression model were B0 = 3.43 
and B1 = -0.20 respectively. The cubic regression model was significant 
(F[3,17] = 5.95, p = 0.0057, partial R2 
Taken together, these two models suggest that tonic CEE dose had 
a curvilinear or U-shaped relationship with total working/recent memory 
errors committed across all days and repeat working/recent memory 
errors committed during the learning phase. Specifically, the no 0μg/day 
(Ovx-Veh), low 6μg/day, high 60μg/day, and high 72μg/day dose of CEE 
had more errors relative to the middle 36μg/day dose of CEE. 
Nonsignificant regression models were found when attempting to describe 
= 0.06), but the gain in prediction F-
test was not significant for the full model (F[3,15] = 1.62, p = 0.2217), 
suggesting that a quadratic model fit the data appropriately.  
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the form of the relationship between CEE dose and total errors committed 
during the baseline learning phase or repeat errors for overall 
performance. Table 3 summarizes the form of the relationship between 
each composite dependent variable and E2 or CEE dose with Ovx-Veh 
animals serving as a 0μg/day dose. 
Discussion 
To the author’s knowledge, the present study is the first to evaluate 
more than three doses of E2 and CEE on cognition in a single study. In 
middle-aged surgically menopausal rats, the peripheral markers of 
estrogenic action suggested that Ovx ablated the endogenous source of 
estrogens before experimental exogenous treatment began, and that all 
Ovx-E2 and Ovx-CEE, but not Ovx-Veh treated animals, had hormone on 
board for the duration of the study. The dose response results suggest 
that as the tonic dose of E2 increased from 0μg/day in Ovx-Veh animals to 
3.75μg/day in E2 high dose animals, the number of repeat working/recent 
memory errors decreased in a linear fashion during learning (i.e., days 1-
5) and across all days (i.e., 1-7). In CEE treated animals, as the tonic dose 
of CEE increased from 0μg/day in Ovx-Veh animals to 72μg/day in the 
CEE high group, the number of total working/recent memory errors 
committed across all test days followed a curvilinear cubic relationship. A 
quadratic U-shaped relationship in CEE treated animals was found for 
repeat working/recent memory errors committed during the learning phase 
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(i.e., days 1-5), with the optimal middle dose being approximately 
36μg/day (Table 3).  
I did not find my hypothesized U-shaped relationship with 
working/recent memory in E2-treated animals. This is likely due to my use 
of lower tonic doses of E2 in comparison to most reports using 10μg and 
above (see Dohanich, 2002). I specifically chose lower tonic E2 doses in 
this study because my lab and I have found that higher long-term (i.e., ≥ 
28 days) tonic doses of E2 administered via Alzet®
Chapter 4; Bimonte-Nelson et al., 2006
 pumps (Durect 
Corporation, Cupertino, California) or E2 pellets (Innovative Research of 
America, Sarasota, Florida) without the coadministration of progesterone 
caused health problems and increased mortality in my lab’s previous 
studies ( ). Still, these present E2 
linear relationships with spatial working/recent memory corroborate 
previous findings whereby E2 benefited spatial WM in Ovx rats (Chapter 
4; Bimonte and Denenberg, 1999; Daniel et al., 1997; Daniel et al., 2005; 
Gibbs, 1999; Gibbs, 2000b; Gibbs, 2002; Gibbs, 2007; Gibbs and 
Johnson, 2008; Luine et al., 1998a; Rodgers et al., 2010). Interestingly, 
my results here evaluating working/recent memory on the DMS Plus Maze 
correspond with my prior findings testing RM on the Morris maze, 
indicating that this may relationship may exist within other memory 
domains (Talboom et al., 2008). Indeed, higher levels of circulating E2 
were linearly related to better spatial RM performance.  
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Linear relationships between E2 and memory have been noted in 
several other reports. Asthana and colleagues (1999) found that plasma 
E2 levels, after exogenous E2 treatment via a transdermal patch, were 
positively related in a linear fashion to verbal memory in aged women 
diagnosed with probable AD. Others have also noted linear relationships 
between semantic and verbal memory and E2 in middle-aged women 
(Phillips and Sherwin, 1992; Ryan et al., 2010); however, it is important to 
note that other studies have not found these relationships in aged women 
(e.g., Almeida et al., 2005; Barrett-Connor and Goodman-Gruen, 1999). 
Interestingly, my previous study also noted that linear relationships 
between E2 and memory were present in young and middle-aged, but not 
aged rats (Talboom et al., 2008), suggesting that age may attenuate, 
mask, or abolish relationships between E2 and memory in both rodent and 
human females. Collectively, my data suggest that E2 has a positive linear 
relationship with regard to working/recent memory performance (i.e., 
higher doses had fewer errors and better performance), and this 
relationship is supported in part by other reports in both the human and rat 
literature. 
The current curvilinear/U-shaped relationship between CEE dose 
and spatial working/recent memory is in part corroborated by previous 
findings where higher doses of CEE, or a separate component estrogen of 
CEE, ∆8E1 (still below 60μg/day), benefited spatial working and/or recent 
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memory in Ovx rats (Chapter 4; Acosta et al., 2009b; Engler-Chiurazzi et 
al., 2009; Talboom et al., 2010). Specifically, in the current study, CEE 
dose exhibited a U-shaped relationship with total errors across all days 
(i.e., 1-7) and repeat working/recent memory errors during learning (i.e., 1-
5), where previous studies evaluating CEE’s effects on the DMS Plus 
Maze noted CEE- facilitated enhancements to working/recent memory 
assessed via total errors committed during the learning phase (i.e., days 
1-5) (Chapter 4; Acosta et al., 2009b). Of particular interest is the fact that 
my previous studies suggested a U-shaped or linear relationship between 
CEE/∆8
Acosta et al., 2009b
E1and WM errors, since lower doses had no effect or impaired 
performance, and the ≈ 36μg dose enhanced performance relative to Ovx 
animals ( ; Engler-Chiurazzi et al., 2009; Talboom et 
al., 2010). I must note that there is some disparity between the error types 
and day blocks in which I noted CEE effects on working/recent memory 
between the current study and lab’s previous reports. Specifically, in my 
current study I did not find a relationship between CEE dose and total 
errors committed across the learning phase. However, the design and 
conducted analyses between studies were conceptualized differently since 
I set out to describe relationships via multiple regression in the current 
study (using more groups with fewer subjects), while previous studies 
were designed to evaluate pairwise comparisons via ANOVA (using fewer 
groups with more subjects). Nonetheless, even with this caveat in mind, 
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the current results are in line with previous reports whereby CEE can be 
beneficial to working and/or recent memory with the appropriate treatment 
dose. 
While the gain in prediction test indicated that a quadratic model 
was not an ideal model to describe the relationship between CEE dose 
and total working/recent memory errors committed during all days of 
testing (i.e., Days 1-7 Trials 1-6), the medium to large effect size (i.e., 
quadratic partial R2 = 0.32) and the quadratic coefficient (i.e., B2 = 0.008) 
suggest that the model was a decent fit. In fact, the quadratic model, in 
respect to the partial R2 and quadratic curvature, appeared to be a better 
fit than the cubic model (i.e., cubic partial R2
Yerkes and Dodson, 1908
 = 0.18 & nonsignificant cubic 
term). Collectively, this suggests that some interpretations can be made 
from the quadratic model in this instance and that another model aside 
from cubic should be used to evaluate these data. With that in mind, the 
U-shaped relationship between CEE dose and working/recent memory is 
particularly exciting because it identifies the 36μg/day as the optimal dose 
for working/recent memory performance. The U-shaped relationship also 
suggests that CEE’s effects on memory systems may follow the Yerkes-
Dodson law ( ). The Yerkes-Dodson law states 
that low and high levels of arousal are detrimental to performance but a 
midlevel of arousal is beneficial, outlining the quadratic or inverted-U 
shaped relationship (Yerkes and Dodson, 1908). Of interest is the fact that 
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the Yerkes-Dodson law seems to explain relationships between memory 
performance and circulating levels of glucocorticoids (i.e., cortisol, a stress 
hormone) in humans as well as glucocorticoid levels (i.e., corticosterone) 
and LTP in rats (i.e., a hypothesized neurobiological underpinning of 
memory) (for review see Lupien et al., 2007). Together, this adds validity 
to my CEE findings, since other hormone systems also demonstrate a U-
shaped relationship with regard to memory.  
It is not surprising that animals receiving the 6μg/day dose 
exhibited more errors in relation to the 36μg/day dose; CEE is comprised 
of ≈ 50% E1 which has a lower binding affinity to the ERα and ERβ (Kuhl, 
2005; Sitruk-Ware, 2002). The reason for the 12μg/day, 60μg/day, and 
72μg/day doses of CEE increasing the number of errors in relation to the 
36μg/day dose may be due in part to the rat pharmacokinetics of CEE, 
specifically, in the circulating ratio of E1 to E2. My lab has noted that a 
12μg/day dose of CEE impaired WM and RM and produced serum levels 
of E1 that differed from Ovx animals, but serum E2 levels that did not 
differ from Ovx animals (Engler-Chiurazzi et al., 2009). In this study serum 
E1, and the ratio of serum E1 to E2, also correlated with WM performance 
(Engler-Chiurazzi et al., 2009). This suggests a possibility that the current 
12μg/day, 60μg/day, and 72μg/day CEE doses may have produced high 
levels of E1 in the presence of low levels of E2, causing decrements in 
WM performance that may be related to weaker estrogens such as E1 
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acting as a competitive ligand to E2 and its effects. Collectively, the 
quadratic U-shaped relationship between CEE and memory is not 
surprising since quadratic relationships exist between other hormones and 
memory. Furthermore, the CEE data indicated that the 36μg/day is optimal 
for working/recent memory where other doses are not, perhaps due to 
weaker estrogenic action and the pharmacokinetics of CEE producing 
higher levels of E1 and lower levels of E2. 
Higher doses of E2 and the 36μg/day dose CEE likely facilitated 
better performance on the DMS Plus Maze by predisposing animals to use 
a place strategy (allocentric) as opposed a response strategy (egocentric) 
to locate the escape platform (Korol and Kolo, 2002). In my DMS Plus 
Maze task, animals using a response strategy (i.e., turn left or turn right) 
would have been inefficient at locating the platform. I speculate that the 
use of a place strategy allowed higher dose Ovx-E2 and medium dose 
Ovx-CEE animals to accumulate fewer errors by creating a more stable 
cognitive map, in part by having a better ability to hold the spatial location 
of the platform in WM (Barnes et al., 1997; Wilson et al., 2004). Indeed, 
this cognitive map was likely successively enhanced as the tonic dose of 
E2 increased, and was therefore maximally enhanced in CEE treated 
animals at the tonic 36 μg/day dose. WM and RM performance is reliant 
on integrity of the hippocampus and surrounding cortices, including the 
entorhinal cortex (for review see Morris et al., 1982; Zola-Morgan et al., 
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1994), and WM is also reliant on the prefrontal cortex (for review see 
Jones, 2002). The hippocampus, entorhinal cortex, and prefrontal cortex 
receive cholinergic innervation from the BF, which supports memory 
function (Hasselmo, 2006; Henny and Jones, 2008). E2 potentiates 
increases in hippocampal ACh levels during maze learning relative to 
vehicle treatment in Ovx rats (Marriott and Korol, 2003), and E2-induced 
memory enhancements are present in animals with intact BF cholinergic 
neurons, but not in animals with BF cholinergic lesions (Gibbs, 2002). 
Treatment with E2 and CEE increases the number of ChAT-IR positive 
neurons in the BF (Acosta et al., 2009b; Gibbs, 1997), and E2 and CEE 
treatment also protect against muscarinic challenges (i.e., scopolamine-
induced amnesia) in rats (Acosta et al., 2009b; Savonenko and 
Markowska, 2003). Similarly, the dose response relationship between E2 
and CEE could reflect enhanced cholinergic neuronal function in the BF 
and elevated ACh tone in the hippocampus.  
In conclusion, Ovx abolished or decreased peripheral markers of 
estrogenic action, while E2 and CEE treatment increased peripheral 
markers, suggesting that Ovx surgery and hormone treatments were 
successful. My dose response results suggested that as the tonic dose of 
E2 increased, the number of repeat working/recent errors decreased in a 
linear fashion. In CEE treated animals, as the tonic dose of CEE 
increased, the number of total and repeat working/recent errors followed a 
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quadratic U-shaped relationship, identifying the 36μg/day dose as optimal 
for performance. Future studies could expand the dose range of E2 in 
order to elucidate a possible U-shaped relationship with regard to WM 
performance as well as evaluate an alternative to the cubic model. 
Another future direction is to look for these same linear and quadratic 
relationships after E2 and CEE treatment in measures assessing the 
biological underpinnings of memory. For example, future studies could 
assess the dose response effects of E2 and CEE on BF and hippocampal 
ACh levels as well as hippocampal and prefrontal cortex LTP. It is my 
hope that these findings will aid in the planning of future evaluations of the 
effects of these and other hormones on memory, ultimately helping to 
elucidate the many parameters that dictate whether HT is detrimental or 
beneficial to the ever expanding aging population.  
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CHAPTER 6 
A COMPONENT OF PREMARIN®
CEE contains the sulfates of more than 10 estrogens, is over 50% 
E1, 20-25% equilin, 3.5% ∆
 ENHANCES MULTIPLE COGNITIVE 
FUNCTIONS AND INFLUENCES NICOTINIC RECEPTOR EXPRESSION 
8
Bhavnani, 2003
E1, and contains only trace amounts of E2 
(the most potent naturally circulating estrogen in women and rats); after 
metabolism, the resulting biologically active circulating hormones are 
primarily E1 and equilin, and after E1’s conversion, E2 ( ; 
Bhavnani et al., 1998; Mayer et al., 2008; Sitruk-Ware, 2002). In the last 
decade, landmark basic science research from the Brinton laboratory has 
led to several discoveries regarding the neuroprotective properties of 
estrogens. This work demonstrated that some components of CEE 
enhanced markers of neuroprotection, while others showed little benefit 
(Brinton et al., 1997; Zhao and Brinton, 2006). The estrogens ∆8
Zhao and Brinton, 2006
E1 and 
equilin, found naturally in horses but not in women or rats, were the two 
primary CEE components that showed the most consistent and potent 
neuroprotective effects in vitro ( ). ∆8
BF cholinergic neurons project to the hippocampus and 
surrounding cortical areas, and play an important role in learning and 
E1- and 
equilin-facilitated neuroprotection in vitro could potentially translate to 
improved function of neural networks and brain regions directing cognitive 
function, resulting in memory enhancements in vivo. 
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memory (Hasselmo, 2006). E2 enhances BF cholinergic function, as 
evidenced by expression of different cholinergic markers and 
pharmacological cholinergic challenges (e.g., Gibbs, 2000a; Markowska 
and Savonenko, 2002a; Packard and Teather, 1997). In fact, ChAT 
increases in the BF months after transient exposure to E2, noting effects 
are sensitive to several variables including timing and dose (Bohacek et 
al., 2008; Gibbs, 1997; Rodgers et al., 2010). My laboratory has 
demonstrated CEE-induced benefits to the cholinergic system, whereby 
CEE 
Acosta et al., 2009b
treatment prevented scopolamine-induced amnesia and increased 
number of ChAT positive neurons in the vertical diagonal band of the BF 
in Ovx rats ( ). Cholinergic signaling is directed by 
muscarinic mAChR and nAChR, which are present in brain regions known 
to be responsible for memory processing (Clarke et al., 1985; Court and 
Clementi, 1995; Tice et al., 1996; Vaucher et al., 2002) and are implicated 
in memory processing (Hasselmo, 2006; Konopacki et al., 1992; Rouse et 
al., 1999). Nicotine administration improves memory in humans 
(Buccafusco et al., 2005), and my lab and others have noted nicotine-
induced memory enhancement in rats across multiple memory domains 
(Arendash et al., 1995; French et al., 2006; Riekkinen and Riekkinen, 
1997; Socci et al., 1995). E2 and ethinyl β-estradiol bind to the α4β2-
nAChR, the most abundant nAChR subtype in the brain, and directly 
potentiate the function of human α4β2-nAChRs (hα4β2-nAChR); ethinyl β-
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estradiol, but not E2, potentiates rat α4β2-nAChRs (rα4β2-nAChR) (Curtis 
et al., 2002; Paradiso et al., 2001). Recently, in vivo research has 
demonstrated that nicotine co-administered with estradiol potentiates 
visual spatial memory in Ovx rats, beyond that of either compound 
administered alone (Taylor and Maloney, 2010). Collectively, these 
studies suggest a link between estrogens, nAChRs, and memory. 
Numerous studies have demonstrated that E2 benefits spatial 
working and RM in young Ovx rats (Bimonte and Denenberg, 1999; Daniel 
et al., 1997; Daniel et al., 2005; El-Bakri et al., 2004; Fader et al., 1998; 
Feng et al., 2004; Gibbs, 2007; Hruska and Dohanich, 2007; Korol and 
Kolo, 2002; Luine and Rodriguez, 1994), as well as in middle-aged Ovx 
rats (Bimonte-Nelson et al., 2006; Foster et al., 2003; Markham et al., 
2002; Talboom et al., 2008). CEE can also benefit cognition in middle-
aged Ovx rats, although these effects are dose and task specific (Acosta 
et al., 2009b; Engler-Chiurazzi et al., 2009; Walf and Frye, 2008). The 
current study utilized a similar model, the middle-aged Ovx rat, to test the 
impact of ∆8
Acosta et al., 2009a
E1 and equilin on memory and rα4β2-nAChR expression and 
function. I used a battery of water-escape mazes previously shown to be 
influenced by age as well as ovarian hormone loss and estrogen treatment 
( ; Acosta et al., 2009b; Bimonte-Nelson et al., 2006; 
Engler-Chiurazzi et al., 2009; Talboom et al., 2008). These mazes 
evaluate WM, which is information that needs to be updated and is 
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pertinent for a short time, and RM, which is information that remains 
constant over time (see Jarrard et al., 1984; Jones, 2002). 125I-labeled 
epibatidine (I-epi) radioligand binding assays were used to evaluate 
rα4β2-nAChR expression levels in the hippocampus and entorhinal 
cortex, and cell culture was used to evaluate whether ∆8E1 and equilin 
directly altered hα4β2-nAChR function via 86Rb+
Methods 
 efflux experiments. 
Lastly, several peripheral markers routinely noted to change with E2 
treatment, including serum luteinizing hormone (LH) levels, vaginal 
smears, and uterine weights, were assessed. 
Subjects 
Subjects were 50 middle-aged (12-13 month old) Fischer-344 
female rats born and raised at the National Institute on Aging colony at 
Harlan Laboratories (Indianapolis, IN). Animals were acclimated for 
several weeks to the vivarium at Arizona State University, had exposure to 
food and water ad-lib, and were maintained on a 12-h light/dark cycle at 
23 °C. Procedures were approved by Arizona State University IACUC and 
adhered to the Guide for the Care and Use of Laboratory Animals and NIH 
standards. 
Hormone Manipulation 
Ovx, group assignment and hormone dosing. 
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Thirty days after arrival, all rats received Ovx under isoflurane 
anesthesia. Dorsolateral incisions were made in the skin and peritoneum, 
and ovaries and tips of uterine horns were ligated and removed. Rats 
were randomly assigned into a control group receiving vehicle only or 
groups receiving one of three doses of hormone delivered via osmotic mini 
pump. Specifically, the groups were: Ovx plus vehicle (Ovx-Veh, n=8), 
Ovx plus 2.6 µg/day of ∆8E1 (Ovx-∆8E1-Low, n=7), Ovx plus 17.5 µg/day 
of ∆8E1 (Ovx-∆8E1-Med, n=7), Ovx plus 35 µg/day of ∆8E1 (Ovx-∆8E1-
High, n=7), Ovx plus 2.6 µg/day of equilin (Ovx-Equilin-Low, n=7), Ovx 
plus 6.25 µg/day of equilin (Ovx-Equilin-Med, n=7), and Ovx plus 12.5 
µg/day of equilin (Ovx-Equilin-High, n=7). All hormones were purchased 
from Steraloids Inc. (Newport, RI). Low doses of ∆8E1 and equilin were 
derived from studies demonstrating cognitive enhancement using 3.6 μg 
of CEE. Doses were adjusted to account for ∆8E1 and equilin being in its 
unconjugated form1
Acosta et al., 2009b
, and to approximate the rat body weight equivalent of 
the 0.625 mg dose, which was used in the WHIMS and is what women are 
most commonly prescribed ( ; Engler-Chiurazzi et al., 
2009). The high doses for ∆8E1 and equilin were based on the only other 
available reports in the rat model using these hormones, wherein ∆8E1 
decreased depolarization-induced cardiac synapse norepinephrine 
release, and equilin elevated vascular reactivity in the mesenteric vascular 
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bed (Eskin et al., 2003; Mark et al., 2007). The medium doses of ∆8E1 and 
equilin were half of the high doses.  
1
 The 20-36 µg of CEE powder that my lab has shown to enhance cognition was actually 
2.0-3.6 µg of estrogens, respectively, since it was ≈ 10% hormone and ≈ 90% filler (Acosta 
et al., 2009b; Engler-Chiurazzi et al., 2009). CEE is a mixture of estrogens conjugated to 
sulfate; the hormones must be deconjugated by the liver to become bioactive (Bhavnani et 
al., 1998). I used bioactive, unconjugated ∆
8
E1 and equilin in this study. To attain an 
approximately equivalent amount of estrogen molecules between my current ∆
8
E1 and 
equilin low dose, and my previous CEE dose, I had to account for the fact that estrogens in 
CEE are conjugated, and conjugated estrogens weigh more. Since the molecular weights 
of ∆
8
E1 sulfate and equilin sulfate (the conjugated estrogens) are each 370.08 (as 
monosodium salts), while that of ∆
8
Hormone treatment procedure. 
E1 and equilin (as unconjugated estrogens) are each 
268.35, the final concentrations for the low doses were reduced by 28% (i.e., 3.6 μg/day - 
28% ≈ 2.6 μg/day).  
 
Hormone treatment began approximately 16 days after Ovx 
(Bimonte-Nelson et al., 2006), 12 days before behavior testing began. 
Vehicle only (PEG, average molecular weight of 300, Sigma-Aldrich, St. 
Louis, Missouri), or ∆8E1 or equilin in vehicle, was administered via Alzet® 
pumps (Model 2004; Durect Corporation, Cupertino, California). The 
concentration of ∆8E1 or equilin, suspended in PEG, in the pumps was 
calculated to deliver the low, medium or high dose for each hormone per 
day. Pumps were prepared the day before surgery and allowed to 
equilibrate in physiological saline at 37 °C overnight. For pump insertion, 
animals were anesthetized under vaporized isoflurane anesthesia, an 
incision was made in the dorsal scruff of the neck, the pump was inserted, 
and the skin was stapled. Pumps remained in the subjects throughout 
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behavioral testing and until sacrifice (approximately 4 weeks), which 
provided consistent exposure to their assigned treatment for the duration 
of behavioral testing, through sacrifice.   
Behavior Testing 
DMS Plus Maze (spatial working and recent memory). 
I used the DMS Plus Maze task to test spatial working and recent 
memory. The protocol was based on studies showing E2- and CEE- 
induced improvements in Ovx rats (Acosta et al., 2009b; Gibbs, 2000b; 
Korol and Kolo, 2002; Sandstrom and Williams, 2004). The black 
Plexiglass maze (each arm was 38.1cm x 12.7cm) was filled with water 
made opaque with black non-toxic paint. The submerged platform was 
hidden at the end of one of the four arms. The start location varied across 
trials, and the platform location stayed in the same arm within a day, but 
semi-randomly changed arms across days. This a place learning task, 
whereby animals must learn to navigate to a hidden escape platform by 
using distal spatial cues (Restle, 1957). Since the platform changed 
position relative to space each day, this task is differentiated from other 
match-to-sample or match-to-position tasks where animals solve the task 
using response learning (i.e., making the same turn regardless of the 
spatial location) (Restle, 1957). Rats received 6 consecutive trials within a 
daily session, for 7 days, and were given 90 seconds to locate the 
platform. Once on the platform, the rat remained on it for 15 seconds, 
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followed by placement into a heated cage for a 30s inter-trial interval. An 
arm entry was counted when the tip of a rat’s snout reached a mark 
delineated on the outside of the arm (11 cm into the arm). Entry into any 
non-platformed arm was counted as an error, and fewer errors are 
indicative of better performance. At the start of an animal’s daily testing 
session, it had no information regarding the platform location. Hence, on 
trial 1, the rat swam until it located the platform. The rat then needed to 
remember this platform location and return to it on subsequent trials. WM 
performance was evaluated by assessing the ability to navigate to the new 
platform location on trial 2. Hence, trial 1 was the information trial, trial 2 
was the WM test trial, and trials 3-6 six were recent memory test trials 
(Acosta et al., 2009b; Engler-Chiurazzi et al., 2009). The dependent 
variables were the number of initial and repeat errors committed during 
trial 2 (as a measure of WM) or trials 3-6 (as a measure of recent 
memory). Day 1 was considered the training day, as no prior information 
regarding task demands or platform location was available to the animals. 
My lab routinely treats day 1 as a training day on WM tasks (Acosta et al., 
2009a; Bimonte-Nelson et al., 2003a; Bimonte-Nelson et al., 2003b; 
Bimonte-Nelson et al., 2004b; Bimonte and Denenberg, 1999; Bimonte et 
al., 2003; Huentelman et al., 2009). 
Morris maze (spatial RM). 
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Using a previously published protocol (Markham et al., 2002), three 
days after DMS Plus Maze testing concluded, I tested spatial RM via the 
Morris maze, as I and others have shown enhancements due to E2 
treatment in Ovx rats on this task (Bimonte-Nelson et al., 2006; Markham 
et al., 2002; Talboom et al., 2008). Similar to the DMS Plus Maze, the 
Morris maze task assesses place learning; however, in the Morris maze 
the platform remains in the same spatial location for all days and trials, 
making it a spatial RM task. This can be contrasted with the DMS Plus 
Maze, which is a spatial WM task since the platform is moved to a new 
spatial location every day. The Morris maze (Morris et al., 1982) consisted 
of a round tub (188 cm in diameter) filled with water made opaque with 
black, non-toxic paint. The rat was placed in the maze from any of four 
locations (North, South, East, or West) and had 60 seconds to locate a 
submerged hidden escape platform which remained in a fixed location (NE 
quadrant) throughout testing. After 15 seconds on the platform, the rat 
was placed into its heated cage until the next trial; the inter-trial-interval 
was 5-8 minutes. For each rat, the testing session consisted of 6 trials/day 
for 3 days. A video camera recorded each rat, and a tracking system 
(Ethovision XT 5.1, Noldus Information Technology, Wageningen, 
Netherlands) analyzed each rat’s path. The dependent measure was swim 
distance (cm), with less swim distance interpreted as better spatial RM 
performance. To assess possible differences in the learning rates among 
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my treatment groups, data were collapsed into 3-trial blocks so that 
Treatment x Block interactions could be tested. To assess platform 
localization, a probe trial was given on an additional trial (trial 7) on the 
last day of testing, whereby the platform was removed from the maze. For 
the probe trial, percent of total swim distance (cm) in the target NE 
quadrant (i.e., quadrant that contained the platform on the test trials) as 
compared the opposite SW quadrant, was the dependent measure. 
Visible Platform (motoric and visual competence). 
One day after Morris maze testing, I evaluated motoric and visual 
competence using the visible platform task. A rectangular tub (39 x 23 in) 
was filled with clear room temperature water. A black platform (10 cm 
wide) was positioned 1.5” above the water surface following previously 
published methods (Hunter et al., 2003). Opaque curtains covered 
extramaze cues. Animals were given 6 trials in 1 day. The drop off location 
remained the same across trials, and the platform location for each trial 
varied semi-randomly. Each rat had 90 seconds to locate the platform, 
where it remained for 15 seconds before being placed back into its heated 
cage awaiting the next trial. The inter-trial-interval was 5-8 minutes. 
Latency (seconds) to reach the platform was the dependent measure. 
Evaluation of Vaginal Smears, Uteri, and Serum LH  
I evaluated the effects of ∆8E1 or equilin treatments on several 
peripheral markers that are routinely noted to change with E2 treatment. 
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To confirm Ovx as well as ∆8
Goldman et al., 
2007
E1 and equilin treatments, vaginal smears 
were taken prior to Ovx and pump surgery, immediately before behavior 
testing, and the day before sacrifice. Vaginal cytology via smears was 
classified as proestrus, estrous, metestrus or diestrus (
). Final vaginal smears were stained with eosin Y and hematoxylin 
(Sigma) for further brightfield microscopic examination. At sacrifice, 
animals were anesthetized with isoflurane. I confirmed complete Ovx via 
visual inspection of uterine horns, and I evaluated uterine weights as 
conducted in previous studies (Acosta et al., 2009b). A ventral incision 
was made in the abdominal region, and the uterus was cut above the 
junction with the cervix and on the uterine horn below the ligature 
remaining from Ovx (Ashby et al., 1997b). Uteri were trimmed of all visible 
fat and were immediately weighed to obtain wet weight, which was the 
dependent measure. Also, at this time, blood was collected via 
cardiocentesis. Five subjects per treatment group were randomly chosen 
to obtain serum LH levels. LH was determined at the Core Endocrine 
Laboratory at Pennsylvania State University College of Medicine by 
competitive radioimmunoassay using reagents obtained from ALPCO 
Diagnostics (Salem, NH), based on prior protocols (Roman et al., 2003). 
The assay uses 125I-labeled rat LH tracer for binding to a highly specific 
rabbit polyclonal antibody and separation of bound from free trace with an 
anti-rabbit IgG precipitating antibody. Results are expressed in ng/ml. 
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Lower limit of quantification for the assay is 0.5 ng/ml and within run and 
between run accuracy averaged 7% and 9% respectively at a 
concentration of 4.2 ng/ml. 
Brain Dissection and nAChR Agonist Binding  
Using radioligand binding assays, I investigated whether treatment 
with ∆8
Whiteaker et al., 2000
E1 or equilin affected rα4β2-nAChR expression levels. I-epi binding 
was used to estimate number of β2*- and β4*-nAChRs in the 
hippocampus and entorhinal cortex ( ; Whiteaker et 
al., 2008). At sacrifice, brains were rapidly dissected; one subject was 
excluded due to technical error. Each brain was cut on the coronal plane. 
Next, the entorhinal cortex (taking a 2- to 3- mm sample ventral to the 
hippocampus) and the CA1/CA2 region of the hippocampus (dentate 
gyrus and alveus excluded) were dissected. Dissected tissues were 
immediately placed in microcentrifuge tubes, frozen on dry ice, and stored 
at -70 °C until analysis. Hippocampal and entorhinal cortex tissues were 
separately homogenized in ice-cold 1x Ringer’s buffer with sodium azide 
(in mM : 144 NaCl, 2 KCl, 2 CaCl2, 1 MgSO4, 50 Tris-base; and 0.02 % 
(w/v) NaN3; pH 7.4; binding buffer). Homogenates were washed three 
times by centrifugation (12,000 x g; 15 minutes; 4 °C) and rehomogenized 
into 1x binding buffer and stored, pelleted, at 4 °C. I-epi binding was 
assessed at 1 nM. Non-specific binding was assessed in the presence of 
300 mM carbamylcholine. Specific binding was defined as the difference 
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between total and non-specific binding as fmol per mg of protein; this 
served as the dependent variable for statistical analyses. Since spatial 
memory processing is dependent on both the hippocampus and entorhinal 
cortex, and the functioning of these regions is intimately linked (for review 
see Jarrard, 1993; Zola-Morgan et al., 1994), specific I-epi binding data in 
the hippocampus and entorhinal cortex were analyzed together creating a 
single measure; the combined hippocampal and entorhinal cortex data will 
now be referred to as the hippocampus+entorhinal cortex. In the 
hippocampus/entorhinal cortex the contribution of β4*-nAChR was minimal 
(data not shown). Accordingly, I-epi binding populations in the 
hippocampus/entorhinal cortex are considered to represent β2 subunit-
containing nAChR, likely α4β2-nAChR (Whiteaker et al., 2000), as such, 
specific I-epi binding will be referred to as rα4β2-nAChR expression. 
86Rb+ Efflux For ∆8
Routine culture of SH-EP1 cells. 
E1 and Equilin Effects on hα4β2-nAChR Function 
To ascertain whether hormone effects could be due to direct 
actions on receptor function, I evaluated whether ∆8E1 or equilin exposure 
directly affected function of heterologously expressed, hα4β2-nAChR 
assessed using 86Rb+
Eaton et al., 
2003
 efflux experiments. SH-EP1 cells stably expressing 
hα4β2-nAChR were maintained as previously described (
). Briefly, cells were grown in Dulbecco’s modified Eagle’s medium 
(high glucose, bicarbonate-buffered, with 1 mM sodium pyruvate and 8 
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mM L-glutamine) supplemented with 10% horse serum, 100 U/ml 
penicillin, 100 µg/ml streptomycin, and 0.25 µg/ml amphotericin B (all from 
Invitrogen, Carlsbad, CA) plus 5% fetal bovine serum (Hyclone, Logan, 
UT) on 100-mm diameter plates in a humidified atmosphere containing 5% 
CO2 in air. Positive selection for the human α4 and β2 subunits (in 
pcDNA3.1/zeo and pcDNA3.1/Hygro, respectively; also from Invitrogen) 
was maintained by further supplementation of the growth medium with 
0.25 mg/ml zeocin (Invitrogen), and 0.4 mg/ml hygromycin B (Calbiochem, 
San Diego, CA). Cells were maintained at low passage numbers (1-26 
from frozen stocks), and passaged weekly by splitting confluent cultures 
1/20 – 1/40 to maintain cells in proliferative growth.  
86Rb+
Cells were harvested at confluence from 100-mm plates by mild 
trypsinization before being resuspended in growth medium and evenly 
seeded at a density of one confluent 100-mm plate per 24-well plate. Cells 
were allowed to adhere for a minimum of 6hrs. Medium was removed and 
replaced with 250 µl/well of medium supplemented with approximately 
300,000 cpm of 
 efflux assays in the presence of acute hormone. 
86Rb+ (PerkinElmer; counted at 40 % efficiency using 
Cerenkov counting, PerkinElmer Tricarb 1900 LSC). After 4hrs of loading, 
86Rb+ Lukas et al., 
2002
 efflux was measured using the flip-plate technique (
). Following aspiration of the bulk of 86Rb+ loading medium from each 
well of the cell plate, each well containing cells was rinsed three times with 
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2 ml of fresh efflux buffer (130 mM NaCl, 5.4 mM KCl, 2 mM CaCl2, 5 mM 
glucose, and 50 mM HEPES, pH 7.4) to remove extracellular 86Rb+. After 
removal of residual rinse buffer by aspiration, the flip-plate technique was 
used again to simultaneously introduce fresh efflux buffer containing drugs 
of choice at indicated final concentrations from a 24-well “efflux/drug plate” 
into the wells of the cell plate. In the case of the acute hormone effect 
experiments, the drugs used consisted of a test agonist (carbamylcholine 
at 100 µM) in the presence of ∆8
see Woolley, 2007
E1, equilin, and PEG (95 fM-1 µM), 
representing concentrations below, at, or above physiological relevant 
brain levels of E2 ( ). After a 5m incubation, the solution 
was “flipped” back into the efflux/ drug plate, any remaining medium was 
removed by aspiration. Suspensions in each well were then subjected to 
Cerenkov counting (PerkinElmer Wallac Micobeta Trilux 1450; 25% 
efficiency) after placement of inserts (PerkinElmerWallac 1450-109) into 
each well to minimize cross-talk between wells. Specific 86Rb+ efflux was 
calculated as efflux above the no-agonist control and expressed as a 
percentage of efflux evoked by a maximally-effective carbamylcholine (1 
mM) control stimulation. Increases or decreases in specific agonist-
induced efflux (i.e. efflux above non-specific levels) would be interpreted 
as direct, nAChR- facilitated, acute allosteric agonist or antagonist 
(respectively) effects. Intrinsic agonist activity of ∆8E1, equilin or PEG was 
calculated in samples containing the same concentrations tested in the 
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presence of agonist. The amount of specific 86Rb+ efflux, expressed as % 
of control, in response to log dilutions of ∆8E1, equilin, and PEG served as 
the dependent measure of hα4β2-nAChR receptor function. 
86Rb+
Cell plating for chronic hormone studies were the same as 
described previously for assessment of acute hormone effects, with the 
exception that cells were seeded more thinly into the 24-well plates (one 
half of a confluent 100-mm plate per six 24-well plates), allowing them to 
be grown for 48hrs in the presence of either ∆
 efflux assays after chronic hormone treatment. 
8E1 or equilin (9 aM - 1 µM) 
or 0.1% PEG and to reach confluence at the end of this period. Effects of 
chronic hormone exposure on 86Rb+ efflux were assessed as previously 
described for measurement of acute effects with minor exceptions. Briefly, 
after the 48hr hormone pretreatment period, media containing the 
hormone was removed and replaced fresh media containing 86Rb+ but 
devoid of hormone for the 4hr isotope loading period. Cells were rinsed 
free of extracellular isotope, and hormones at desired concentrations or 
0.1% PEG (matching conditions used in the preincubation period) were 
then simultaneously introduced in fresh efflux buffer with or without 
carbamylcholine from a 24-well “efflux/drug plate” into the wells of the cell 
plate. After a 5m incubation, the solution was “flipped” back into the 
efflux/drug plate, any remaining medium was removed by aspiration. The 
dependent measure was identical to the acute experiment (see above). 
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Statistical Methods 
For behavior assessments, I used StatView (version 5.01, The SAS 
Institute Inc., Cary, NC) to analyze data using an omnibus mixed model 
ANOVA with Treatment as the between variable, and Days, Block, and/or 
Trials as the within variable(s), as appropriate for the specific maze test. 
rα4β2-nAChR expression data were analyzed using an omnibus factorial 
ANOVA with Treatment and Brain region as between variables. Uterine 
weight and LH levels were analyzed using an omnibus one-way ANOVA 
with Treatment as between variable. In all ANOVAs conducted, each 
hormone type was analyzed separately, so each omnibus ANOVA 
included the Ovx-Veh group as well as the Low, Med, and High group of 
either ∆8
Keppel and 
Wickens, 2004
E1 or equilin. Since my interest was to determine whether each 
hormone dose enhanced performance relative to the Ovx-Veh group, all 
follow-up comparisons employed Fisher’s PLSD post hoc tests when a 
significant omnibus ANOVA was found, noting that Type 1 error correction 
is not necessary with orthogonal planned comparisons (
). For efflux experiments, I used GraphPad Prism (version 
5.03, GraphPad Software, La Jolla, CA) to perform multiple regression 
analyses that evaluated if the slope of the “line of best fit” differed from 0, 
followed by a Wald runs test for randomness to determine if the data 
deviated from linearity (Wald and Wolfowitz, 1940). 
Results 
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DMS Plus Maze: Spatial Working and Recent Memory 
Spatial WM was assessed using the win-stay DMS Plus Maze task. 
Analysis of repeat errors committed on trial 2 alone (the WM trial) for ∆8E1 
revealed a significant main effect of Treatment (F[3,25] = 3.02, p = 
0.0405). The Ovx-∆8E1-Med and Ovx-∆8E1-High groups made fewer 
repeat errors on trial 2 as compared to the Ovx-Veh group (ps < 0.0107, 
Figure 21a). The analysis of repeat errors for trials 3-6 (recent memory 
trials) revealed a marginal Treatment main effect for ∆8E1 (F[3,25] = 2.45, 
p = 0.0867). When all DMS test trials were combined (trials 2-6, working 
and recent memory trials) there was a Treatment main effect for ∆8E1 
(F[3,25] = 3.61, p = 0.0272). The Ovx-∆8E1-Med and Ovx-∆8
Morris Maze: Spatial RM 
E1-High 
groups made fewer repeat errors for all test trials combined as compared 
to the Ovx-Veh group (ps < 0.0107). There were no main effects or 
interactions for repeat errors for equilin (Figure 21b), nor were there 
effects for initial errors for either hormone. 
Animals were tested on the Morris maze to evaluate spatial RM. 
There was a main effect of Treatment (F[3,26] = 6.64, p = 0.0018), in the 
absence of a Block x Treatment interaction (F[3,26] = 0.21, p = 0.8921). 
Post-hoc analyses revealed that Ovx-∆8E1-Low, Ovx-∆8E1-Med, and Ovx-
∆8E1-High groups each swam less distance than the Ovx-Veh group 
(post-hoc ps < 0.0027, Figure 22a). For equilin, there were no significant 
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main effects or interactions (Figure 22b). For the probe trial, each 
treatment group localized to the NE quadrant which previously contained 
the hidden escape platform, with a higher percent distance in the NE 
quadrant (Quadrant main effect: ∆8
Visible Platform Task: Motoric and Visual Competence 
E1 F[1,26] = 181.21, p < 0.0001, Figure 
22c; Equilin F[1,26] = 116.19, p < 0.0001, Figure 22d). This was in the 
absence of a Treatment x Quadrant interaction for either hormone, 
indicating that all groups localized to the previously platformed quadrant. 
Motor and visual competence was assessed using a visible 
platform task. There were no main effects of Treatment for ∆8E1 or equilin, 
thereby indicating that animals, regardless of hormone status, were able 
to locate the visible platform (∆8
nAChR Agonist Binding: rα4β2-nAChR Expression Levels 
E1 F[3,26] = 0.83, p = 0.4908, Figure 23a; 
Equilin F[3,26] = 0.59, p < 0.6302, Figure 23b). All animals found the 
platform within 10 seconds on the last two trials, thereby indicating that all 
animals were able to perform the procedural components of a swim maze 
task. 
 I investigated whether treatment with ∆8E1 or equilin affected 
nAChR expression levels using a radioligand binding assay. Analysis of 
∆8E1 in the hippocampus+entorhinal cortex revealed a significant main 
effect of Treatment (F[3,48] = 4.33, p = 0.0089), with each ∆8E1 group 
showing decreased rα4β2-nAChR expression as compared to the Ovx-
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Veh group (ps ≤ .05, Figure 24a). Moreover, when Ovx-∆8E1-Low, Ovx-
∆8E1-Med and Ovx-∆8E1-High groups were combined into one ∆8E1 
group, there was a Treatment main effect (F[1,54] = 5.25, p = 0.0259, 
Figure 24a). There were also greater rα4β2-nAChR levels in the entorhinal 
cortex compared to the hippocampus (Brain Region main effect: (F[1,48] = 
59.81, p < 0.0001, Figure 24a), and there was a nonsignificant Treatment 
x Brain Region interaction indicating this pattern was shown for all ∆8E1 all 
doses. In the equilin analysis, there was no significant Treatment main 
effect (F[3,50] = 1.84, p = 0.1517); however, as seen in the ∆8
Regression: Relation between Nicotinic Receptor Agonist Binding 
and Memory 
E1 omnibus 
ANOVA, there were greater rα4β2-nAChR levels in the entorhinal cortex 
compared to the hippocampus (Brain Region main effect: (F[1,50] = 41.63, 
p < 0.0001, Figure 24b), in the absence of a Treatment x Brain Region 
interaction. 
Since a decrease in rα4β2-nAChR expression was noted with ∆8E1 
treatment in the hippocampus+entorhinal cortex, I conducted primary 
regression analyses relating rα4β2-nAChR expression in the 
hippocampus+entorhinal cortex to maze performance. Specifically, rα4β2-
nAChR expression in the hippocampus+entorhinal cortex was the 
predictor variable in the model, and Morris maze swim distance collapsed 
across all days, repeat DMS Plus Maze errors on trial 2 alone (collapsed 
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across days 2-7), or repeat DMS Plus Maze errors on trials 2-6 (collapsed 
across days 2-7), was the outcome variable. There was a positive 
relationship between rα4β2-nAChR expression in the 
hippocampus+entorhinal cortex and Morris maze swim distance (b = 0.03, 
r = 0.64, z[28] = 3.75, p = 0.0002, Figure 25). Since greater swim distance 
indicates poorer performance, better spatial RM performance was 
associated with less rα4β2-nAChR expression in the 
hippocampus+entorhinal cortex. When the data were centered to control 
for group membership (for more detailed methods and rationale see 
Enders and Tofighi, 2007; Hallahan and Rosenthal, 2000), the regression 
analysis remained significant (b = 7.71, r = 0.44, z[28] = 2.36, p = 0.0182). 
There were no significant regression analyses relating rα4β2-nAChR 
expression in the hippocampus+entorhinal cortex to working or recent 
memory repeat errors on the win-stay DMS Plus Maze (trial 2: b = 0.001, r 
= 0.06, z[28] = 0.26, p = 0.7829; trials 2-6: b = 0.001, r = 0.15, z[28] = 
0.78, p = 0.4365). 
Efflux Experiments: Evaluation of Direct Estrogenic Actions on 
hα4β2-nAChR Function  
I evaluated whether ∆8E1 or equilin exposure directly affected the 
function of hα4β2-nAChRs assessed using 86Rb+ efflux experiments in 
vitro. For either acute or chronic administration, regression analyses 
revealed that slopes of the best fit line did not differ from zero (ps > 0.05), 
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and the data did not deviate from linearity (Wald runs test for randomness, 
all ps > 0.05, Figures 26a, 26b and 26c). PEG did not affect or act 
together with ∆8E1 or equilin in altering 86Rb+
Vaginal Smears, Uterine Weights and Serum LH: Classic Estrogenic 
Actions 
 efflux during acute, or after 
chronic exposure. This indicates that neither acute nor chronic effects of 
hormone or vehicle on hα4β2-nAChR function occur at the concentrations 
tested.  
I tested peripheral markers that are routinely noted to change with 
E2 treatment. Before Ovx surgeries, all animals demonstrated normal 
cyclicity. After Ovx (but before hormone treatment), all rats consistently 
exhibited leukocytic, diestrus smears, as expected. Two days prior to 
behavior testing, after assigned vehicle or hormone had been 
administered, all Ovx-Veh-treated rats presented consistent diestrus 
smears, whereas hormone-treated rats showed constant cornified, estrous 
smears demonstrating uterine stimulation. These cytological profiles 
remained stable through sacrifice (Figure 27). Furthermore, each ∆8E1 
group, and each Equilin group, had increased uterine weight compared to 
the Ovx-Veh group (∆8E1 F[3,25] = 13.51., p < 0.0001, Figure 28a; Equilin 
F[3,25] = 34.96, p < 0.0001, Figure 28b, post-hoc ps < 0.0028), and lower 
LH levels as compared to the Ovx-Veh group (∆8E1 F[3,15] = 4.95, p = 
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0.0139, Figure 28c; Equilin F[3,15] = 8.67, p = 0.0014, Figure 28d, post-
hoc ps < 0.0143).  
Discussion 
The present study is the first to evaluate whether ∆8
Brinton et al., 1997
E1 and equilin, 
two primary components of CEE shown to have the most neuroprotective 
effects in vitro ( ; Zemlyak et al., 2002; Zhao and 
Brinton, 2006), influence cognition. In middle-aged surgically menopausal 
rats, ∆8E1 treatment enhanced spatial reference, working, and recent 
memory. In these same animals, ∆8E1 treatment decreased rα4β2-nAChR 
expression (i.e., specific I-epi binding) in the hippocampus and entorhinal 
cortex, which was related to better spatial RM performance on the Morris 
maze. Equilin treatment did not impact spatial memory or rα4β2-nAChR 
expression. There were no direct effects on hα4β2-nAChR function with 
acute or prolonged exposure to ∆8
∆
E1, equilin or PEG (vehicle). 
8
The ∆
E1 And Equilin Effects on Spatial Working and Recent Memory 
8E1 medium and high doses enhanced working and recent 
memory performance on the DMS Plus Maze task, while equilin did not. 
These ∆8E1-induced spatial WM enhancements corroborate previous 
findings whereby E2, and higher doses of CEE, 
Acosta et al., 2009b
benefited spatial WM in 
Ovx rats ( ; Bimonte and Denenberg, 1999). It is 
conceivable that the ∆8E1 medium and high doses facilitated better 
performance on this task by predisposing these animals to use a place 
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strategy, as this is seen with E2 treatment (Korol and Kolo, 2002). In my 
DMS Plus Maze task, animals using a response strategy (i.e., turn left or 
turn right) would have been inefficient at locating the platform, as the start 
location was varied and the goal arm remained in the same place in space 
within a day, leading to more errors. I speculate that the use of a place 
strategy allowed ∆8
MacLusky et al., 2006
E1 medium and high dose treated animals to 
accumulate fewer errors by creating a more stable cognitive map, in part 
by having a better ability to hold the spatial location of the platform in 
WM( ; Wilson et al., 2004).  
∆8
I found that all doses of ∆
E1 and Equilin Effects on Spatial RM 
8E1 enhanced spatial RM performance. 
This was evidenced by less overall Morris maze swim distance in the ∆8E1 
treated groups as compared to the Vehicle group. Equilin treatment did 
not affect Morris maze performance. Tonic subcutaneous ∆8
Bimonte-Nelson et al., 2006
E1-induced 
spatial RM enhancements are in accordance with Morris maze 
improvements shown by others after tonic subcutaneous E2 treatment 
( ; Foster et al., 2003; Talboom et al., 2008), 
and after cyclic subcutaneous CEE treatment (Acosta et al., 2009b), in 
middle-aged Ovx animals. Interestingly, ∆8E1’s spatial RM enhancement 
did not vary within the dose range studied, and the effect was robust. In 
fact, ∆8E1’s effects noted here are relatively more pronounced as 
compared to other reports using E2 or CEE, where effects were specific to 
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aiding overnight retention or performance during the first 6 test trials 
(Acosta et al., 2009b; Markham et al., 2002; Talboom et al., 2008).  
It is noteworthy that the Morris maze learning curves and probe trial 
data suggest that by the last testing day all groups learned the task and 
localized to the platform quadrant. Further, all animals readily learned the 
visible platform task with no group differences. That all animals could learn 
these two tasks suggests that my observed Treatment effects were not 
likely due to differences in visual competence or motoric ability. 
∆8
All doses of ∆
E1 and Equilin Effects on α4β2-nAChR Expression and Function 
8
Cardoso et al., 2004
E1 decreased rα4β2-nAChR expression in the 
hippocampus and entorhinal cortex, while equilin did not alter rα4β2-
nAChR expression in any region. My hippocampus and entorhinal cortex 
nAChR data are in agreement with other studies demonstrating that E2 
treatment decreased the number of nAChRs and mAChRs in the central 
nervous system of Ovx rodents ( ; El-Bakri et al., 
2002), although not all studies show this effect (see Centeno et al., 2006; 
Lapchak et al., 1990). The current results also indicate that 
hippocampus+entorhinal cortex rα4β2-nAChR expression has implications 
for cognition. Indeed, a decrease in rα4β2-nAChR expression in the 
hippocampus+entorhinal cortex was associated with better spatial RM 
performance (i.e., r = 0.64), representing a large effect size as defined by 
Cohen (Chakraborty and Gore, 2004). 
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I performed a follow-up study to assess possible direct actions of 
∆8
Paradiso et al., 2001
E1and equilin on hα4β2-nAChR, as ethinyl β-estradiol has been found 
to directly potentiate both hα4β2- and rα4β2-nAChR function (i.e., ion 
efflux) in vitro ( ). I found that exposure to ∆8
see Woolley, 2007
E1 or 
equilin, below, at, or above physiologically relevant brain concentrations of 
E2 (95 fM-1 µM for my acute experiments, and 9 aM-1 µM for my chronic 
experiments) ( ), had no detectable effect on function of 
hα4β2-nAChRs. Previous in vitro studies reporting potentiation of α4β2-
nAChRs by estrogens found that in some cases, rα4β2-nAChRs and 
hα4β2-nAChR do not show comparable responses to the same estrogens, 
and the concentrations of estrogens used were higher in comparison to 
the current evaluations (Paradiso et al., 2001). These higher 
concentrations may not be physiologically relevant in the context of 
endogenous estrogen levels (Paradiso et al., 2001). This previous report 
also suggests that the lack of a hydroxyl group at the 17th position on ∆8
Paradiso et al., 2001
E1 
may prevent it from potentiating hα4β2-nAChR ( ). 
Taken together with my data indicating the absence of direct ∆8E1 effects 
on hα4β2-nAChR, I hypothesize that ∆8E1-facilitated alterations in rα4β2-
nAChRs expression reflect an adaptation to ∆8
Marriott and Korol, 2003
E1 directed changes to 
other aspects of the cholinergic system. It is possible that, similar to E2 
( ), ∆8E1 treatment leads to enhanced ACh release 
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in the hippocampus and entorhinal cortex which may, in turn, result in 
reduced expression of α4β2-nAChRs as a compensatory mechanism. 
A Potential Source of ∆8
∆
E1’s Effects and Future Directions 
8
Bhavnani et al., 2008
E1 and equilin bind to, and produce biological activity via, both 
ER subtypes ( ). It is likely that ∆8
Zurkovsky et al., 2006
E1-facilitated spatial 
memory enhancements are primarily, but not solely, directed by ER 
activation, as E2’s place learning enhancement is influenced by 
hippocampal ER activation ( ). Recent evidence also 
suggests that estrogenic effects are influenced by the putative G-protein 
coupled membrane-bound ER (ER-X; reviewed in  Toran-Allerand, 2005) 
and/or GPR30, a G-protein coupled receptor that responds rapidly to 
estrogen (reviewed in  Prossnitz et al., 2008a). It is possible that ∆8
Hammond et al., 2009
E1’s 
cognitive effects are directed in part by these non-classic ERs. In fact, 
recently, Gibbs and colleagues found that the GPR30 agonist G1 
enhanced delayed-match to position learning ( ). It is 
also noted that ∆8
Prokai and Simpkins, 2007
E1-induced memory enhancements could be related to 
non-genomic mechanisms as well, as estrogens impart robust non-
genomic effects ( ) 
My current experimental design did not allow me to decipher the 
effects of behavior testing from the effects of hormone treatment on 
rα4β2-nAChRs expression. Indeed, rα4β2-nAChR expression may have 
been influenced by behavior testing alone, in a similar manner as that 
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previously noted for hippocampal dendritic spines (see Frick et al., 2004). 
In addition, the regulation of nicotinic receptor expression by ligands 
occurs by diverse mechanisms, and these are conserved across different 
systems (for review see Beato et al., 1996; Morris et al., 1986; Singh et 
al., 1996). However, the use of a model system allowed me to study 
hormone effects on a single, well-defined subtype. In my in vitro model 
system, whole-animal pharmacokinetics and the effects of brain-region 
differences were not an issue. Due to the lack of effect in the model 
system (where there is no synaptic function), in contrast to the effects in 
vivo, I conclude that my in vivo effects on 4β2-nAChRs likely reflect a 
functional adaptation in response to the ∆8E1 treatment, and not a direct 
effect of the hormones on the receptors themselves. Further studies are 
necessary to detail the specific contributions of ∆8E1 on cholinergic 
function and rα4β2-nAChR expression, independent of behavioral testing 
effects, as well as to fully identify the mechanisms of ∆8
Conclusions 
E1-facilitated 
memory enhancements both at the cellular and the systems level. 
There is increasing evidence that ∆8
Baracat et al., 1999
E1 demonstrates unique 
properties compared to more widely-studied estrogens such as 17α- and 
E2 ( ; Bhavnani, 1998). Data from other laboratories 
have demonstrated that ∆8
Zhang et al., 2001
E1 has an attenuated toxic potential compared 
to other CEE components ( ), shows distinct tissue and 
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cell-specific estrogenic properties in relation to E1 (Baracat et al., 1999), 
and appears to be converted to only one metabolite in women, giving 
∆8 Bhavnani, 1998E1 a unique pharmacokinetic profile ( ). Two studies 
have evaluated ∆8E1 in women. These works found that ∆8
Baracat et al., 1999
E1 exerted an 
overall beneficial profile for health-related concerns associated with 
menopause ( ; Bhavnani et al., 1998; for review see 
Utian et al., 2006). Together with the data presented here, the collected 
evidence suggests that ∆8E1 is a uniquely beneficial estrogen that 
warrants further study as a potential nootropic therapy. In summary, ∆8E1 
enhanced multiple domains of learning and memory, with a link to the 
cholinergic system as shown by changes in nicotinic receptor expression. 
Equilin did not affect spatial memory and had no effects on nicotinic 
receptor expression. Select components of CEE 
 
may offer promising new 
HT options that positively impact brain health during aging. An exciting 
new direction might be to further define the individual components of CEE. 
This would allow composition of a novel combined ET, with the ultimate 
goal to optimize the potential benefits, and obviate the risks, of currently 
used estrogen therapies. 
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CHAPTER 7 
AGE AND OVARIAN HORMONE STATUS ALTERS THE NUMBER OF 
PUTATIVE SYNAPSES IN SPECIFIC LAMINA OF THE FEMALE RAT 
HIPPOCAMPUS  
Novel memory formation allows adaptability in an organism. It 
allows acquisition and updating of knowledge and skills within different 
and overlapping neurobiological domains (Kausler, 1994). As individuals 
age, it is well documented that some memory loss occurs (Erickson and 
Barnes, 2003; Tulving and Craik, 2000), and age-related cognitive decline 
likely involves changes in neuroplasticity and factors influencing synaptic 
transmission within the brain (see Chapter 1). In the United States, the 
proportion of the population that is over 65 is increasing. Today, about 
12% of the population is over 65, and this percentage is expected to 
substantially increase to 20% by the year 2020 due to aging of the “baby 
boomer” generation (U.S. Census Bureau, 2007).  
Several basic and clinical studies have linked age-related cognitive 
decline with age-related alterations in the ovarian hormone milieu (for 
review see Bimonte-Nelson et al., 2010; Sherwin and Henry, 2008). For 
example, ovarian hormone loss due to surgical or natural menopause has 
been associated with cognitive decline in women (Nappi et al., 1999; 
Phillips and Sherwin, 1992; Sherwin, 1988). In animals, previous studies 
have found that Ovx in young female rats is detrimental to spatial WM 
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performance (Bimonte and Denenberg, 1999), while Ovx in aged female 
rats facilitates spatial WM performance (Bimonte-Nelson et al., 2003b). 
However, it is important to note that slight differences existed in how 
spatial WM was assessed on the WRAM task between these two previous 
studies (i.e., 4 arms were baited instead of 7). Despite this small 
discrepancy, the collected human and animal findings suggest that 
ovarian hormone loss alters memory; thus, similar to age-related cognitive 
decline, hormone loss-facilitated cognitive alterations likely involve 
changes in measures of neuroplasticity within the brain (see Woolley, 
2007).  
In young female rats, E2 treatment in Ovx animals increased 
hippocampal spine density, an effect dependent on the duration of ovarian 
hormone deprivation (i.e., Ovx), dose of E2, and the addition of 
progesterone (Gould et al., 1990; McLaughlin et al., 2008; Woolley, 1998; 
Woolley and McEwen, 1992). E2 supplementation reversed the age-
related decreases in hippocampal MAP2 staining in a mouse model of 
Down Syndrome, suggesting an increase in dendritic density due to E2 
(Granholm et al., 2003). Further, chronic E2 and β-Estradiol-3-benzoate 
treatment increased hippocampal synaptophysin protein levels in middle-
aged female mice in a dose-specific manner, an effect that corresponded 
with enhanced object recognition performance (Fernandez and Frick, 
2004; Frick et al., 2002). Although not a highly investigated area, research 
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conducted thus far suggests that progesterone, when given alone, 
increases hippocampal synaptophysin levels (Choi et al., 2003). These 
studies strongly support the hypothesis that estrogen and progesterone 
influence synaptic plasticity. Yet, the work done to date has primarily 
tested Ovx animals with and without hormone treatment, leaving the 
question of effects of ovarian hormone loss as yet unanswered. For 
example, the only research evaluating Ovx-induced changes in dendritic 
spine density in hippocampus has been done in young animals, with 
decreases seen in CA1, but not CA3 (Wallace et al., 2006; for review see 
Woolley, 1998). There has been no published study evaluating Ovx effects 
in aged rats.  
The current study assessed how age and ovarian hormone loss 
altered the distribution of excitatory and inhibitory putative synapses in 
several hippocampal laminas of female rats. Many, but not all, studies 
assessing age- and hormone- related changes in synaptic density have 
been limited to non-specific markers such as synaptophysin and synapsin. 
An inherent weakness of evaluating general markers of synaptic density 
using SNARE proteins (e.g. synaptophysin, synapsin) is that the functional 
subtypes of synapses are not revealed (excitatory vs. inhibitory). 
Therefore, I assessed specific markers of excitatory and inhibitory 
synapses to estimate the balance of excitation and inhibition in 
hippocampal circuits. The hypothesis was that age and ovarian hormone 
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loss via Ovx would act together to alter the number of excitatory and 
inhibitory putative synapses within distinct lamina of the hippocampus in 
female rats. Specifically, using immunohistochemical (IHC) staining 
techniques and fluorescent confocal microscopy, this experiment 
evaluated the number excitatory putative synapses, assayed via a primary 
antibody targeting the NR1 subunit of the NMDA receptor followed by a 
fluorescent secondary antibody, and inhibitory putative synapses, assayed 
via a primary antibody targeting the vesicular GABA transporter (vGAT) 
followed by a fluorescent secondary antibody. ICH methods of this nature 
combined with fluorescent confocal microscopy reveal points or spots of 
NR1 or vGAT protein aggregation staining termed “punctate”, and are 
thought to represent putative synapses (Jelks et al., 2007; Khan et al., 
2010). In fact these studies have used punctate staining to identify 
putative synapses using both NR1 and vGAT (Jelks et al., 2007; Khan et 
al., 2010).  
Methods 
Subjects 
Subjects were female Fisher-344 rats aged 5 (young), 12 (early 
middle-aged), 18 (late middle-aged), or 20 (aged) months at the time of 
testing. Each age consisted of ovary-intact Sham and Ovx groups as 
follows: 5 month Sham (n = 4), 5 month Ovx (n = 4), 12 month Sham (n = 
4), 12 month Ovx (n = 4), 18 month Sham (n = 4), 18 month Ovx (n = 4), 
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20 month Sham (n = 3), and 20 month Ovx (n = 4). Rats were pair-housed 
with a same-treatment cage mate in the animal facility of the Psychology 
department at Arizona State University, were given food and water ad 
libitum and maintained on a 12hr light-dark cycle. All procedures were 
approved by the local Institutional Animal Care and Use Committee and 
adhered to National Institute of Health (NIH) standards.  
Surgical Procedures and Vaginal Smears 
All rats received surgery approximately 6 weeks before behavioral 
testing and 9 weeks before sacrifice. Rats were anesthetized with an 
intraperitoneal injection of a cocktail of 70 mg/kg ketamine (Fort Dodge 
Animal Health, Fort Dodge, IA, USA) and 6 mg/kg xylazine (Lloyd 
Laboratories, Shenandoah, IA, USA). Rats of each age received either 
Sham surgery (5 month Sham, 12 month Sham, 18 month Sham, 20 
month Sham) or Ovx (5 month Ovx, 12 month Ovx, 18 month Ovx, & 20 
month Ovx). For Ovx, dorsolateral incisions were made in the skin and 
peritoneum, and the ovaries and tips of uterine horns were ligated and 
removed. The muscle was then sutured and the skin stapled. Sham 
surgery consisted of skin incision and staple in the same manner 
(Talboom et al., 2008).  
Vaginal smears were performed before and after behavioral testing 
to confirm hormone status (Acosta et al., 2009b; Engler-Chiurazzi et al., 
2009; Talboom et al., 2010). A cotton swab was dipped in saline and the 
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vaginal lumen was gently swabbed. Vaginal smears were viewed under a 
light microscope and classified as proestrus (round nucleated epithelial 
cells), estrous (cornified cells), metestrus (epithelial, cornified and 
leukocytic cells) or diestrus (primarily leukocytes) (Goldman et al., 2007). 
As expected, all Ovx animals exhibited leukocytic acyclic smears. Five 
and 12 month old Sham animals showed smears reflective of normal 
cycles, while 18 and 20 month old Sham animals showed persistent 
diestrous smears. 
Sacrifice, Brain Dissection, Post Fixation, and NR1 and vGAT 
Fluorescence IHC 
 Approximately 3±1 days after all animals were tested on a battery 
of water-escape mazes assessing working and RM (data now shown 
here), animals were anesthetized with isoflurane (Vetone, Meridian, 
Indiana), decapitated (i.e., according to NIH euthanasia guidelines), and 
their brains dissected promptly. Each blocked posterior half of the brain 
was post fixed in 4% paraformaldehyde in PB (pH 7.4) for 48 hours, and 
then the tissues were transferred to PB until sectioning. Blocked brains 
were sectioned (plates 55-68 in the Rat Brain Atlas 5th Edition Paxinos 
and Watson, 2005) on a Vibratome (Model 3000, Vibratome, 
Bannockburn, IL) in PBS (pH 7.4) at 75 μm throughout the dorsal 
hippocampus (i.e., anterior portion containing CA1, CA2, CA3 and dentate 
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gyrus) and collected for IHC (similar to Chapter 4; Acosta et al., 2009b; 
Granholm et al., 2002).  
Four nonconsecutive sections through the dorsal hippocampus 
(free-floating section) from each animal were selected for NR1 and vGAT 
antibody stain, placed in a 24 well tissue culture plate (Evergreen) and 
incubated at RT for 15 min in PBS (pH 7.4) and 0.03% Triton (Triton 
100X) to permeabilize the tissue. To increase the punctate signal, each 
tissue slice was incubated at 37 C° for 30 min with pepsin solution (25% 
1N HCl and 0.375 (w/v) Pepsin [Sigma]) followed by one PBS wash (5 
min). Next, in order to evaluate the number putative excitatory synapses, I 
used a primary polyclonal antibody targeting the NR1 subunit of the 
NMDA receptor, while putative inhibitory synapses were assessed via a 
primary monoclonal antibody targeting the vesicular GABA transporter. 
Sections were incubated with primary antibodies, rabbit anti-NR1 (1:500, 
Millipore) and mouse anti-vGAT (1:500, Synaptic Systems) in BKS (10 % 
heat inactivated horse serum, 2% BSA and 0.25% Triton X100 in PBS), 
overnight at 4 °C on a Rocker II plate rocker (Boekel Scientific, 
Feasterville, PA). Sections were washed four times in PBS for 20 min (5 
min each) followed by immersion in the secondary antibody (1:500 Alexa 
Fluor 488 goat anti-Rabbit IgG and Alexa Fluor 633 goat anti-mouse IgG 
(Invitrogen) in PBS for 20 min on a Titer Plate Shaker (Barnstead 
International, Dubuque, IO) at RT. Sections were then washed four times 
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in PBS for 80 min (20 min for each wash). Brain sections were mounted 
on Superfrost Slides (Fisher) and excess moisture was aspirated via a 
vacuum line. Slides were coverslipped with Vectorshield (Vector 
Laboratories), and then sealed with clear nail polish.  
Slides were then stored in the dark at 4 °C. These methods were 
similar to ones previously published (see Tyler and Pozzo-Miller, 2003). 
Each group was equally represented in each round of staining to avoid 
group inter-variability in staining. Due to variations in antibody lot, one 
round of staining was excluded from analysis since values that were not 
concordant with the other rounds. As a control for the IHC methods, tissue 
sections were evaluated whereby the primary antibodies were omitted; 
this resulted in no distinct punctate staining for either NR1 or vGAT, as 
expected. 
Hippocampal Lamina Image Capture and Analysis 
Images were acquired using FluoView software (5.0 Olympus 
America, Inc., Center Valley, PA) from a FV-300 laser-scanning confocal 
microscope (Olympus America, Inc., Center Valley, PA). Excitation of 
Alexa Fluor 488 (i.e., NR1 secondary) was achieved using the 488 nm 
argon laser, and Alexa Fluor 633 (i.e., vGAT secondary) was excited using 
a 633 nm HeNe laser. A ×60 (1.41 NA; Olympus; digital 2X) PlanApo oil 
immersion lens was used to capture images. Confocal microscopy image 
z-stacks with an effective lateral (x-y axis) pixel resolution of 0.09 µm 
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pixel−1
Captured images for each lamina were then semi-automatically 
counted using NIH ImageJ software (Rasband, 1997-2004). Raw 
FluoView (Olympus America, Inc., Center Valley, PA) tiff image z-stacks 
were first split between the two channels (i.e., one for 488 NR1 and one 
for 633 vGAT) into separate image z-stacks. The first and the last images 
were deleted so that 4 images remained in a z-stack. For the stratum 
pyramidale and stratum granulosum, a region of interest (ROI) was traced 
around the cell bodies with the “Polygon Selections” tool, and only putative 
synapses within that ROI were counted (i.e., only those that were located 
on the cell bodies). Next, a spot detector based on a “3D LoG” filter, with a 
“sigma X” of 2 and a “sigma Y” of 2, was applied to the four images to 
reduce noise and enhance the punctate (Figure 30a) (
 (calculated via reconstructing fluorescent microspheres) and a 
step-size of ≈ 7-10μm between optical planes were acquired, yielding 6-8 
images per stack that were collected at randomly selected sites within 
stratum oriens (dorsal to CA1), CA1 stratum pyramidale, the polymorphic 
layer of the dentate gyrus, and in stratum granulosum (i.e., the ventral 
blade of the dentate gyrus). Figure 29a illustrates the lamina where 
images were acquired in the hippocampus and Figure 29b shows two 
representative fluorescent micrographs for NR1 and vGAT in the 
polymorphic layer and stratum granulosum dentate of the gyrus, 
respectively.  
Sage et al., 2005). 
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Images were thresholded via “Mixture Modeling” (Figure 30b) (Mei and 
Dauphin, 2003), and the ImageJ “Analyze Particles” tool was used to 
automatically quantify the number of punctate in each of the four images 
with a size (pixel^2) of 13-150 and a circularity of 0.00-1.00 (Figure 30c). 
Raw data were then exported pasted into Excel 2007 (Microsoft, 
Redmond, WA) and saved for analysis. Steps used to quantify putative 
synapses were identical for both NR1 and vGAT, and the number of NR1 
and vGAT punctate in each separate hippocampal lamina were the 
dependent variable used for statistical analysis. This method of counting 
yielded accurate putative synapse counts when compared to manual 
counting in a small subset of the images (Figure 30d) as well as what I 
consider unbiased counts, since I did not use different threshold values for 
each image/z-stack (i.e., the ImageJ “Mixture Modeling” plugin did not 
have parameters to adjust) (see discussion in Hiscock et al., 2000). 
Statistical Methods 
 Using StatView (version 5.01, The SAS Institute Inc., Cary, NC) for 
each hippocampal lamina imaged, I first performed an omnibus mixed 
model ANOVA within each age (5, 12, 18, & 20) and treatment (Sham & 
Ovx) group. Age and Treatment were the between-subjects factor while 
Section (1–4) and Image (1–4) were the repeated measures. For all 
pairwise ANOVAs (i.e., Ovx vs. Sham), Cohen’s d was employed as a 
measure of effect size that assessed the difference between two group 
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means represented in standard deviation units (Cohen, 1988). Lastly, for 
linear trend analyses of age in relation to putative synapse numbers, I 
evaluated polynomial contrasts under the general linear model using 
SPSS (version 18.0; IBM Corporation; Somers, NY). Linear trends were 
assessed from 5 to 20 months of age to assess linear effects of age on 
putative synapses numbers. I also assess linear trends from 12 to 20 
months of age, since estropause begins by 12 months of age (Dudley, 
1982) and may be the age range where previous studies in my lab found 
that Ovx in young female rats is detrimental to spatial WM performance 
(Bimonte and Denenberg, 1999), but facilitates spatial WM performance in 
aged Ovx female rats (Bimonte-Nelson et al., 2003b). 
To evaluate effects of age I performed planned contrasts with 
specific a priori comparisons in mind to aid in the interpretation of results 
and increase the statistical power in comparison to a less focused 
omnibus test (see section 8.5 in Cohen et al., 2003). Similar to a t-test, 
planned contrasts compare the means of two groups or a combination of 
groups; however, the error term (i.e., unexplained variance, MS within-
groups/error) is calculated from all the groups in the study (i.e., pooled 
within-group variance), not just the two groups being compared (see 
Rosenthal and Rosnow, 1985). Hence, statistical power can be increased 
by having a better estimate of the unaccounted for variance (i.e., increase 
the t-value/ratio). This study was designed a priori to evaluate the effects 
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of age and ovarian hormone loss on putative synapse numbers, while 
paying particular attention to changes that may account for the previously 
observed transition where Ovx is detrimental to WM when young (Bimonte 
and Denenberg, 1999), but Ovx facilitates WM when aged (Bimonte-
Nelson et al., 2003b). To this aim, two contrasts were used to evaluate 
pairwise effects of age as follows: 1) 5 month old as compared to 20 
month old animals (i.e., young verses aged contrast) and 2) 12 month old 
(i.e., estropause begins by 12 months of age; Dudley, 1982) as compared 
to 20 month old animals (i.e., early middle-aged verses aged contrast). 
Results 
Treatment Effects: Ovx Compared to Sham Animals 
 When evaluating the effects of Ovx or Sham surgery, there was a 
significant main effect of Treatment for NR1 in stratum granulosum 
(F[1,20] = 4.34, p ≤ 0.05, d = 0.93, Figure 31), indicating that Ovx animals 
had fewer putative excitatory synapses in comparison to ovary-intact 
Sham animals. The Cohen’s d statistic was considered a large effect by 
convention (Cohen, 1988). This suggests that the loss of ovarian 
hormones decreased the number of putative excitatory synapses on 
stratum granulosum, the granular cells of the ventral blade of the dentate 
gyrus. There were no other main effects of Ovx for the discrete region 
analyses. 
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Trend Analyses: Lineal Relationships between Age and Putative 
Synapse Numbers 
 An evaluation of age via linear trend analyses revealed that the 
number putative inhibitory synapses in stratum pyramidale decreased 
from 5 to 20 months of age in Ovx and Sham animals (vGAT F[1,19] = 
5.94, p = 0.0248). When I analyzed Ovx and Sham groups separately, 
Ovx (vGAT F[1,8] = 6.84, p = 0.0308, Figure 32a) but not Sham (vGAT 
F[1,7] = 0.38, p = 0.5547) animals, showed this effect. The of number of 
putative inhibitory synapses decreased from 12 to 20 months of age in the 
polymorphic layer of both Ovx and Sham animals (vGAT F[1,14] = 6.58, p 
= 0.0224, Figure 32b). This effect was not seen when the Ovx (vGAT 
F[1,5] = 2.91, p = 0.1489) or Sham (vGAT F[1,6] = 3.18, p = 0.1247) 
groups were analyzed alone. Together, these trend analyses suggest that 
age and ovarian hormone loss act together to decrease the number of 
putative inhibitory synapses on the pyramidal cells of CA1 (from 5-20 
months of age), while age alone (from 12-20 months of age) may be the 
factor that decreases the number of putative inhibitory synapses along the 
axons of the granular cells in the polymorphic layer of the dentate gyrus. 
Planned Contrasts: Pairwise Comparisons between 5 and 20, as well 
as 12 and 20, Month Old Animals  
 When evaluating pairwise differences via planned contrasts, I found 
a significant young verses aged contrast in stratum pyramidale of Ovx and 
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Sham animals (vGAT F[1,19] = 6.02, p = 0.0239), as well as Ovx (vGAT 
F[1,8] = 6.48, p = 0.0344, Figure 33a) but not Sham (vGAT F[1,7] = 0.52, 
p = 0.4935) animals when evaluating the treatment groups alone, 
indicating that putative inhibitory synapses decreased from 5 to 20 months 
of age on the pyramidal cells of CA1 primarily in Ovx animals. A significant 
young verses aged contrast was found in stratum oriens of Ovx and Sham 
animals (vGAT F[1,27] = 5.20, p = 0.0306). Showing the same pattern as 
in the stratum pyramidale, when the treatments were evaluated 
separately, the age effect was significant for the Ovx animals (vGAT 
F[1,12] = 4.69, p ≤ 0.05, Figure 33b), but not Sham (vGAT F[1,11] = 1.02, 
p = 0.3332) animals, suggesting that Ovx animals were responsible for the 
decreased number of putative inhibitory synapses from 5 to 20 months of 
age on the dendrites of CA1 pyramidal cells. I also noted that in the 
polymorphic layer, the number of putative inhibitory synapses decreased 
from 12 to 20 months of age in Ovx and Sham animals (significant early 
middle-aged verses aged contrast vGAT F[1,17] = 6.34, p = 0.0221, 
Figure 33c), but not in Ovx (vGAT F[1,6] = 2.32, p = 0.1785) or Sham 
(vGAT F[1,7] = 3.38, p = 0.1087) animals alone. This indicated that age 
and not ovarian hormone loss is likely responsible for the decreased 
number of putative inhibitory synapses along the axons of the granular 
cells in the dentate gyrus. Collectively, aging and ovarian hormone loss 
does appear to act together to decrease the number of inhibitory synapses 
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in the stratum pyramidale and stratum oriens between 5 and 20 months of 
age. Furthermore, as aging ensues from 12 to 20 months of age, inhibitory 
synapses decrease in the polymorphic layer of the dentate gyrus of female 
rats, an effect that is likely facilitated by age and not ovarian hormone 
loss. Table 4 summarizes the effects of age and ovarian hormone loss on 
putative synapse numbers. 
Discussion 
Here, utilizing fluorescent confocal microscopy and methods similar 
to previous studies identifying putative synapses (Jelks et al., 2007; Khan 
et al., 2010), I capitalized on the modular features of ImageJ to automate 
aspects of counting discrete punctate (i.e., putative synapses) (Rasband, 
1997-2004). I found that Ovx decreased the number of excitatory putative 
synapses on the granular cell bodies in the ventral blade of the dentate 
gyrus, as compared to the Sham group. Trend analyses revealed that 
putative inhibitory synapse counts decreased in a linear fashion from 5 to 
20 months of age primarily in Ovx animals on the CA1 pyramidal cell 
bodies, while putative inhibitory synapse counts decreased in a linear 
fashion from 12 to 20 months of age only when Ovx and Sham animals 
were evaluated together in the polymorphic layer of the dentate gyrus. 
Lastly, contrast analyses revealed that the number of putative inhibitory 
synapse counts decreased between 5 and 20 months of age mainly in 
Ovx animals on the CA1 pyramidal cell bodies and in the stratum oriens 
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dorsal to CA1. Paralleling the trend analysis, there was a decrease in the 
number of putative inhibitory synapse counts between 12 and 20 month 
old in Ovx and Sham animals in the polymorphic layer of the denate gyrus. 
Collectively, these data suggest that ovarian hormone loss decreases 
excitatory synapse numbers on the granular cells of the dentate gyrus, 
while age and ovarian hormone loss may act together to decrease 
inhibitory synapse numbers on the pyramidal cells of CA1 and in the 
stratum oriens dorsal to CA1. The data suggested the age and ovarian 
hormone loss act together because I found that the age-related decreases 
in putative inhibitory synapses were primarily found in Ovx, but not Sham, 
animals. Notably, these data identified ovarian hormone loss as a principal 
factor that decreased putative synapse numbers in the female rat 
hippocampus. 
Effects of Ovarian Hormone Loss on Synapses 
Although to my knowledge no single study has assessed the effects 
of age and ovarian hormone loss on putative synapse numbers in the 
hippocampus, my findings that ovarian hormone loss decreased putative 
synapse numbers are in accordance with several studies assessing the 
effects of E2 treatment in systems devoid of E2. Specifically, previous 
research has noted that in young Ovx animals or in cultured hippocampal 
neurons grown in sera devoid of ovarian hormones, E2 treatment 
increases excitatory and decreases inhibitory neurotransmission in the 
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hippocampus or hippocampal cells of rats. In young Ovx rats, E2 
increases NR1 immunofluorescence on the soma and dendrites of CA1 
cells and on the soma of granular cells in the dentate gyrus (Gazzaley et 
al., 1996b). Others have found in vitro that E2 treatment (10 nm) for 48 
hours increases NR1 and vGLUT colocalization along dendrites; they also 
noted that ER were located along the NR1 containing dendrites (Jelks et 
al., 2007). In regard to in vitro inhibitory neural transmission, ERs 
colocalize with neurons expressing glutamate decarboxylase (GAD, the 
enzyme that synthesized GABA), and a 24hr E2 exposure decreases GAD 
content by up to 80% and GAD cell population to 12%. In this same study, 
E2 treatment was found to decrease GABAergic miniature inhibitory 
postsynaptic currents in size and frequency, while miniature excitatory 
postsynaptic currents increased (Murphy et al., 1998). Furthermore, E2 
treatment increases GAD mRNA levels in GABAergic neurons in CA1 but 
not in the stratum oriens; progesterone was found to abolish this effect 
(Weiland, 1992). Conceivably, this could be a compensatory mechanism 
to the fast E2-facilitated suppression of inhibitory neurotransmission 
(Murphy et al., 1998). Collectively, these studies suggest that E2 
treatment after ovarian hormone removal alters markers of the GABAergic 
system and enhances markers of the glutamatergic system. These effects, 
while noting some important differences (e.g., no comparison to sham 
animals, in vivo vs. in vitro methods, & not all studies evaluated 
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progesterone), essentially parallel the present findings. When E2 
treatment conditions were compared to Ovx animals or neuronal cultures 
that were devoid of E2, there were decreases in excitatory markers of 
synaptic transmission and alterations in markers of the GABAergic 
system. This suggests that the Ovx-facilitated changes in excitatory and 
inhibitory markers/neurotransmission during aging may well be, or result 
in, my observed decrease in excitatory and inhibitory putative synapses. 
I hypothesize that if E2 treatment after Ovx increases excitatory 
transmission and decreases inhibitory transmission, then E2’s removal for 
long periods of time may imbalance excitatory verses inhibitory 
neurotransmission resulting in declines in excitatory synaptic numbers. It 
is also noted that another laboratory has found results that appear in direct 
opposition to my own. Specifically, rats with short-term Ovx (1 mo) have 
substantially higher NMDA receptor subunit mRNA levels than animals 
with long-term Ovx (6 mo); however, the most dramatic increases in NR1 
mRNA were seen during aging in the ventral hippocampus (Adams et al., 
2001). With this said, it important to note two caveats to this study in 
comparison to my own: 1) Adams and colleagues (2001) only found 
effects in the ventral (i.e., not dorsal) hippocampus; I noted all of my 
effects in the dorsal hippocampus, and 2) the NR1 antibody targets NR1 
protein and not mRNA; hence, my IHC methods targeted NR1 that had 
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already been translated. Indeed, increases in mRNA are not always 
concomitant with increases in the translated protein.  
Effects of Aging on Synapses 
A previous study using male and female Macaca mulatta monkeys 
found age-related declines in synaptic markers that are in line with the 
current study. Specifically, in aged monkeys, as compared to adult 
monkeys, there was a 30% decrease in NR1 immunofluorescence on the 
granule cells of the dentate gyrus (Gazzaley et al., 1996a). In addition to 
non-human primate work, previous studies using rodents have noted 
similar effects; however, an important caveat is that only males were 
evaluated in these studies. A comparison of 4 to 24 month old rats 
showed that NR1 protein levels decreased in the CA1 region of the ventral 
hippocampus (Liu et al., 2008). Recently, a comparison between young (2 
month old) and aged rats found that markers of the synapses 
synaptophysin (between 18-24 months of age) and SNAP-25 (between 
18-24 months of age), markers of the glutamatergic terminals vGluT1 
(between 12-18 months of age) and vGluT2 (between 12-18 months of 
age), markers of cholinergic terminals vAChT (between 12-18 months of 
age), and vGAT (at 24 months of age) all decreased with age (Canas et 
al., 2009). The authors concluded that aging causes an imbalance of 
excitatory versus inhibitory markers primarily leading to a decrease in 
inhibitory mechanisms (Canas et al., 2009), which is notably a similar and 
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independent conclusion to the present findings. Indeed, aside from vGAT 
differences not being evident until 24 months of age (perhaps due to strain 
or sex differences), these results map almost directly on to the ones 
presented here. Furthermore, the findings of Canas and colleagues (2009) 
are particularly exciting and relevant to the current discussion because 
they suggest a mechanism within a similar age range where my lab 
previously found that Ovx in young female rats is detrimental to WM 
(Bimonte and Denenberg, 1999), while Ovx in aged female rats facilitates 
WM (Bimonte-Nelson et al., 2003b). Indeed, changes in cholinergic 
function, plasticity, and glutamatergic transmission outside the realm of 
synaptic number and the scope of the present study may well underlie this 
transition. In summary, these collective results corroborate my current 
findings and suggest that as aging ensues there is a decrease in markers 
of both excitatory and inhibitory synapses. 
It is noteworthy that the majority of studies evaluating synaptic 
alterations (for example, synaptic density as revealed via synaptophysin 
evaluations) in healthy individuals have shown an age-related decline, 
resulting in a potentially interesting dissociation between synapse loss and 
neuron loss (Hof and Morrison, 2004; Terry, 2006). In fact, in 
corroboration with my findings, there is evidence using updated stereology 
techniques that number of hippocampal synapses decreases with the 
progression from young adulthood to normal aging, and that synapse 
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numbers in AD hippocampi are fewer than in those of normally aged 
(Bertoni-Freddari et al., 2003). It has been well established that there are 
profound age-related changes in the strength of synaptic connections in 
the hippocampus (Erickson and Barnes, 2003; Rosenzweig and Barnes, 
2003). Interestingly, there is also evidence of a link between hippocampal 
synaptic density and cognition during aging. For example, a recent report 
indicates that a decrease in CA1 stratum radiatum perforated postsynaptic 
density is related to age-related learning impairment (Nicholson et al., 
2004). Earlier work has shown a similar relationship in the dentate gyrus 
(Geinisman et al., 1986). Here, I demonstrate that there is likely a 
decrease in the number of actual synapses and that age and ovarian 
hormone loss differentially affect excitatory and inhibitory synapse loss 
within the female rat hippocampus. 
Broader Interpretations 
Interpretations of the lamina specific decreases in putative synapse 
numbers have specific implications in relation to memory. A straight 
forward interpretation of the decrease in putative excitatory synapses on 
the granular cells of the dentate gyrus is that the decrease may be the 
primary drive of age- and ovarian hormone loss-facilitated spatial memory 
impairment. In fact, this may indeed be a principal factor in why Ovx has 
been found to be detrimental to spatial memory (reviewed in Bimonte-
Nelson et al., 2010). Specifically, glutamatergic neurotransmission is 
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critical for memory processing (see Bliss et al., 2003; Izquierdo et al., 
1993), the granular cells of the dentate gyrus are principally important for 
the relay of information between the hippocampus and entorhinal cortex 
(i.e., the perforant pathway) (see Andersen, 2007), and the hippocampus 
and entorhinal cortex as well as their interactions are critical for spatial 
memory processing (Morris et al., 1982; Pappas et al., 2005; Zola-Morgan 
et al., 1994). Collectively this suggests that disruptions in excitatory 
transmission in the granular cells, and thus along the perforant pathway, 
may drive spatial memory impairment in Ovx animals.  
Interestingly, a majority of my age effects were found to be primarily 
in Ovx animals and always in measures of inhibitory synapses (i.e., vGAT 
punctate). Specifically, I found age related declines in putative inhibitory 
synapses found on the cell bodies of CA1, as well as in the stratum oriens 
dorsal to CA1. Analogous to disruptions in excitatory neurotransmission, 
here a disruption of inhibitory transmission may cause memory impairment 
since CA1 cells and GABAergic neurotransmission are known to be critical 
in memory processing (Andersen, 2007; Daumas et al., 2005; Izquierdo et 
al., 1993). Furthermore, stratum oriens contains the dendrites of CA1 cells 
receiving inputs from other pyramidal cells, cholinergic basal septum 
fibers, and connections with the contralateral hippocampus (see 
Andersen, 2007), which are all factors that are necessary to properly 
process memory (see Andersen, 2007; Hasselmo, 2006). Thus, memory 
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would more likely than not be impaired if inhibitory synaptic transmission 
were disrupted. This suggests that the current age- and Ovx-facilitated 
decrease in putative inhibitory synapse numbers may underlie in part the 
previously noted age- and Ovx-facilitated alterations in spatial memory 
(see Bimonte-Nelson et al., 2010).  
My data also indicated that age and perhaps not ovarian hormone 
loss is primarily responsible for the decrease in putative inhibitory 
synapses from 12 to 20 months of age in the polymorphic layer of the 
dentate gyrus, since age effects were only found when Ovx and Sham 
animals were evaluated together. The ploymorphic layer shows aged 
related declines in synaptic markers (Gazzaley et al., 1996a), and 
contains several interneurons, which may explain why I observed a 
decrease in putative inhibitory synapses since many interneurons are 
GABAergic (see Ji and Dani, 2000). Furthermore, the axons of the dentate 
gyrus granular cells pass through this layer on their way to CA3 (see 
Andersen, 2007), underscoring the importance of correct synaptic 
transmission since this is a part of the perforant pathway and is critical for 
spatial memory processing (Morris et al., 1982; Pappas et al., 2005; Zola-
Morgan et al., 1994). Collectively, the results suggest that the polymorphic 
layer of the dentate gyrus is vulnerable to age, and alterations in 
neurotransmission with it, (i.e., specifically inhibitory) may in part underlie 
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the age-related changes in memory seen in rodents (see Bimonte-Nelson 
et al., 2010).   
In conclusion, my data suggest that Ovx decreases the number of 
excitatory synapses on the granular cell bodies of the dentate gyrus. 
Aging and ovarian hormone loss likely act together to decrease the 
number of inhibitory synapses in CA1 stratum oriens and on CA1 
pyramidal cell bodies, whereas age alone may have a greater effect on 
the observed decrease in the number of putative inhibitory synapses in the 
polymorphic layer of the dentate gyrus. Future evaluations could assess 
the effects of age and ovarian hormone loss, as well as subsequent 
treatment, on synapse number using cholinergic, glutamatergic, and 
GABAergic markers using electron microscopy. Indeed, more studies are 
necessary to evaluate the effects that ovarian hormone loss has on the 
molecular and neurobiological correlates of memory. Future studies could 
also use measures of the numbers of specific synapses and synaptic 
markers to assess relationships with memory. For example, excitatory and 
inhibitory synapse numbers could be used to predict spatial memory 
outcome measures assessed on mazes via regression analyses. 
Evaluations of this nature as well as the data from the current study are 
critical in order to fully elucidate the mechanism of how age and ovarian 
hormone loss alter memory in both humans and rodents. The translation 
of these findings to humans has exciting and far reaching potential; 
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indeed, such studies may lead to novel therapies and pharmaceuticals 
that can attenuate or ameliorate the effects of age and ovarian hormone 
loss on the brain with a concomitant improvement in memory, thus taking 
a substantial burden off of the ever-aging population. 
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CHAPTER 8 
GENERAL DISCUSSION 
The research in this dissertation has implications that promote an 
understanding of the effects of cognitive practice on aging memory, why 
males and females respond differently to cognitive practice, and the 
parameters and mechanisms underlying estrogen’s effects on memory. 
This body of work suggests that cognitive practice can enhance memory 
when aged and that estrogen is a probable candidate that facilitates the 
observed differences in the effects of cognitive practice depending on sex. 
The effects of estrogen on memory appear to be dependent on several 
factors such as age, memory domain, dose, and the type of estrogen. 
Lastly, the present data indicates that the cholinergic system and 
hippocampal synapses are likely two non-mutually exclusive mechanisms 
involved in the effects of estrogen on memory.  
In Chapter 2, I found that RM cognitive practice enhanced memory 
in both aged male and female rats on the RM cognitive practice task, and 
attenuated age related memory decline on a novel WM task. A notable 
finding of this study was that aged males and females differed in their 
response to RM cognitive practice on a novel RM task, and in the 
relationship between RM performance when young and aged neurotrophin 
levels in cognitive brain regions. Females in this study transferred the 
benefits of RM cognitive practice to a novel RM task when aged (i.e., 
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Morris maze overnight retention), whereas males did not. Females also 
appeared to be responsible for the relationship between better RM 
performance when young and higher levels of hippocampal and frontal 
cortex NGF levels when aged. Collectively, Chapter 2 suggested that 
ovary intact females are more cognitively plastic than their male 
counterparts, an effect may be related to the interaction between 
estrogens and NGF (Engler-Chiurazzi et al., 2009; Fernandez and Frick, 
2004). This enhanced cognitive plasticity in females was intriguing and led 
to studies that helped to elucidate some of the parameters and 
mechanisms of this observed enhanced cognitive plasticity. A logical place 
to start searching for this sex difference was to examine the major 
difference in sex hormone milieu between males and females (see 
Tarnopolsky, 1999). Decades of accumulating evidence has demonstrated 
that E2 enhances memory, influences neuronal plasticity and growth 
factor levels in cognitive brain regions, and attenuates neurotoxicity (for 
review see Bimonte-Nelson et al., 2010). For this reason, estrogens 
became a primary research target to elucidate the parameters and 
mechanisms of this female specific enhancement in cognitive plasticity.  
In Chapter 3, I evaluated E2’s effects on RM in young, middle-
aged, and aged animals, and determined whether or not circulating serum 
E2 levels were related to RM performance. The results from Chapter 3 
suggested that E2 loses its ability to enhance RM in aged female rats, and 
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that better RM performance was related to higher circulating E2 levels in 
young and middle-aged female rats. This age-related alteration in the 
ability of estrogen to enhance RM performance has been corroborated by 
others (Foster et al., 2003). Of interest is the fact that some studies have 
shown that aged female rodents exhibit RM enhancements in response to 
estrogen treatment (Frick et al., 2002; Markowska and Savonenko, 
2002a); however, this may be due to the dose administered because only 
high supraphysiological doses of estrogen were able to influence RM 
retention in 17 month old rats (Foster et al., 2003). Thus, a higher E2 dose 
may be necessary to enhance RM in rats approaching old age. Notably, 
Chapter 3 supported the concept that E2 can enhance RM performance, 
with higher circulating E2 levels relating to better RM performance. 
Important as the findings were in Chapter 3, they did not address a 
possible mechanism for E2’s effects on memory or cognitive plasticity. 
Chapter 4 was designed to evaluate E2’s effects on both WM and RM and 
to determine a possible mechanism underlying E2’s enhancement of 
memory and cognitive plasticity. Chapter 4 also directly compared the 
effects of E2 to the complex hormone preparation CEE as well as DHED, 
the prodrug of E2, on spatial memory and putative mechanism of cognitive 
plasticity. I evaluated these additional compounds in comparison to E2 
because CEE is the estrogenic component of HT that is most commonly 
prescribed to women, and DHED is conceivably E2 that only becomes 
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bioactive in the brain (Hersh et al., 2004; Prokai et al., 2003). Specifically, 
I wanted to examine the WM, RM, and ChAT-IR positive BF neuron profile 
of the estrogen most commonly evaluated in basic research (i.e., E2), as 
compared to the estrogen that women are commonly prescribed for HT 
(i.e., CEE; Hersh et al., 2004) and a prodrug of E2 which has the potential 
to become a novel HT (i.e., DHED, see Prokai et al., 2003). Middle-aged 
rats were chosen for Chapters 4-7 since this is the approximate age when 
ovarian hormone production is altered and E2 responsiveness starts to 
decline in both female rats and humans (see Bimonte-Nelson et al., 2010; 
Dudley, 1982). In Chapter 4 I found that DHED is readily converted to E2 
in a brain homogenate, but not in an inert buffer. Surprisingly, the results 
also indicated that a higher tonic CEE dose was more beneficial to 
memory than a tonic E2 or tonic DHED dose; that is, the 24μg/day dose of 
CEE enhanced overnight retention on the Morris maze, as well as 
acquisition and retention on the DMS Plus Maze, whereas E2 and DHED 
only enhanced retention on the DMS Plus Maze. Corroborating earlier 
findings regarding CEE (Acosta et al., 2009b) and E2 (Gibbs, 1997), I 
found that E2, CEE and DHED all increased the number of BF ChAT-IR 
neurons, suggesting that all three compounds altered the cholinergic 
system. Importantly, the increased number of BF ChAT-IR positive 
neurons represented a putative mechanism of estrogen’s enhancement of 
memory (see Gibbs and Aggarwal, 1998; Hasselmo, 2006).  
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One explanation for the disparate effects of E2 and CEE on WM 
and RM performance found in Chapter 4 is that a more optimal dose of 
CEE and a less optimal dose of E2 were evaluated. Although all hormone 
dose(s) in Chapter 4 were based off of previous studies (Acosta et al., 
2009b; unpublished observations; Talboom et al., 2008), the idea of 
differential effects being determined by the dose and estrogen type 
highlighted the fact that the dose response relationship between E2 and 
memory, as well as CEE and memory, is not fully understood. Indeed, an 
evaluation of the relationship that E2 and CEE have on memory had not 
been conducted, since no studies including the study in Chapter 4 
employed a large enough dose range (i.e., greater than 3) to correctly 
evaluate and interpret dose response relationships.  
Chapter 5 was designed to assess the relationship that a baseline 
Ovx (i.e., a “0” dose) and a range of 5 separate tonic doses of E2 and 
CEE had on WM performance. Using linear and nonlinear regression 
models, Chapter 5 revealed that E2 from 0μg/day to 3.75μg/day exhibited 
a linear dose response relationship to working and recent memory 
performance, with higher doses being related to better performance. CEE 
exhibited a quadratic or inverted U shape dose response relationship to 
working and recent memory performance, with the middle 36 μg/day dose 
representing the “optimal” dose. While noting some differences in the 
memory domains that were evaluated, the linear relationship between E2 
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memory performance corroborated other linear relationships found 
between E2 and memory in previous studies (Chapter 3; Asthana et al., 
1999; Phillips and Sherwin, 1992; Ryan et al., 2010). Chapter 5 also 
identified the 36μg/day dose of CEE as optimal dose for working and 
recent memory performance, which is corroborated by previous studies 
assessing CEE or one of its component estrogens (Acosta et al., 2009b; 
Engler-Chiurazzi et al., 2009; Talboom et al., 2010). Collectively, Chapter 
5 indicated that the dose response relationship of E2 and CEE to memory 
did differ, further suggesting that the dose and type of estrogen evaluated 
are important factors that dictate whether estrogen is beneficial or 
detrimental to memory. 
In examining the idea that different estrogens have different effects 
on memory independent of other factors, another explanation for the 
disparate memory effects found in Chapter 4 and the differing 
relationships to memory found in Chapter 5, when comparing E2 to CEE, 
is revealed. Unlike E2, which is a single estrogen with a consistent 
molecular structure, CEE is a complex formulation containing several 
different estrogenic components all having slightly different molecular 
structures (see Bhavnani, 1998). Since CEE is comprised of so many 
different estrogenic components, it is conceivable to think that some 
component estrogens may be more efficacious to cognition than others, a 
hypothesis supported by the fact that many of the component estrogens 
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vary in their ER binding affinities as well as their pharmacokinetic and 
pharmacodynamic profiles (Bhavnani, 1998; Bhavnani, 2003; Bhavnani et 
al., 2008). Indeed, this tenet was realized and capitalized on by Dr. Brinton 
and colleagues (1997; 2006) in research where they found that certain 
select estrogenic components of CEE were more efficacious than others 
in enhancing markers of neuronal health in vitro. Chapter 6 extended 
these findings by testing Δ8
Zhao and Brinton, 2006
E1 and equilin, the top two neuroprotective 
estrogenic components of CEE ( ), in vivo for their 
effects on learning and memory and on markers of the cholinergic system. 
Chapter 6 found that Δ8
for discussion see Bhavnani et al., 
2008
E1 benefited spatial WM and RM and that it 
altered markers of the cholinergic system, while equilin did not. Taken 
together with the disparate CEE and E2 effects in Chapters 4 and 5, 
Chapter 6 suggests that different estrogens with slightly different 
molecular compositions and receptor affinities can have radically different 
behavioral and neurobiological effects (
). 
Now with many parameters of estrogen’s effects on memory 
elucidated, Chapter 7 examined a potential mechanism behind estrogen’s 
ability to enhance plasticity and cognitive performance. Chapter 7 
addressed the effects of age and ovarian hormone loss on hippocampal 
putative excitatory and inhibitory synapse counts. This measure and 
mechanism was chose as synapses are thought to be the structural 
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component of memory, are influenced by estrogen, and are altered during 
aging in cognitive brain regions (see Bliss et al., 2003; Geinisman et al., 
1986; Nicholson et al., 2004; Woolley, 2007). I found that putative 
excitatory synapses were decreased in the dentate gyrus by ovarian 
hormone loss, an effect that is in line with, but not directly comparable to, 
previous literature reporting E2’s effects on dendritic spines after Ovx (see 
Woolley, 2007). Ovarian hormone loss was also found to act together with 
age and affect putative inhibitory synapse counts in the dorsal cell layer of 
CA1, with putative inhibitory synapses numbers decreasing with age in 
Ovx animals. Taken together with the findings from previous literature (see 
Andersen, 2007; Bliss et al., 2003; Woolley, 2007) and the memory results 
from Chapters 2 through 6, the data from Chapter 7 suggest that 
estrogen’s enhancement of spatial memory is likely directed via alterations 
in synaptic plasticity in the hippocampus and perhaps surrounding cortex. 
This ovarian hormone loss effect on hippocampal putative synapses may 
be an intrinsic effect in the hippocampus (Woolley et al., 1997), initiated by 
alterations in cholinergic signaling and NGF levels (see Granholm, 2000; 
Hasselmo, 2006), or comprise an interaction of all three. 
Collectively, this body of work suggests that cognitive practice can 
benefit memory when aged in both males and females. In females, 
estrogen may enhance the effects of cognitive practice as it has been 
found to enhance memory and hippocampal synaptic plasticity. The 
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memory enhancements and alterations in hippocampal synaptic plasticity 
are at least partially directed by enhancements in cholinergic signaling 
from the BF. Lastly, age, dose, and type of estrogen utilized are important 
factors to consider when evaluating estrogen’s effects on memory and its 
underlying mechanisms. For example, age, dose, and the type of estrogen 
utilized are important factors to consider when evaluating estrogen’s 
effects on memory and its underlying mechanisms, since age alters the 
responsiveness to estrogen treatment and the dose of estrogen as well as 
small alterations in the molecular structure of estrogen can have a 
profound impact on estrogen’s efficacy on memory. Many parameters 
including the ones described here become important considerations when 
designing future behavioral interventions/therapies and HTs, and this body 
of work helps to determine a few of those parameters. Ideally, this work 
will aid in understanding of the underlying mechanism that is responsible 
for estrogen’s ability to enhance memory, and plasticity. These properties 
could then be used in turn to help design the next generation of 
interventions, therapies, and nootropic agents that will hopefully enact 
lasting improvements in public health.  
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Table 1 
Summary of Dependent Variable Composites  
Composite Memory Type 
 
Day and Trial Blocks 
 
 
1. RM T Maze 
  
All days and trials 1st
session at 6 months of age 
 practice RM Days 1-5 Trials 1-6 
All days and trials RM Days 1-5 Trials 1-6 
Last 3 days all trials RM Days 3-5 Trials 1-6 
   
2. RM Morris Maze   
All days and trials RM Days 1-5 Trials 1-6 
Last 3 days all trials RM Days 3-5 Trials 1-6 
Overnight retention RM Retention Days 2-5 Trial 1 
   
3. WM and RM WRAM   
WMC all days and trials WM Days 1-12 Trials 2-4 
WMC last 4 days all trials WM Days 9-12 Trials 2-4 
WMI all days and trials WM Days 1-12 Trials 1-4 
WMI last 4 days all trials WM Days 9-12 Trials 1-4 
RMW all days and trials RM Days 1-12 Trials 1-4 
RMW last 4 days all trials RM Days 9-12 Trials 1-4 
WMC all days trial 4 alone WM Load Days 1-12 Trial 4 
WMC last 4 days trial 4 alone WM Load Days 9-12 Trial 4 
WMI all days trial 4 alone WM Load Days 1-12 Trial 4 
WMI last 4 days trial 4 alone WM Load Days 9-12 Trial 4 
RMW all days trial 4 alone RM Days 1-12 Trial 4 
RMW last 4 days trial 4 alone RM Days 9-12 Trial 4 
   
4. Novel Global Memory 
Composite 
  
Mean z-score of all days and all 
trials for tasks novel to the Aged-
Cog Prac group: RM T Maze, RM 
Morris Maze, and WM RM WRAM 
 
Global Novel WM 
and RM 
All Test Days all Trials 
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Table 2 
Mean ±SE, median, and range of E2 levels for each group 
  
Group Mean E2 level ±SE 
Range of E2 
levels 
Median E2 
level 
1. Study 1 
Young Sham 13.50±4.11 Undetectable-26 17.5 
Young Ovx 3.78 ±1.91 Undetectable-13 0 
Young Ovx + 0.25 E 65.88 ±10.75 56-98 77 
Young Ovx + 0.50 E 61.75 ±12.30 22-114 49.5 
Middle-aged Sham 21.88 ±1.89 13-29 23 
Middle-aged Ovx 5.11 ±2.70 Undetectable-21 0 
Middle-aged Ovx + 
0.25 E 54.80 ±6.19 32-68 57 
Middle-aged Ovx + 
0.50 E 53.38 ±13.24 15-121 44 
2. Study 2 
Young Sham 16.83±4.56 Undetectable-34 18.5 
Aged Sham 19.20 ±2.06 12-24 20 
Aged Ovx 11.00±2.15 Undetectable-19 11 
Aged Ovx + 0.25 E 112.50 ±20.79 55-180 104 
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Table 3 
Summary of Relationships between Tonic E2 or CEE Dose and 
Working/Recent Memory 
  
Groups and Composite Form of the Relationship with Dose 
  
1. Ovx-Veh group and all E2 doses 
 
 
Ovx-E2 and Ovx-Veh Total Errors  Baseline 
Learning (Days 1-5 Trials 1-6) Form Not Described 
Ovx-E2 and Ovx-Veh Total Errors Overall 
Performance (Days 1-7 Trials 1-6) Form Not Described 
Ovx-E2 and Ovx-Veh Repeat Errors Baseline 
Learning (Days 1-5 Trials 1-6) Negative Linear 
Ovx-E2 and Ovx-Veh Repeat Errors Overall 
Performance (Days 1-7 Trials 1-6) Negative Linear 
  
2.  Ovx-Veh group and all CEE doses 
  
Ovx-CEE and Ovx-Veh Total Errors Baseline 
Learning (Days 1-5 Trials 1-6) Form Not Described 
Ovx-CEE and Ovx-Veh Total Errors Overall 
Performance (Days 1-7 Trials 1-6) Cubic 
Ovx-CEE and Ovx-Veh Repeat Errors Baseline 
Learning (Days 1-5 Trials 1-6) Quadratic/U-Shaped 
Ovx-CEE and Ovx-Veh Repeat Errors Overall 
Performance (Days 1-7 Trials 1-6) 
 
Form Not Described 
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Table 4 
Summary of the Effects of Age and Ovarian Hormone Loss on Putative 
Synapse Numbers 
 
Analysis Putative Synapse Type 
Hippocampal 
Lamina Group(s) Effect 
1. Pairwise 
ANOVA: 
Ovx vs. Sham 
    
Significant 
ANOVA Excitatory(NR1) 
Stratum 
Granulosum Ovx ↓Decrease↓ 
2.  Age Linear 
Trends  
    
Significant 
Trend from 5 to 
20 mo 
Inhibitory(VGAT) Stratum Pyramidale 
Ovx & 
Sham ↓Decrease↓ 
Significant 
Trend from 5 to 
20 mo 
Inhibitory(VGAT) Stratum Pyramidale Ovx ↓Decrease↓ 
Significant 
Trend from 12 
to 20 mo 
Inhibitory(VGAT) Polymorphic Layer 
Ovx & 
Sham ↓Decrease↓ 
3. Pairwise  
Age Contrasts  
    
Significant 
Contrast: 5 vs. 
20 mo 
Inhibitory(VGAT) Stratum Pyramidale 
Ovx & 
Sham ↓Decrease↓ 
Significant 
Contrast: 5 vs. 
20 mo 
Inhibitory(VGAT) Stratum Pyramidale Ovx ↓Decrease↓ 
Significant 
Contrast: 5 vs. 
20 mo 
Inhibitory(VGAT) Stratum Oriens Ovx & Sham ↓Decrease↓ 
Significant 
Contrast: 5 vs. 
20 mo 
Inhibitory(VGAT) Stratum Oriens Ovx ↓Decrease↓ 
Significant 
Contrast: 12 vs. 
20 mo 
Inhibitory(VGAT) Polymorphic Layer 
Ovx & 
Sham ↓Decrease↓ 
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Figure 1. A time line of experiment 1 listing each group in the study and 
summarizing the sequence of cognitive practice and/or the length of 
practice/testing absence that each group received through the final 
battery, ending with sacrifice and an evaluation of NGF levels. 
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Figure 2. a) Plot of the linear growth model displaying the mean growth 
rate of Cog Prac animals during the first cognitive practice session at 6 
months of age (sample) and the model estimated linear growth rate. b) 
Simplified path diagram depicting the linear growth model estimating the 
number of correct arm entries made on day 1 (i.e., initial performance or 
Intercept) and the change in the number of correct arm entries made per 
day (i.e., change per day or Slope) for Cog Prac male and female rats 
during their first cognitive practice session at 6 months of age. a) The 
mean growth rate of Cog Prac animals at 6 months of age closely followed 
the linear trajectory estimated by the model. b) The full growth model was 
constructed by adding Sex as a binary predictor of the Intercept and Slope 
as well as the Slope of young animals predicting the Aged Novel Global 
Memory Composite. Numbers represent the unstandardized path 
coefficients estimated by maximum likelihood. * p ≤ .05 ** p < .0001. 
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Figure 3. Effects of cognitive practice. a) Mean ±average SE number 
correct arm entries made on two separate composite measures summed 
across all days and trials and the last 3 days of testing with all test trials on 
the RM T-Maze. b) Mean ±average SE for a composite measure of swim 
distance (cm) summed across the last 3 days of testing and all test trials 
on the RM Morris Maze. c) Mean ±average SE RM Morris Maze swim 
distance (cm) summed across days 2-5 from trial 4 of the previous day to 
trial 1 of the next day. d) Mean ±SE RM Morris Maze percent of total swim 
distance in the target NE and opposite SW quadrants during the probe 
trial. e) RM Morris Maze mean ±average SE total number of platform 
crossings made during the probe trial. f) Mean ± average SE WMI errors 
committed on the WM and RM WRAM for a composite measure of WMI 
errors summed across the last 4 days of testing for trial 4 alone. * p < .05 . 
# p < .10.  
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Figure 4. The effects of cognitive practice to attenuate or obviate age-
related memory decline and the effects of the procedural components of 
testing on memory. a) Mean ±average SE number correct arm entries 
made on two separate composite measures summed across all days and 
trials and the last 3 days of testing for all test trials on the RM T-Maze. b) 
Mean ±average SE female swim distance (cm) during days 2-5 for trial 1 
on the RM Morris Maze. c) Mean ±average SE WMI errors committed on 
the WM and RM WRAM from a composite measure of WMI errors 
summed across the last 4 days of testing on trial 4 alone. d) Mean 
±average SE WMC errors committed on the WM and RM WRAM from a 
composite measure of WMC errors summed across all days and trials. a) 
For both composites, the Aged-Cog Prac group outperformed the Young-
Naïve group during the final battery on the cognitive practice RM task. b) 
Young-Naïve females did not differ from Aged-Cog Prac females on the 
RM Morris Maze. c) Young-Naïve animals committed fewer WMI errors in 
comparison to the Aged-Cog Prac group. d) Summed across all days and 
trials, Aged-Naïve animals committed less WMC errors when compared to 
the Aged-Swim Only group. * p < .05.  
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Figure 5. The effects of age. a) Mean ±average SE number correct arm 
entries made on two separate composite measures summed across all 
days and trials and for the last 3 days of testing for all test trials on the RM 
T-Maze. b) Mean ±average SE female swim distance (cm) during days 2-5 
on trial 1 alone on the RM Morris Maze. c) Mean ±average SE WMC 
errors committed on the WM and RM WRAM from a composite measure 
of WMC errors summed across the last 4 days of testing for all test trials. 
d) Mean ±average SE WMI errors committed on the WM and RM WRAM 
from a composite measure of WMI errors summed across the last 4 days 
of testing on trial 4 alone. a) The Young-Naïve group did not differ from 
the Aged-Naïve group on both composite measures of RM T-Maze 
performance. b) Young-Naïve females demonstrated superior RM Morris 
Maze performance in comparison to Aged-Naïve females. c) Young-Naïve 
animals committed fewer WMC errors when compared to the Aged-Naïve 
group during the last 4 days of testing. d) For the composite of WMI 
errors, the Young-Naïve group committed fewer errors in comparison to 
Aged-Naïve animals. * p < .05. 
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Figure 6. NGF Contrast Analyses. a) Mean ±average SE NGF levels 
(pg/mg) in the striatum, frontal cortex, parietal cortex and temporal cortex 
of Young-Naïve and Aged-Cog Prac animals. b) Mean ±average SE NGF 
levels (pg/mg) in the parietal cortex of Young-Naïve and Aged-Naïve 
animals. c) Mean ±average SE NGF levels (pg/mg) in the parietal cortex 
of Young-Naïve and Aged-Never Test animals. a) The Aged-Cog Prac 
group had increased NGF levels in the striatum, frontal cortex, parietal 
cortex, and temporal cortex as compared to Young-Naïve animals. b) and 
c) Both the Aged-Naïve and Aged-Never Test groups had increased NGF 
levels in the parietal cortex as compared to the Young-Naïve group. 
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Figure 7. Primary regression analyses. Scatterplots representing the 
relationship between RM T-Maze number of correct arm entries made 
during the first cognitive practice session when animals were 6 months of 
age (Y axis) and aged NGF levels (X axis): a) in the ventral hippocampus 
(CA1/2) of male and female Aged-Cog Prac animals, b) in the ventral 
hippocampus (CA1/2) of female Aged-Cog Prac animals, and c) in the 
frontal cortex of female Aged-Cog Prac animals. The line represents the 
linear regression analysis of best fit. a) In both males and females, young 
RM performance was positively related to aged ventral hippocampal NGF 
levels. b) and c) In females alone, young RM performance was positively 
related to aged ventral hippocampal and frontal cortex NGF levels. 
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Figure 8. For Study 1, mean± SE distance scores (cm) across days of 
testing on the Morris maze for a) Young Sham, Ovx and Ovx-E groups 
and b) Middle-Aged Sham, Ovx and Ovx-E groups; the inset graphs 
represent the data collapsed across days. For Young animals, Ovx 
impaired performance on the latter portion of testing, as represented by 
the Ovx x Day interaction. There was no effect of Ovx in middle-aged 
animals. E2 treatment enhanced performance in both age groups. Thus, 
there was a dissociation between sensitivity to Ovx and responsiveness to 
E2 treatment. c) Mean ±SE distance scores for each trial for days 2-5 for 
Middle-Aged-Ovx and Middle-Aged-Ovx-E groups for Study 1. There was 
a significant Trial x E2 Treatment interaction, indicating that E2 aided in 
remembering the platform location overnight in middle-aged rats. d) Mean 
percent distance ±SE spent in the target (NE) and opposite (SW) quadrant 
for each treatment group within each age for Study 1. Neither Ovx nor E2 
treatment influenced performance on the probe trial. All groups localized 
to the platform location, spending a greater percent distance in the target 
versus the opposite quadrant. * p < .05, # p = .06 , *** p < .0001. 
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Figure 9. Mean ±SE swim speed for each treatment group for a) young 
animals and b) middle-aged animals for Study 1. While there was no effect 
of swim speed in young animals, middle-aged animals showed a main 
effect of Treatment. Follow-up analyses showed that Ovx did not influence 
swim speed in middle-aged animals, and E2 treatment decreased swim 
speed.  
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Figure 10. For Study 1, scatterplots for serum E2 levels and a) the last trial 
on the last day of day of testing with the platform in the maze, and b) 
percent distance in the previously platformed quadrant on the probe trial. 
Higher levels of E2 treatment, as determined by serum E2 levels, 
correlated with better performance (lower distance) on the last test trial as 
well as a higher percent distance in the previously platformed quadrant, 
representing superior platform localization. 
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Figure 11. a) Mean ±SE distance scores (cm) across day of testing on the 
Morris maze for Aged-Sham, Aged-Ovx, Aged-Ovx-E and Young groups 
for Study 2. There were no significant main effects or interactions for 
distance scores due to Ovx or E2 treatment in aged animals. b) mean ±SE 
swim speed for each aged group for each test day. The omnibus ANOVA 
revealed that Treatment affected swim speed as days progressed, with a 
significant Day x Treatment interaction. As observed in middle-aged 
animals, Ovx did not influence swim speed and E2 treatment decreased 
swim speed. c) Mean ±SE percent distance in the target (NE) and 
opposite (SW) quadrants on the probe trial for Aged-Ovx-E and Aged-Ovx 
groups for Study 2. There was a Quadrant x Treatment interaction, and a 
post-hoc t-test showed that aged Ovx animals receiving E2 spent a higher 
percent distance in the target quadrant as compared to aged Ovx animals 
that did not, suggesting better platform acquisition in aged Ovx animals 
given E2 treatment. d) Mean ±SE percent distance in the target (NE) and 
opposite (SW) quadrants on the probe trial for Aged-Ovx and Aged-Ovx-E 
groups for Study 2. There was a Quadrant x Treatment interaction, and a 
post-hoc t-test showed that aged Ovx animals receiving E2 spent a higher 
percent distance in the target quadrant as compared to aged Ovx animals 
that did not, suggesting better platform acquisition in aged Ovx animals 
given estradiol treatment. ** p < .01 * p < .05, *** p < .0001.   
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Figure 12. a) DHED converts to E2 in brain tissue, as shown by LC-
MS/MS analysis of product formed from 100 μM of DHED after 2.5-min 
incubation in rat-brain homogenate (20% w/v) with an initial rate of E2 
formation corresponding to approximately 200 nmol min-1 (mg protein)-1. 
b) The absence of E2 formation was observed after incubation in buffer 
only (i.e., the control). 
 
  
  
267 
 
 
  
  
268 
Figure 13. Mean ±SE swim distance (cm) across days of testing on the 
Morris maze for (a) Ovx-Veh and each group and; the inset graph 
represents overnight forgetting data from trial 4 day 2 to trial 1 day 3. b) 
depicts the Mean ±SE percent distance swam in the target and opposite 
quadrants on the probe trial for each experimental group. There were no 
treatment effects across, however the analysis of overnight forgetting 
reveled that only the Ovx-CEE-High group had enhanced retention from 
day 2 trial 4 to day 3 trial 1. On the probe trial, all animals localized to the 
quadrant that previously contained the platform (target, NE) as compared 
to the opposite quadrant (SW). * p < 0.05.  
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Figure 14. a) Mean number ±SE of total errors across test trials for 
acquisition days 1-5 on the DMS Plus Maze for each group. b) Mean 
number ±SE of total errors committed across both delay challenges for 
each group. c) Mean number ±SE of total errors committed from the last 
day of baseline (day 11) to the interference challenge (day 12) for each 
group. d) Mean number ±SE of total errors committed from the last day of 
baseline (day 11) to the scopolamine challenge (day 13) for each group. 
a) The Ovx-CEE-High group displayed superior acquisition during the 
initial learning phase. No other estrogen impacted performance during 
acquisition or initial learning. b) After the acquisition, I increased the 
memory demand of the task to test retention by instituting a 4hr and a 6hr 
delay challenges. Each hormone group made fewer errors than the Ovx-
Ovx-Veh group. In figures c) and d) all animals were impaired with the 
delay and interference challenge as evidenced by the increase from 
baseline.  * p < 0.05. 
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Figure 15. a) Mean ±SE stereological ChAT-IR neuron counts in MS of the 
BF of each group. The Ovx-E2, Ovx-CEE-Low and Ovx-DHED-Low 
groups all had a higher number of ChAT-IR neuron count in the MS, as 
compared to the Ovx-Veh group. b) Representative photomicrographs 
show ChAT-IR neurons in sections through the MS of the BF of each 
group. * p < 0.05. 
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Figure 16. Bars represent mean serum hormone levels ±SE (pg/ml) for a) 
E2 b) E1. For both E2 and E1 the Ovx-E2 group exhibited the highest 
serum levels. Due to the high variability of the E2 group, analyses without 
the Ovx-E2 group reveled that both CEE doses increased serum E2 and 
E1 levels. Importantly, both DHED doses did not produce levels of E2 or 
E1 which differed from the Ovx-Veh group. * p < 0.05. 
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Figure 17. Bars depict the mean uterine weight ±SE for each group. The 
Ovx-E2 group exhibited the highest uterine weights. Due to the high 
variability of the E2 group, analyses without the Ovx-E2 group reveled that 
both CEE doses increased uterine weights. Importantly, both DHED doses 
did not produce uterine weights which differed from Ovx animals. * p < 
0.05. 
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Figure 18. Figure a) and b) centered scatterplots of serum E2 and E1 
levels respectively and the number of MS ChAT-IR neurons for the Ovx-
E2, Ovx-CEE-Low and Ovx-CEE-High groups. Higher serum E2 and E1 
levels were related to less ChAT-IR positive cells in the MS. Fig. 5 c) and 
d) scatterplots of centered data for serum E2 and E1 levels respectively 
and Morris maze distance scores collapsed across all days for the Ovx-
E2, Ovx-CEE-Low and Ovx-CEE-High groups. Higher serum E2 and E1 
levels were related to less better performance (lower distance) across 
Morris maze testing. 
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Figure 19. Mean ±SE uterine weights (g) per group. At sacrifice, each 
tonic E2 and CEE treated group had higher uterine weights in comparison 
to the Ovx-Veh group. * p < .05. 
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Figure 20. Scatterplots of E2 or CEE dose (μg/day) and the sum of 
working/recent memory errors (i.e., trials 2-6) committed on the DMS Plus 
Maze. a) Repeat errors committed across the baseline learning phase 
(days 1-5) by the Ovx-Veh and all Ovx-E2 groups, b) repeat errors 
committed across all test days (days 1-7 overall performance) by the Ovx-
Veh and all Ovx- E2 groups, c) total errors committed across all test days 
(days 1-7 overall performance) by the Ovx-Veh and all Ovx-CEE groups, 
and d) repeat errors committed across the baseline learning phase (days 
1-5) by the Ovx-Veh and all Ovx-CEE groups.  
  
  
283 
 
 
  
  
284 
Figure 21. DMS Plus Maze. Mean number ±SE of repeat errors committed 
on the WM trial across testing days 2-7 for: a) Ovx-Veh and each ∆8E1 
group, and b) Ovx-Veh and each Equilin group. On the WM trial, the 
medium and high doses of ∆8
 
E1 decreased the number of repeat errors 
committed relative to the Ovx-Veh group. Equilin treatment did not yield 
significant effects. * p < 0.05. 
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Figure 22. Morris maze. Mean ±SE swim distance (cm) collapsed across 
days for: (a) Ovx-Veh and each ∆8E1 group, and b) Ovx-Veh and each 
Equilin group; the inset graphs represent swim distance over the 6 blocks 
of testing. c) and d) depict mean ±SE percent swim distance in the target 
and opposite quadrants on the probe trial for the Ovx-Veh and each ∆8E1 
group, and the Ovx-Veh and each Equilin group, respectively. Each ∆8
 
E1 
dose enhanced spatial RM relative to the Ovx-Veh group, collapsed 
across all days. Equilin did not impact spatial RM performance. For the 
probe trial, all groups localized to the quadrant that previously contained 
the platform (target, NE) as compared to the opposite quadrant (SW). * p 
< 0.05. 
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Figure 23. Visible Platform. Mean ±SE latency (seconds) to reach the 
platform on the visible platform task for: a) Ovx-Veh and each ∆8
 
E1 group, 
and b) Ovx-Veh and each Equilin group. There were no Treatment effects, 
and all groups readily located the visible platform within 10 seconds. 
These data confirm visual and motor competence by all subjects for 
platform search and localization. 
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Figure 24. Mean ±SE rα4β2-nAChR expression in the hippocampus and 
entorhinal cortex for: a) Ovx-Veh and each ∆8E1 group, and b) Ovx-Veh 
and each Equilin group. As represented in the left panel, for the 
hippocampus+entorhinal cortex (regions combined), all ∆8E1 groups had 
decreased α4β2-nAChR expression as compared to the Ovx-Veh group. 
Equilin treatment did not alter rα4β2-nAChR expression. As represented in 
the right panel, both the ∆8
 
E1 and equilin analyses, more α4β2-nAChRs 
were present in the entorhinal cortex as compared to the hippocampus. * 
p < 0.05. 
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Figure 25. Scatterplot representing the relation between rα4β2-nAChR 
expression levels in the hippocampus+entorhinal cortex and Morris maze 
swim distance across all days and trials for all ∆8
 
E1 groups and the Ovx-
Veh group. The line represents the linear regression analysis of best fit. 
Better RM performance (lower swim distance) was related to lower rα4β2-
nAChR expression.  
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Figure 26. Concentration-response profiles showing effects on hα4β2-
nAChR function (i.e., ion efflux) following: a) acute treatment with ∆8E1, 
equilin or vehicle PEG, b) 48hr treatment with ∆8E1 and c) 48hr treatment 
with equilin. The lines on each graph represent the linear regression 
analysis of best fit. No systematic effect of acute or 48hr hormone or 
vehicle exposure on specific 86Rb+
 
 efflux was observed over the range of 
hormone or vehicle concentrations tested.  
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Figure 27. Representative brightfield eosinY- and hematoxylin- stained 
vaginal cytology pictures (10X) from Ovx-Veh, ∆8E1, and Equilin groups, 
taken the day before sacrifice. Ovx-Veh animals displayed few cells, 
consistent with diestrus and no uterine stimulation. Each group receiving 
∆8
 
E1 or equilin had numerous stained cornified cells, indicative of estrous 
and uterine stimulation. 
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Figure 28. Mean ±SE uterine weight (grams) for: a) Ovx-Veh and each 
∆8E1 group, and b) Ovx-Veh and each Equilin group. Mean ±SE serum LH 
levels (ng/ml) for: c) Ovx-Veh and each ∆8E1 group, and d) Ovx-Veh and 
each Equilin group. Each dose of ∆8
  
E1 and equilin increased uterine 
weights and decreased serum LH levels as compared to the Ovx-Veh 
group. * p < 0.05. 
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Figure 29. a) Illustration detailing where each image stack was acquired in 
order to assess putative synapse numbers throughout the female rat 
hippocampus. Four images/z-stack were acquired and quantified in CA1 
stratum oriens and CA1 stratum pyramidal as well as the polymorphic 
layer and granular cell layer of the dentate gyrus. b) Representative 
fluorescent micrographs of NR1 and vGAT punctate staining in the 
hippocampus of female rats. Both NR1 and vGAT IHC procedures 
produced distinct punctate staining revealed via laser scanning confocal 
microscopy throughout the female rat hippocampus.  
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Figure 30. a) through c) represents a step by step presentation of the 
ImageJ procedures used to quantify the number of punctate staining in 
each of the four images in a z-stack. d) Scatter plot of the number of 
punctate counted via the ImageJ semi-automatic method related to the 
number of punctate counted manually in the same image sections; the 
dotted line represents the linear regression line of best fit. Separately for 
both NR1 and vGAT z-stacks, after the first and last images were deleted, 
the raw FluoView tiff 4 image z-stacks had a: a) spot detector based on a 
“3D LoG” filter applied to each image to decrease background and 
enhance the punctate staining, next b) each image was thresholded via 
“Mixture Modeling,” and c) the ImageJ “Analyze Particles” tool was used to 
automatically count each punctate across all 4 images in a z-stack. d) 
Primary regression analysis revealed that there was a strong linear 
relationship (R2
  
 = 0.85) between the number of punctate that the semi-
automatic and the manual method counted. 
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Figure 31. Mean ±SE number of NR1 punctate counted in the stratum 
granulosum of the dentate gyrus. Ovx animals in comparison to Sham 
ovary intact animals had a decreased in the number of putative excitatory 
synapses found on ventral blade granular cells of the dentate gyrus. * p ≤ 
0.05. 
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Figure 32. Mean ±SE number of vGAT punctate in separate age groups 
counted in a) CA1 stratum pyramidale and b) the polymorphic layer of the 
dentate gyrus; solid lines represent linear trends (i.e., linear contrasts) 
across the mean punctate count for each age group. a) The number of 
putative inhibitory synapses decreased in linear fashion from 5 to 20 
months of age on the pyramidal cells of CA1 in Ovx animals. b) Putative 
inhibitory synapse numbers decreased in linear fashion from 12 to 20 
months of age in the polymorphic layer of the dentate gyrus when Ovx and 
Sham animals were evaluated together. δ linear trend p ≤ 0.05. 
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Figure 33. Mean ±SE number of vGAT punctate between 5 and 20 as well 
as 12 and 20 month old age groups counted in a) CA1 stratum 
pyramidale, b) stratum oriens, and c) the polymorphic layer of the dentate 
gyrus. a) The numbers of putative inhibitory synapses on the pyramidal 
cells of CA1 in Ovx animals were decreased in the 20 month old group 
when compared to the 5 month old group. b) In Ovx animals, the numbers 
of putative inhibitory synapses in stratum oriens dorsal to the CA1 cell 
layer were decreased in the 20 month old group when compared to the 5 
month old group. c) Putative inhibitory synapse numbers decreased in the 
20 month old group when compared to the 12 month old group in the 
polymorphic layer of the dentate gyrus when Ovx and Sham animals were 
evaluated together. * p ≤ 0.05. 
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APPENDIX A 
SECURED PERMISSION TO INCLUDE PUBLISHED RESEARCH 
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I have secured permission from all authors to include published research 
in the current dissertation. 
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APPENDIX B 
DIRTY VODKA MARTINI 
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Ingredients 
6 fluid ounces vodka 
1 dash dry vermouth 
1 fluid ounce brine from olive jar 
4 stuffed green olives 
 
Directions 
In a mixing glass, combine vodka, dry vermouth, brine and olives. Pour 
into a glass over ice and stir gently. Either drink on the rocks, or strain into 
a chilled cocktail glass. 
 
